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Abstract 
 
 
Elevated vascular smooth muscle cell (VSMC) proliferation is a feature of various 
cardiovascular conditions including restenosis, abdominal aortic aneurysm (AAA) and 
atherosclerosis. Voltage-gated T-type Ca2+ channels are implicated in VSMC 
proliferation as their expression is markedly up-regulated in proliferative phases of the 
VSMC cell-cycle (Kuga et al., 1996). The Thioredoxin (Trx) system is also associated with 
proliferative disorders of the heart and vasculature, e.g. Trx concentrations are 
elevated in AAA (Martinez-Pinna et al., 2010) and atherosclerosis (Okuda et al., 2001). 
Trx has recently been shown to regulate T-type Ca2+channels (Boycott et al., 2013). 
This PhD has investigated the hypothesis that VSMC proliferation is modulated by 
interactions between Trx and T-type Ca2+ channels. 
 
Proliferation assays revealed that the T-type Ca2+ channel inhibitor NNC55-0396 (NNC, 
1-3µM) decreased A7r5, HEK293/CaV3.1 and HEK293/CaV3.2, but not wt HEK293, cell 
proliferation. In contrast the L-type Ca2+ channel inhibitor nifedipine (2µM) was 
without effect. The Trx inhibitors PX-12 (1µM) and auranofin (AuF, 300nM) 
preferentially inhibited the proliferation of CaV3.2-expressing cells, i.e. A7r5 and 
HEK293/CaV3.2 cells. Basal Ca
2+ influx in A7r5 cells was also significantly reduced by 
NNC (3µM) and AuF (3µM). Whole-cell patch-clamp recordings in recombinant cells 
revealed that PX-12 (1-300μM) inhibited CaV3.1 and CaV3.2 currents with similar 
sensitivities. In contrast, Trx (4µg.ml-1) enhanced CaV3.2, but not CaV3.1, peak current 
amplitude. Similarly, AuF (3µM) selectively reduced the current-density of 
HEK293/CaV3.2 cells. Data suggest that CaV3.2 channels are positively and selectively 
regulated by Trx, yet PX-12 could inhibit T-type Ca2+ channels independently of Trx. 
The sensitivity of CaV3.2 channels to Trx was found to be dependent on an extracellular 
histidine residue at position 191 (H191), especially as mutation to a glutamine (Q) 
residue (H191Q) abolished Trx-sensitivity. In summary, these data indicate that 
interactions between Trx and CaV3.2 channels can regulate the proliferation of CaV3.2–
expressing cells. 
 
 
 
v 
 
Table of contents 
 
Heading page 
Intellectual Property and Publication Statements II 
Acknowledgements  III 
Abstract  IV 
Table of contents V 
Figures  XI 
Tables XV 
Abbreviations  
 
XVI 
Chapter 1 – Introduction  1-46 
1.1. Vascular smooth muscle cells (VSMCs) and blood vessels 1 
1.1. Vascular smooth muscle cells (VSMCs) and blood vessels 1 
1.2. Phenotypic switching, VSMC proliferation and cardiovascular disorders 2 
1.2.1. Restenosis 2 
1.2.2. Atherosclerosis 4 
1.2.3. Aortic aneurysm 6 
1.2.4. Hypertension 6 
1.2.5. Diabetes 8 
1.3. Voltage-gated Ca2+ (CaV) channels 9 
1.3.1. Structure-function relationships of CaV channels 10 
1.3.2. T-type Ca2+ channels: three distinct isoforms 12 
1.4. Isoform specific expression and physiological roles of CaV3.x channels 17 
vi 
 
1.4.1. Peripheral and central nervous system 17 
1.4.2. Heart 19 
1.4.3. Endocrine tissue 21 
1.4.4. Blood vessels and VSMCs 22 
1.5. The role of T-type Ca2+ channels in proliferation 28 
1.6. The thioredoxin (Trx) system 32 
1.6.1. Structure- function relationships of the Trx system 32 
1.6.2. The intracellular functions of Trx as a disulphide reductase 
molecule 
 
36 
1.6.3. Emerging roles for Trx as an extracellular signalling molecule 38 
1.7. Clinical implications of Trx expression in proliferative disorders 41 
1.7.1. Cardiovascular disorders 41 
1.7.2. Cancers 44 
1.8. Aims and hypothesis: 45 
Chapter 2 – Methods and materials 47-70 
2.1. Cell culture 47 
2.1.1. A7r5 cells 47 
2.1.2. wt HEK293 and recombinant HEK293/CaV3.1 and HEK293/CaV3.2 
cells 
 
48 
2.2. Real-time polymerase chain reaction (qRT-PCR) 48 
2.2.1. Cell culture and RNA extraction 49 
2.2.2. cDNA generation and qRT-PCR protocol 50 
2.2.3. Data analysis- comparative CT method for relative quantification 50 
2.3. Immunohistochemistry 51 
vii 
 
2.3.1. Image acquisition and analysis 52 
2.4. MTT viability assays 52 
2.5. Proliferation assays - direct cell counting 54 
2.6. Proliferation assays - EdU incorporation assay 55 
2.6.1. Cell culture and EdU incubation 56 
2.6.2. Cell fixation, permeabilization and EdU detection 56 
2.6.3. Image acquisition and analysis 57 
2.7. Ca2+  microfluorimetry 57 
2.7.1. Cell culture 58 
2.7.2. Depolarisation induced intracellular Ca2+ oscillation protocol - A7r5 
cells 
59 
2.7.3. Window current protocol 61 
2.7.4. Data analysis 61 
2.8. Electrophysiology 62 
2.8.1. Cell culture 63 
2.8.2. Electrophysiology rig set up 63 
2.8.3. Whole-cell recording configuration 64 
2.8.4. Single step (SS) voltage protocols 65 
2.8.5. Current-voltage (IV) relationship protocol and data analysis 66 
2.9. Thioredoxin assays 66 
2.9.2. Cell sample preparation 67 
2.9.3. Bicinchoninic acid (BCA) assay 68 
2.9.4. Assay protocol and data analysis 68 
2.10. Preparation of reduced thioredoxin (rTRX) 69 
viii 
 
2.11. Statistical analysis 69 
Chapter 3 - The role of T-type Ca2+ channels in cellular proliferation and [Ca2+]i 
mobilisation 
 
 
71-120 
3.1. Introduction 71 
3.2. Results 72 
3.2.1. Characterisation of CaV channels in A7r5 cells 72 
3.2.2. The effects of subtype specific CCBs on A7r5 proliferation and Ca2+  
handling 
 
86 
3.2.3. Effects of CaV3.1 and CaV3.2 expression on HEK293 cell 
proliferation and Ca2+ handling 
 
98 
3.2.4. Sub-cellular localisation of CaV3.1 and CaV3.2 within recombinant 
HEK293 cells 
 
101 
3.2.5. T-type Ca2+ channels facilitate the window current in recombinant 
HEK293 cells. 
 
107 
3.3. Discussion 111 
3.3.1. A7r5 cells express functional T- and L-type Ca2+  channels 111 
3.3.2. Potential expression of HVA T-type Ca2+ channel splice variants 113 
3.3.3. T-type Ca2+ channels regulate A7r5 proliferation. 114 
3.3.4. T- and L-type Ca2+ channels regulate basal and oscillatory Ca2+ 
levels within A7r5 cells 
 
115 
3.3.5. Recombinant expression of CaV3.1 and CaV3.2 increases cellular 
proliferation and window current. 
 
119 
3.3.6. Summary and conclusions 120 
Chapter 4 - The role of thioredoxin (Trx) in cellular proliferation and [Ca2+]i 
handling 
 
 
121-163 
4.1. Introduction 121 
4.2. Results 123 
ix 
 
4.2.1. Trx measurement within A7r5 and recombinant HEK293 cells 123 
4.2.2. The effects of Trx inhibitors on A7r5 cell viability and proliferation 128 
4.2.3. The effects of AuF on A7r5 Ca2+ handling 133 
4.2.4. Effects of Trx inhibitors on HEK293 cell viability and proliferation 138 
4.3. Discussion 148 
4.3.1. Comparison of methods for the quantification of endogenous Trx 
levels 
148 
4.3.2. High concentrations of Trx inhibitors induce cell death 152 
4.3.3. Low concentrations of Trx inhibitors selectively reduce cellular 
proliferation in CaV-expressing cells. 
 
155 
4.3.4. The potential for Trx as a T-type Ca2+ channel modulator 162 
4.3.5. Summary and conclusions 163 
Chapter 5 -The effects of thioredoxin (Trx) and inhibitors on voltage-gated Ca2+ 
(CaV) channels 
 
 
164-204 
5.1. Introduction 164 
5.2. Results 165 
5.2.1. The effects of Trx inhibitors on native and recombinant T-type Ca2+ 
currents 
 
165 
5.2.2. Mechanism of Trx-mediated CaV3.2 regulation 180 
5.3. Discussion 191 
5.3.1. Trx regulates CaV3.2 channels via an extracellular histidine residue 
at position 191 (His191) 
 
191 
5.3.2. PX-12 may inhibit CaV3.x channels via interaction with conserved 
cysteine residues 
 
196 
5.3.3. Potential interaction of Trx with CaV3.2 channel trace metal 
binding 
 
199 
  
x 
 
5.3.4. Summary and conclusions 204 
Chapter 6 - The implications of Trx-mediated CaV3.2 channel regulation on 
cellular proliferation 
 
 
205-213 
6.1. Principle findings 205 
6.1.1. HEK293 cells 205 
6.1.2. A7r5 cells 206 
6.2. Clinical significance 207 
6.2.1. Hypoxia-induced vascular remodelling 207 
6.2.2. MI-induced cardiac remodelling 209 
6.2.3. Cancer 211 
6.3. Summary and conclusion 212 
References  214-236 
  
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
Chapter 1 - Introduction 
This PhD project has explored the regulation of T-type Ca2+ channels by thioredoxin 
(Trx) and the potential significance of this modulation on vascular smooth muscle cell 
(VSMC) proliferation. The following introduction initially outlines a range of 
cardiovascular disorders associated with pathological VSMC proliferation. Central 
observations detail how increased levels of T-type Ca2+ channels and Trx have 
coincidentally been reported in numerous proliferative disorders. The established 
structure-function relationships, expression profiles and physiological roles of T-type 
Ca2+ channels and Trx are subsequently discussed in detail.  
 
1.1. Vascular smooth muscle cells (VSMCs) and blood vessels 
Within the human body, the walls of arteries and veins are composed of three layers. 
The outer tunica adventitia is made up of connective tissue, the central tunica media is 
comprised of VSMCs and structural proteins i.e. collagen and elastin, and the internal 
tunica intima is formed by endothelial cells. Compared to veins, the medial layer of 
arteries is considerably thicker, as summarised by Figure 1.1. This underpins the 
greater tensile strength and elasticity of arterial vessels. Capillaries are contrastingly 
made up of a single intimal layer supported by pericytes (Zhang & Wang, 2015). VSMCs 
typically align circumferentially within the medial layer of blood vessels and are also 
present within the walls of organs and bronchi. Typically 100µm x 5µm in size, 
differentiated VSMCs are spindle shaped in appearance. The contraction and 
relaxation of VSMCs underlies their primary function in the regulation of blood vessel 
diameter and correspondingly local blood flow (Matsumoto & Nagayama, 2012).  
 
VSMC function is heavily reliant on Ca2+ signalling which is influenced by numerous 
factors including Ca2+ influx via plasma membrane channels and also Ca2+ release from 
internal stores. Regarding contraction, depolarisation of the VSMC plasma membrane 
can activate voltage-gated L-type Ca2+ channels which facilitate Ca2+ influx and large 
increases in intracellular Ca2+ levels ([Ca2+]i). Subsequent activation of Ca
2+/calmodulin-
dependent myosin light chain kinase (MLCK) initiates VSMC contraction. Increases in 
[Ca2+]i also activates ryanodine receptors (RyR) on the surface of the sarcoplasmic 
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reticulum (SR), leading to Ca2+-induced Ca2+ release (CICR) and subplasmalemmal Ca2+ 
sparks. Activation of Ca2+-activated K+ channels can then repolarise the VSMC and 
enable blood vessel relaxation. Contraction of VSMCs occurs slowly and often tonically, 
which directly contrasts with the rapid contractile activities of cardiac myocytes, as 
reviewed (House et al., 2008).  
 
Excessive VSMC proliferation is a common pathological feature observed in a variety of 
cardiovascular disorders. VSMCs exhibit considerable phenotypic plasticity and readily 
dedifferentiate from their contractile phenotype in response to functional demand. 
There are several non-contractile phenotypes including proliferative, migratory and 
inflammatory VSMCs. This process of dedifferentiation is referred to as the 
“phenotypic switch” and is a key feature of normal blood vessel development and 
repair. Whilst adult VSMCs typically exhibit a stable contractile phenotype, in 
pathological conditions such as restenosis, hypertension and atherosclerosis, 
phenotypic switching is common. This often results in excessive VSMC proliferation 
and a narrowing of lumen diameter (Matchkov et al., 2012), as shown in Figure 1.1(B). 
The following section discusses the significance of pathological VSMC proliferation 
within the development of specific cardiovascular disorders.  
 
 
1.2. Phenotypic switching, VSMC proliferation and cardiovascular disorders 
1.2.1. Restenosis 
Restenosis is a common consequence of surgical vascular intervention, such as 
coronary artery bypass grafting. Arbitrarily defined as ≥50% narrowing of luminal 
vessel diameter, restenosis is characterised by increased VSMC proliferation and 
migration, growth factor release, platelet aggregation and inflammatory cell invasion. 
Vascular injury produces platelet deposition which release mitogenic factors and 
cytokines, such as platelet-derived growth factor (PDGF). This stimulates the 
phenotypic switch and subsequent VSMC proliferation and migration. Two weeks post-
injury, VSMCs can multiply 3-5 times resulting in neointima formation and luminal 
narrowing (Marx et al., 2011).  
.  
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Figure 1.1. Schematic diagrams showing blood vessel structure 
The walls of arteries and veins are made up of three layers: tunica adventitia (A), 
tunica media (M) and tunica intima (I). A, representative cross-sectional views of 
showing the thickness of layers within an artery, vein and capillary B, representation of 
the internal structure of an artery showing endothelial cells (ECs) within the intima on 
top of the basement membrane (BM), vascular smooth muscle cells (VSMCs) within 
the media and connective tissue comprising the adventitia. Dashed oval area highlights 
increased VSMC proliferation and subsequent narrowing of the lumen (L). Diagrams 
adapted from Clemmons (2007) and Lafleur et al, (2003). (Clemmons 2007; Lafleur et 
al., 2003) 
 
Quiescent or contractile VSMCs are maintained in the non-proliferative G0 phase of the 
cell-cycle. Following vascular injury, growth factors stimulate VSMCs to enter the G1 
gap phase, where factors are produced for DNA replication within the subsequent 
synthetic (S) phase. Cells then progress to the G2 gap-phase where protein synthesis 
occurs prior to mitosis (M phase). Restriction (R) phases, at the interfaces of G1-S and 
G2-M, enable the regulation of VSMC cell-cycle progression by various factors including 
cyclins and cyclin-dependent kinases (CDKs). Regarding VSMC migration, activation of 
cell-surface receptors initiates remodelling of the cytoskeleton, reduces matrix 
adhesiveness and activates motor proteins. As VSMC migration can only occur within 
the G1 phase of the cell-cycle, it is intimately associated with proliferation (Marx et al., 
2011).  
 
4 
 
Carotid artery ligation or wire injury is commonly used to induce neointima formation 
in animals, and provides an effective model of arterial stenosis. For example, wire 
injury of carotid arteries of mice led to increased VSMC proliferation and significant 
neointima formation 2 weeks post-surgery (Lindner et al., 1993; Tzeng et al., 2012). 
Immunohistochemical staining demonstrated that VSMCs were the primary cell type 
within the neointimal tissue. 5-Bromo-2′-deoxyuridine (BrdU) labelling further revealed 
that the neointimal VSMCs were proliferative (Tzeng et al., 2012). Interestingly, genetic 
knockdown of matrix metalloprotein-8 (MMP-8) within mice subjected to carotid wire 
injury significantly reduced VSMC proliferation and neointima formation. In vitro 
proliferation assays confirmed that VSMCs lacking MMP-8 exhibited slower 
proliferative rates and considerably less migration compared to controls (Xiao et al., 
2014).   
 
1.2.2. Atherosclerosis  
Atherosclerosis, an increasingly common chronic disease of the arterial wall, is a 
leading cause of death in the developed world (Barquera et al., 2015). Atherosclerotic 
remodelling of blood vessel walls is heavily reliant on the VSMC phenotypic switch. 
VSMCs can also transdifferentiate into macrophage- and chondrocyte-like cells which 
additionally contribute to atherosclerotic plaque formation. Whilst proliferative VSMCs 
of local origin are the major component in atherosclerotic plaques, circulating 
peripheral blood mononuclear cells can also transform into VSMCs (Martin et al., 
2009). Within the intima of arteries, oxidation of low-density lipoprotein (LDL) is 
thought to provide the initial atherogenic factor. Lectin-type oxidised LDL (ox-LDL) 
receptors type-1 (LOX-1) are the primary mediators of ox-LDL activity and are 
expressed by VSMCs and endothelial cells (ECs) (Pirillo et al., 2013). Within VSMCs, 
LOX-1 activation promotes the dedifferentiation of VSMCs to proliferative and 
migratory phenotypes (Liu et al., 2014). At higher concentrations, ox-LDL can also 
initiate VSMC apoptosis, which destabilises the plaque eventually leading to its 
rupture. Plaque rupture is a serious event which can lead to acute coronary events 
such as myocardial infarction (MI). Arterial branch points are highly susceptible to 
atherosclerotic plaque formation due to disturbed (i.e. non-laminar) blood flow, 
leading to shear stress and VSMC dedifferentiation. Whilst laminar blood flow down-
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regulates mitogenic factors, disturbed flow stimulates the vascular endothelium to 
secrete pro-inflammatory cytokines and adhesion molecules, such as interleukin-8 (IL-
8) and vascular cell adhesion molecule-1 (VCAM-1). Adhesion molecules attract 
monocytes which secrete interleukin-1β (IL-1β) and tumour necrosis factor-α (TNF-α). 
The VSMC phenotypic switch is subsequently activated. During the advancement of 
plaque formation localised plaque regions are subject to different patterns of shear 
stress. Specifically, high shear stress at the plaque cap can induce VSMC apoptosis and 
subsequent plaque rupture, whilst lower shear stress levels around plaque shoulders 
increases VSMC proliferation and correspondingly plaque size (Fan & Karino, 2010). It 
is also important to consider that changes in many other factors, including gene 
expression, basal lamina (BM) composition and VSMC calcification have also been 
found to influence atherosclerotic phenotypic switching of VSMCs, as reviewed 
(Chistiakov et al., 2015).  
 
Atherosclerosis is a multi-factorial disease involving accumulation of foam cells and 
formation of fatty streaks in addition to plaque formation. The disease is also 
associated with complications such as aneurysms, blood vessel calcification, 
thrombosis and stenosis. As such, the development of an effective animal model 
encompassing all of these features has proven challenging (Kapourchali et al., 2014). 
Apolipoprotein E (apoE) is a glycoprotein which is involved in the clearance of 
lipoproteins from the circulation. Correspondingly, although appearing healthy, apoE 
knockout (KO) (apoE-/- or apoE+/-) mice have increased circulating cholesterol and 
triglyceride levels, develop spontaneous foam-cell rich deposits within proximal aorta 
and show evidence of fatty streaks. Progressive occlusion of coronary arteries was also 
observed in these mice (Zhang et al., 1992). As such, apoE-deficient mice are routinely 
used to study the induction and prevention of atherosclerosis. For example, treatment 
of apoE-/- mice with S-adenosyl-homocysteine significantly increased VSMC 
proliferation and migration, leading to larger atheromatous plaque formation. These 
effects were attenuated by the antioxidant enzyme superoxide dismutase and thus 
confirmed a role for oxidative stress in the development of atherosclerosis (Luo et al., 
2012).  
 
6 
 
1.2.3. Aortic aneurysm  
Localised or diffuse dilation of the aorta to ≥50% normal diameter is classified as an 
aortic aneurysm. Aneurysms can occur throughout the body although aortic 
aneurysms are particularly common within the thoracic abdomen, where they are 
termed thoracic abdominal aortic aneurysms (TAAA). Upon diagnosis, TAAAs are 
generally asymptomatic however resultant acute aortic dissection can lead to 
peripheral malperfusion, cardiac tamponade, paraplegia, stoke and aortic regurgitation 
(Goldfinger et al., 2014). Correspondingly, TAAAs are associated with high mortality 
and morbidity rates, and are increasingly prevalent. The incidence and likelihood of 
TAAA rupture (i.e. aortic dissection) correlates with co-morbid atherosclerosis and 
hypertension. Generally, aneurysms involve all three layers of the blood vessel wall. 
TAAAs put considerable strain on the aorta and dissection occurs via intimal tearing. 
This leads to separation of the aortic wall and the false passage of blood. Increased 
activity of MMPs can induce matrix degradation and medial degeneration which 
correspondingly weakens and reduces the elasticity of the aorta, as reviewed (Zhang & 
Wang, 2015). The role of the VSMC phenotypic switch within aneurysm development 
was also recently explored in more detail. Rat TAAA was successfully induced by 
soaking sections of aorta with porcine pancreatic elastase (PPE). Significant thickening 
of the aortic wall around the site of PPE administration was found to correspond with 
VSMC phenotypic switching. This was evident by a decline in contractile VSMC markers 
such as α-smooth muscle cell actin (α-SMA) and smooth muscle myosin heavy chain 
(SM-MHC). An increase in proliferative markers such as MMP-2 was also observed. In 
addition, VSMCs isolated from TAAA rats proliferated at a significantly higher rate 
when compared to those isolated from control animals (Mao et al., 2015). As these 
pathological characteristics correlated closely with observations made in human 
thoracic aortic dissection (Wang et al., 2012), the PPE animal model of AAA was 
validated.    
 
1.2.4. Hypertension  
Isolated clinical hypertension is defined by persistently elevated blood pressure, with 
mean daytime ambulatory values > 135/85 mmHg (Cuspidi et al., 2007). Secondary 
hypertension is directly linked to a cause, such as renal disease or pheochromocytoma. 
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In contrast, essential hypertension accounts for approximately 90-95% of all 
hypertension cases, and is an insidious disease without an identifiable primary cause. 
Hypertension can lead to cardiac overload, aneurysms and organ damage. In patients 
with established hypertension, cardiac output remains unaltered whilst changes in 
total peripheral resistance (TPR) account for increases in blood pressure. In addition to 
functional changes (e.g. vascular tone), structural changes in resistance vessels 
resulting in luminal narrowing and increased intima/lumen ratios can contribute to 
increased TPR (Mulvany, 2012). Pulmonary hypertension (PH) relates to a group of 
individual conditions with differential causes, which share common hemodynamic 
dysfunction. Specifically, persistently elevated mean pulmonary arterial pressure leads 
to right ventricular (RV) overload, hypertrophic remodelling, RV failure and ultimately 
death (Bogaard et al., 2009). While PH is commonly secondary to an underlying 
condition, familial and idiopathic forms also exist. The majority of research into PH 
relates to pulmonary artery hypertension (PAH), which is characterised by sustained 
vasoconstriction and remodelling of pulmonary vessels. Remodelling is believed to 
occur in response to pulmonary artery EC (PAEC) death and dysfunction. This has been 
shown to trigger the proliferation and migration of pulmonary artery SMCs (PASMCs), 
fibroblasts and PAECs (Hassoun et al., 2009). Increased VSMC proliferation leads to a 
thickening of the medial layer of vessel walls and is accompanied by the formation of 
plexiform lesions and intimal fibrosis. This leads to the progressive obliteration of 
small-resistance pulmonary arteries and arterioles, a pathological hallmark of PAH 
(Vaillancourt et al., 2015). 
 
Current therapies aim to redress the functional effects of PH, for example by reducing 
vasoconstriction. The potential of targeting structural remodelling by reducing PASMC 
proliferation however, although suggested (Paulin et al., 2014), remains clinically 
unexplored. The validity of various animal models of PH is a widely debated topic. It is 
correspondingly suggested that reliable assessment of novel therapeutics should 
involve at least two different models. The most commonly used method to induce PH 
within mice and rats is by exposure to chronic hypoxia (CH) or injection of 
monocrotaline (MCT). Single-pathological-insult (SPI) models, such as the two 
mentioned above, can be combined to produce multiple-pathological-insult (MPI) 
models, which exhibit more severe PH phenotypes (Lawrie, 2014; Maarman et al., 
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2013). Specifically, exposure of mice to hypoxic conditions (10% O2 and 90% N2) for 4 
weeks increased VSMC proliferation leading to medial thickening of pulmonary 
arteries. This was accompanied by increased RV systolic pressure and an increased 
ratio weight of the right ventricle, compared to the left ventricle plus septum. This 
study revealed that cyclophilin A (CyPA), which is secreted by VSMCs under conditions 
of oxidative stress, promotes VSMC proliferation and plays a key role in the 
pathogenesis of PH (Satoh et al., 2014). An alternative study subjected mice to the 
hypoxia SPI model, and rats to MCT and Su5416 SPI models. Brain derived 
neurotrophic factor (BNDF) was found to promote PASMC proliferation in PH, in all 
three SPI models (Kwapiszewska et al., 2012).   
 
1.2.5. Diabetes  
One of the caveats when assessing the effects of hypertension on blood vessel lumen 
diameter in humans is that many hypertensive patients often also suffer from diabetes 
(Rizzoni et al., 2003). This is significant as diabetes itself is associated with pressure-
independent arterial remodelling. Type 2 diabetes mellitus (T2DM) is an increasingly 
common chronic metabolic and inflammatory disease which accelerates vascular 
aging. It also commonly leads to numerous other cardiovascular complications such as 
restenosis and atherosclerosis. A growing amount of evidence shows that the 
metabolic disturbances caused by dysregulated blood glucose alter the phenotype of 
VSMCs which contribute to the increased incidence of macrovascular complications. 
Endothelial damage is believed to be an early pathological event in pre-diabetic 
patients. In addition, EC abnormalities are also commonly observed in T2DM, as 
reviewed (Porter & Riches, 2013). When human VSMCs isolated from T2DM patients 
are cultured ex vivo and compared with VSMCs isolated from non-diabetic patients, 
significant alterations in VSMC morphology are observed. Specifically, T2DM VSMCs 
have a flattened rhomboid morphology in contrast to the elongated “hill and valley” 
spindle-shaped morphology, which typifies contractile VSMCs. In addition, T2DM 
VSMCs have significantly elevated proliferative rates and show considerably more 
migration and adhesion. Collectively, this indicates that T2DM stimulates the 
dedifferentiation of VSMCs (Faries et al., 2001).  
 
9 
 
There are numerous animal models of T2DM ranging from a leptin receptor mutant 
mouse (db/db), equivalent Zucker diabetic fatty (ZDF) rat model and diet-induced 
metabolic syndrome porcine models. These animal models have been shown to 
recapitulate many of the pathological features of T2DM, although to varying extents 
(Porter & Riches, 2013). Animal models of specific T2DM pathologies such as 
nephropathy (Betz & Conway, 2016), retinopathy (Jiang et al., 2015) and neuropathy 
(Gao & Zheng, 2014) are also commonly implemented. For example, an experimental 
study examined the aorta of ZDF and obese Zucker rats (an alternative metabolic 
T2DM model) and compared them against controls, i.e. lean Zucker rats. The anti-
proliferative effects of nitric oxide (NO) on aortic VSMCs isolated from T2DM rats were 
significantly greater than in controls. The degree of neointima formation induced by 
carotid artery wire injury was also far greater in T2DM rats (Ahanchi et al., 2008).  
 
To summarise, the dedifferentiation of VSMCs to a proliferative phenotype is a 
common pathology in a wide range of cardiovascular disorders which are associated 
with high degrees of mortality and morbidity. By developing a more detailed 
understanding of the mechanisms involved in phenotypic switching and elevated 
VSMC proliferation, the identification of much needed novel therapeutics may be 
possible.   
 
 
1.3. Voltage-gated Ca2+ (CaV) channels  
Considerable differences in [Ca2+]i dynamics between different VSMC phenotypes are 
well established. Specifically, dedifferentiated VSMCs exhibit Ca2+ handling responses 
more typical of non-excitable cells such as sustained elevations in basal [Ca2+]i (House 
et al., 2008). Of significant interest to the current investigation is that dramatic 
changes in voltage-gated Ca2+ (CaV) channel expression are observed in proliferating 
VSMCs. Principally, a sharp decline in L-type CaV channels which mediate VSMC 
contraction, and a corresponding increase in T-type CaV channels which are believed to 
be crucial for cell-cycle progression (Kuga et al., 1996).  
 
In addition to being expressed in the majority of excitable cells, CaV channels are also 
present within the VSMC membrane. Activated by membrane depolarisation, CaV 
10 
 
channels facilitate Ca2+ influx which can stimulate a wide variety of cellular processes. 
As such, Ca2+ can function as a second messenger to electrical signalling. Within 
mammalian cells there are 10 subtypes of CaV channels which serve distinct roles in 
signal transduction. CaV channels are broadly categorised into two groups, high-voltage 
activated (HVA) and low-voltage activated (LVA). Biochemical, molecular cloning and 
co-expression studies have shown that HVA CaV channels are heteromeric protein 
complexes, which require the co-assembly of pore forming α1 subunits with auxiliary β, 
α2δ and γ subunits. In contrast, LVA channels are rendered fully functional by 
expression of a single α1 subunit, although auxiliary subunits may alter LVA channel 
trafficking (Catterall, 2011). 
 
1.3.1.   Structure-function relationships of CaV channels 
The α1 subunit is the key determinant of the CaV subtype. HVA channels include: L-type 
(CaV1.1-1.4), P- or Q-type (CaV2.1), N-type (CaV2.2) and R-type (CaV2.3) CaV channels. 
LVA channels or T-type Ca2+ channels facilitate tiny transient currents. Three distinct T-
type isoforms (CaV3.1-3.3) have been identified, which are encoded by separate α1 
subunits (α1G, α1H and α1I respectively). Key differences between LVA and HVA 
channels is that T-type Ca2+ channels are activated at relatively lower voltages, and 
inactivate over a shorter time period at comparatively lower membrane potentials, as 
reviewed extensively (Catterall, 2011; Perez-Reyes, 1999; Perez-Reyes, 2006; Simms & 
Zamponi, 2014).  
 
Mammalian α1 subunits are comprised of approximately 2000 amino acids and share a 
common membrane topology predicted to be similar to that of voltage-gated Na+ (NaV) 
channels. As illustrated by Figure 1.2 (A), α1 subunits are arranged into four domains 
(DI-DIV) which are each made up of 6 transmembrane segments (S1-S6). DI-DIV 
arrange in a clockwise manner within the lipid bilayer to form the 3D α1 subunit 
structure (Figure 1.2 (B)). A key feature within each domain is the charged S4 segment 
which controls voltage-dependent activation. The S4 segment is believed to physically 
orientate within the centre of each domain. It is thought that S4 segments slide 
upwards upon depolarisation to open the CaV channel. Conversely, upon repolarisation 
downward movement of S4 segments may close CaV channels. A further notable 
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feature is the P-loop, which forms between S5-S6 of each domain. The pore loops 
project to the centre of the channel to form a selectivity filter, which provides the ion 
permeation pathway (Figure 1.2 (B)). Highly conserved, negatively charged amino acid 
residues within the P-loop impart a high degree of Ca2+ selectivity. Within HVA 
channels, this sequence is composed of four Glu residues (EEEE), whereas aspartic acid 
residues also contribute to the selectivity filter of T-type Ca2+ channels (EEDD). The 
four domains of the α1 subunit are connected by large cytoplasmic linker regions. The 
N- and C-termini, linked to DI and DIV respectively, are both cytoplasmic. The greatest 
amount of sequence variation between CaV subtypes is observed within cytoplasmic 
regions. Specifically, within the large repeats joining DI-DII and DII-DIII and within the 
relatively smaller linker region between DIII-DIV, Illustrated in Figure 1.2(A). Within 
HVA channels, these regions provide an important contact site for regulatory proteins 
and auxiliary subunits. In contrast with LVA channels, the expression of auxiliary 
subunits is crucial for membrane trafficking and the overall biophysical properties of 
HVA channels (Perez-Reyes, 1999).   
 
Prolonged depolarisation of the plasma membrane can result in Ca2+ overload, 
therefore most CaV channels possess both Ca
2+- and voltage-dependent inactivation 
mechanisms. The extent of voltage-dependent inactivation (VDI) varies drastically 
between different CaV subtypes. For HVA channels, VDI involves structural re-
arrangement of S6 segments to expose a docking site within the DI-DII linker region. 
VDI of HVA channels is also profoundly influenced by β subunit expression. Compared 
to HVA channels, T-type Ca2+ channels show considerably more VDI, predicted to 
involve the DIII-DIV cytoplasmic linker region acting as an inactivation particle. It is 
important to emphasise that resolution of the crystal structure of CaV channels will 
ultimately be required to fully determine structure-function relationships (Simms & 
Zamponi, 2014).    
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Figure 1.2. Schematic diagrams showing the structure of the CaV channel α1 subunit 
All mammalian α1 subunits share a similar membrane topology; i.e. four repeated 
domains (DI-DIV), each made up of 6 transmembrane segments (S1-S6). Views as 
though: (A, C) looking through a cross-section of a stretched lipid bilayer and (D, E) 
looking down on the channel from outside the cell. A, Snake-diagram showing the 
arrangement of the α1 subunit within the lipid bilayer (orange box), DII is highlighted 
(blue box) and magnified in C. B, 3-dimesional (3D) representation of the predicted 
arrangement of DI-DIV, with pore loops angling towards the centre of the channel, DII 
is highlighted (blue box) and magnified in D. C, 2D structure of a single α1 subunit 
domain (DII) magnified from (A), showing the S4 voltage-sensor (red hatched lines) and 
the pore loop between S5-S6, as labelled. Diagrams adapted from Perez-Reyes (1999).  
 
 
1.3.2. T-type Ca2+ channels: three distinct isoforms 
The expression of T-type Ca2+ (CaV3.x) channels has been identified in a number of 
species, ranging from humans to snails. By comparing the amino acid sequences of 
CaV3.x channels isolated from human, cow, dog, rat and mice, several isoform specific 
differences are apparent. Between the five aforementioned species, CaV3.1 channels 
show the highest degree of sequence homology (90-95%), CaV3.2 channels show the 
lowest (70-80%) and CaV3.3 channels show an intermediate degree (85-90%). A high 
degree of evolutionary conservation indicates that CaV3.1 channels serve crucial 
physiological roles. Conversely, the lower degree of evolutionary conservation 
between CaV3.2 channels predicts that these channels have more diverse modulatory 
functions (Perez-Reyes, 2006).   
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In order to isolate T-type Ca2+ currents from native tissues, a major goal has been to 
identify specific pharmacological T-type Ca2+ channel blockers (CCBs). An early 
electrophysiological study conducted in rabbit sinoatrial (SA) node myocytes revealed 
that LVA currents were inhibited by Ni2+ (40µM), which was without effect on HVA 
currents (Hagiwara et al., 1988). However, subsequent studies have noted 
considerable variation in the level of Ni2+-sensitivity of LVA channels recorded from 
different tissues. Providing an extreme example, LVA currents recorded from rat clonal 
pituitary (GH3) cells showed Ni2+-sensitivity comparable to HVA currents (IC50 of 
777µM) (Herrington & Lingle, 1992). Further investigation using recombinant 
expression systems revealed considerable differences in CaV3.x isoform sensitivity. 
Specifically, when expressed in HEK293 cells, CaV3.2 channels were inhibited by 
significantly lower Ni2+ concentrations (IC50 of 13µM) when compared to CaV3.1 and 
CaV3.3 channels (IC50 values of 250µM and 216µM respectively) (Lee et al., 1999). As 
such, the differential Ni2+-sensitivity of LVA currents recorded in native tissues is 
attributable to differential CaV3.x channel isoform expression profiles.  
 
A variety of preceding investigations generated chimeric CaV3.x channels, whereby 
individual domains of the CaV3.2 channel were substituted with equivalent domains 
from an alternative CaV3.x isoform. In combination with site-directed mutagenesis, 
these studies revealed a unique metal binding site within DII of the CaV3.2 channel, 
composed of an Asp-Gly-His (D189, G190, H191) motif within the extracellular S3-S4 
loop. An additional Asp residue (D140) on the extracellular surface of S2 was also 
found to participate. This high affinity binding site was subsequently found to mediate 
the binding of endogenous trace metals such as zinc (Zn2+). Interestingly, Zn2+ is 
thought to bind tonically to CaV3.2 channels in an isoform-specific manner (Kang et al., 
2006; Kang et al., 2010; Nelson et al., 2007b). Trace metal binding at this unique site is 
believed to stabilise CaV3.2 channels in their closed state, as reviewed (Perez-Reyes & 
Lee, 2014).  
 
A further distinguishing feature of CaV3.2 channels is their unique sensitivity to redox 
modulators. This is highlighted by the observation that both native and recombinant 
CaV3.2 channels are selectively inhibited by ascorbate, whilst CaV3.1 and CaV3.3 
channels are relatively insensitive (Nelson et al., 2007a). Ascorbate is an endogenous 
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redox agent which can function as both an anti- and pro-oxidant. Regarding its 
functions as a pro-oxidant, ascorbate can reduce transition metals such as iron and 
copper to generate reactive oxygen species including  hydroxyl radicals (OH-), via a 
process termed metal-catalysed oxidation (MCO) (Stadtman, 1991). Interestingly, the 
His191 residue which forms part of the CaV3.2 unique metal binding site has been 
shown to mediate the inhibitory effects of ascorbate on CaV3.2 activity. This indicates 
that ascorbate may inhibit CaV3.2 channels by interacting with metal contaminants 
bound to the metal binding site and/or by initiating MCO (Nelson et al., 2007a).  
 
Remarkably, ascorbate, Ni2+ and Zn2+ are the most isoform specific T-type Ca2+ channel 
inhibitors currently available. Ni2+ is still occasionally used to differentiate between LVA 
and HVA channels, although subtype specific pharmacological CCBs are more typically 
used for this purpose. Mibefradil is a widely used T-type CCB which was originally 
named Ro 40-5967 and previously licensed as an anti-hypertensive drug. Its potent 
inhibition of T-type Ca2+ channels (IC50 =100nM) was first described in primary cultures 
of neonatal rat azygos VSMCs, although at higher concentrations (10µM) inhibition of  
L-type Ca2+ currents (66%) was also observed (Mishra & Hermsmeyer, 1994). 
Subsequent studies have shown that a metabolite of mibefradil accounts for its non-
specific inhibition of HVA channels (Bezprozvanny & Tsien, 1995; Wu et al., 2000). 
NNC55-0396 (NNC) is a structural analogue of mibefradil which is considerably more 
stable, and is not readily metabolised. As such, NNC was shown to inhibit T-type Ca2+ 
channels whilst having no effect on HVA channels expressed by pancreatic β (INS-1) 
cells when applied at 10-fold greater concentrations (Li et al., 2005). Nifedipine 
belongs to a family of drugs called dihydropyridines (DHPs), which are highly selective 
L-type CCBs. The high selectivity arises as the pore forming α1C subunit of L-type Ca
2+ 
channels has a unique high affinity DHP binding site involving IIIS6 and IVS6 
transmembrane segments (Peterson et al., 1996). In rat arterial smooth muscle cells, 
nifedipine (300nM) was shown to selectively inhibit L-type Ca2+ currents and thus 
enabled successful T-type Ca2+ current isolation (Abd El-Rahman et al., 2013).  
 
Before discussing the kinetic features of CaV3.x channels in detail, it is important to 
define the terminology used to describe ion channel gating in general. Depolarisation 
can stimulate ion channels in their resting state to open, which is referred to as 
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channel activation. A feature of CaV3.x channels is that, similar to NaV channels, they 
rapidly inactivate (close) during a depolarising stimulus. Removal of depolarisation and 
the return to lower (more hyperpolarized) membrane potential allows any channels 
that were still open to close – this process is called deactivation. Furthermore, 
hyperpolarisation enables recovery from inactivation, allowing channels to return to 
their resting state. Recombinant expression of CaV3.x channels produces robust 
currents, with kinetics which are virtually identical to their equivalent, native 
counterparts. Figure 1.3, shows an example CaV3.2 current trace recorded from a 
HEK293 stably-expressing CaV3.2 channels. Importantly, CaV3.x currents both activate 
and inactivate at low voltages, recover rapidly from inactivation and deactivate slowly 
leading to prominent tail currents (Perez-Reyes, 2003).  
 
All three CaV3.x channels begin to activate at approximately -70mV however as their 
current kinetics are highly voltage-dependent, variable current shapes are produced by 
small depolarisations. This is highlighted by the characteristic criss-cross pattern of 
traces evoked by current-voltage (I-V) protocols. As such, when comparing the kinetics 
of CaV3.x isoforms it is useful to examine currents stimulated by relatively higher 
voltages (e.g. -10mV). Depolarisation to -10mV causes rapid activation of CaV3.1 and 
CaV3.2 channels (τ = 1-2ms), alongside relatively slower inactivation (τ = 10-16ms). 
Significantly, CaV3.3 channels activate and inactivate much more slowly when 
compared to CaV3.1 and CaV3.2 channels. Despite differences in inactivation rates, 
steady-state inactivation when measured by applying pre-pulses of varying potentials 
prior to the test pulse (e.g. -30mV), is similar for all CaV3.x channels (Klockner et al., 
1999; Perez-Reyes 2003). Interestingly, the generalised half-maximal steady-state 
inactivation voltage of -72mV indicates that CaV3.x channels can inactivate without 
passing through their open state. Regarding CaV3.3 channels, up to 30% of channels 
have been shown to inactivate without opening during a depolarising pulse (Frazier et 
al., 2001).  Recovery from inactivation of CaV3.x channels is rapid, with CaV3.1 channels 
showing the fastest deinactivation and CaV3.2 channels showing the slowest (Klockner 
et al., 1999). This feature is particularly important for the physiological roles of T-type 
Ca2+ channels in rapid oscillatory activity. Finally, when compared to HVA channels 
CaV3.x channels deactivate (or close) more slowly (10-fold difference), which accounts 
for their prominent tail currents. Specifically, CaV3.3 channels display the quickest 
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deactivation (τ = 1ms), with CaV3.1 channels exhibiting the slowest (τ = 3ms) (Klockner 
et al., 1999; Perez-Reyes, 2003).  
. 
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Figure 1.3. T-type Ca2+ channel gating parameters  
Example CaV3.2 current trace recorded using whole-cell patch-clamp 
electrophysiology, evoked by 200ms step-depolarisations from -80 to -20mV. The 
depolarising pulse opens the channel (activation), the channel then closes in the 
continued presence of the depolarising pulse (inactivation). Removal of depolarisation 
allows the channel to return to its closed resting state (deactivation). Scale bar 200pA, 
40ms.  
 
 
As CaV3.x channel activation and inactivation is observed at similar, relatively low 
voltages, T-type Ca2+ channels can open without fully inactivating. This can produce a 
“window current”, i.e. tonic Ca2+ influx at resting membrane potentials. Specifically, 
window current is defined as the overlap between voltage-dependent activation and 
steady-state inactivation curves, as illustrated in Figure 1.4. As electrophysiological 
protocols predict that T-type Ca2+ channels facilitate a window current at or around 
the resting membrane potential (Vm), CaV3.x channels can be crucial mediators of 
intracellular Ca2+ concentration [Ca2+]i. All three CaV3.x isoforms are predicted to 
mediate window current which is predicted to be facilitated by approximately 1% of 
channels (Perez-Reyes, 2003). As such, recombinant expression of CaV3.1 or CaV3.2 
channels in HEK293 cells produced observable window currents which correspondingly 
resulted in a significant elevation in basal [Ca2+]i (Chemin et al., 2000).            
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Figure 1.4. T-type Ca2+ channels can facilitate a window current 
Schematic diagram showing the voltage-dependence of activation (m, squares) and 
steady-state inactivation (h, circles) of CaV3.2  channels, plotted as % of maximal 
current (ICa2+). Curves represent Boltzmann fits to activation and inactivation. Overlap 
between curves predicts the window current, as highlighted by the pink shaded region. 
Diagram reproduced with permission from data previously gathered by Prof Chris 
Peers (Fearon et al., 2000).  
 
 
 
 
 
1.4. Isoform specific expression and physiological roles of CaV3.x channels  
T-type Ca2+ channel expression has been observed in many areas of the body including 
the heart, kidneys, smooth muscle, endocrine tissues and nervous systems. 
Interestingly, many of the physiological roles of CaV3.x channels within these areas 
concerns their ability to facilitate window currents, as reviewed (Perez-Reyes, 2003). 
This following section will outline some of the characterised expression profiles of 
CaV3.x channels and their associated functions within various areas. It should be noted 
that this summary is not an exhaustive list; a few examples have been selected to 
emphasise the range of physiological functions of T-type Ca2+ channels.  
 
1.4.1. Peripheral and central nervous system  
Due to their potential involvement in pathological brain disorders such as epilepsy, the 
expression and physiological roles of CaV3.x channels within the CNS has been studied 
extensively. Specifically, in situ hybridisation has revealed that CaV3.x channel mRNA 
expression shows unique and largely complementary patterns of distribution within 
the peripheral and central nervous systems (PNS and CNS respectively). Many regions 
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including the cerebral cortex, brainstem and thalamic relay neurons primarily 
expressed CaV3.1 channels. In contrast, dentate gyrus granule neurons and pituitary 
cells expressed CaV3.2 in isolation. In some areas such as the subthalamic nuclei and 
olfactory tubercles CaV3.1 co-localised with CaV3.2 channels. Similarly, CaV3.2 co-
localised with CaV3.3 channels in thalamic reticular neurons. Expression of all three 
CaV3.x isoforms, at similar levels, was demonstrated in areas including the 
hippocampus, caudal hypothalamus and olfactory granule cells (Talley et al., 1999).  
 
Regarding the PNS, CaV3.2 was shown to be the most predominantly expressed 
isoform. CaV3.2 channels were identified within the dorsal root ganglia (DRG), nodose 
ganglia, pituitary and pineal glands. Contrastingly, co-expression of CaV3.3 and CaV3.2 
channels was observed in the DRG, whilst the superior cervical ganglia expressed low 
levels of CaV3.1 mRNA in isolation (Talley et al., 1999). Subsequent studies have also 
revealed differential patterns of CaV3.x channel distribution between dendritic, axonal 
and somatic neuronal compartments (McKay et al., 2006). These studies collectively 
indicate that the physiological roles of CaV3.x channels within the CNS are highly 
complex.  
 
Due to differential patterns of T-type Ca2+ channel isoform expression within different 
brain regions, neuronal subtypes and compartments, the repertoire of the effects of 
LVA Ca2+ channels on cellular excitability is vast. Within some neuronal populations 
activation of CaV3.x channels at low voltages can produce low-threshold Ca
2+ spikes 
(LTCS), leading to the recruitment of NaV channels and burst action potential (AP) firing 
(Powell et al., 2014). Conclusive proof that T-type Ca2+ channels mediate LTCSs and 
correspondingly lead to burst AP firing, is provided by a study which used CaV3.1 KO 
(CaV3.1
-/-) mice. Thalamocortical relay (TCR) neurons play a key role in coordinating 
network activity and exhibit burst AP firing patterns. TCR neurons in CaV3.1
-/- mice 
were found to lack LTCSs and burst AP firing, although tonic AP firing patterns were 
preserved. Furthermore, CaV3.1
-/- mice were largely resistant to spike-and-wave 
discharges, which are characteristic of epileptic absence seizures, stimulated by GABAB 
receptor agonists. It was resultantly shown that CaV3.1 channels within the 
thalamocortical pathways are mediators of epileptogenesis (Kim et al., 2001). LTCSs 
facilitated by CaV3.x channels are believed to be central to their physiological roles in 
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controlling pacemaker activity. Due to the prominent voltage-dependency of CaV3.x 
channel recovery from inactivation, LTCSs are generally activated by hyperpolarising, 
as opposed to depolarising stimulation. LTCSs induce depolarisation leading to NaV and 
KV channel activation and high frequency APs. HVA CaV channels, and subsequently 
Ca2+-activated K+ channels, activate leading to afterhyperpolarisation (AHP). The AHP 
allows CaV3.x channels to deinactivate and the membrane potential returns back to 
resting levels (Perez-Reyes, 2003).  
 
As reviewed by Powell et al., (2014), T-type Ca2+ channels are further implicated in 
hypersynchronous oscillatory activity within thalamocortical neurons in generalised 
absence epilepsy (GAE); and also in the burst firing activity of hippocampal neurons 
associated with temporal lobe epilepsy (TLE). For example, genetic mutations in CaV3.2 
channels have been detected in patients with genetic and childhood GAEs. These 
mutations typically lead to alterations in CaV3.2 surface expression and channel 
kinetics, and ultimately result in neuronal hyperexcitability (Chen et al., 2003b; Heron 
et al., 2007; Vitko et al., 2005). Additionally, the Genetic Absence Epilepsy Rats from 
Strasbourg (GAERS) express a gain-of-function CaV3.2 channel splice variant, and 
correspondingly provide a valuable animal model of GAE. The GAERS splice variant 
arises from a single-point mutation of an arginine residue found within the intracellular 
DIII-DIV linker region of CaV3.2 channels (Powell et al., 2009). In the GAERS model, 
CaV3.2 expression and LVA current amplitude within reticular thalamic nuclei is 
dramatically increased when compared to seizure free animals. Interestingly, as the 
increases in LVA current density were larger than the increases in CaV3.2 mRNA, 
evidence for elevated CaV3.2 membrane trafficking is provided (Tsakiridou et al., 
1995).  
 
1.4.2. Heart  
Whilst CaV3.3 channel expression is generally restricted to the nervous system, CaV3.1 
and CaV3.2 channels are also prominently expressed within the cardiovascular system. 
Within the heart, the physiological role of T-type Ca2+ channels has been explored with 
a particular emphasis on pacemaker activity. Whilst CaV3.x channels are generally 
lacking from adult ventricular myocytes, they are heavily expressed within pacemaker 
20 
 
and conduction cells, particularly in the sinoatrial (SA) node. In the human SA node, 
CaV3.1 is predominantly expressed (Chandler et al., 2009). However, in the murine SA 
node, CaV3.2 channels have also been shown to be expressed alongside CaV3.1 
channels (Bohn et al., 2000). The SA node is the primary rhythmogenic centre of the 
heart and thus regulates myogenic contractility. Pacemaker activities of SA myocytes 
are dependent on the expression of a plethora of ion channels, including CaV and 
hyperpolarisation-activated cyclic-nucleotide-gated 4 (HCN4) channels. At maximal 
diastolic membrane potentials, T-type Ca2+ channels exhibit stable steady-state 
availability which can result in a window current. This contributes to pacemaker 
activity in a manner similar to that described within the CNS. CaV3.x-mediated Ca
2+ 
currents have also been detected within other components of the heart conduction 
system including the atrioventricular (AV) node and Purkinje fibres, as reviewed 
(Mesirca et al., 2014). Whilst the complete physiological contribution of T-type Ca2+ 
channels to cardiac pacemaker activity remains to be fully elucidated within humans, 
KO mouse models have provided some valuable insights. For example, in CaV3.1
-/-/ 
CaV1.3
-/- double KO mice almost complete AV block was observed which resulted is 
dissociated atrial and ventricular rhythms. The myogenic nature of SA node myocyte 
activity was also considerably reduced within CaV3.1
-/-/ CaV1.3
-/- mice (Marger et al., 
2011).  
 
Expression of CaV3.1 and CaV3.2 channels within cardiac myocytes, outside of the 
primary conduction system, is most apparent at birth and gradually declines with age. 
However, in some pathological conditions such as cardiac hypertrophy T-type Ca2+ 
channel re-expression is observed (Martinez et al., 1999; Swynghedauw, 1999). 
Specifically, in rats, cardiac hypertrophy initiated by myocardial infarction increased 
CaV3.1 mRNA expression in viable left ventricular myocytes. Functional upregulation of 
CaV3.2 channels was also observed as an increased sensitivity of LVA currents to Ni
2+ 
(Elvan, 2000). As hypertrophic ventricular modelling involves myocyte proliferation, 
this observation may bear significance to the role of T-type Ca2+ channels in the 
regulation of cell-cycle progression, as subsequently discussed (section 1.5).  
 
A role of CaV3.2 channels within hypertrophic cardiac remodelling has also been 
ascertained from studies using KO mice. Although expressed developmentally, T-type 
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Ca2+ channel expression is typically absent within adult ventricular myocytes. 
Significantly, T-type Ca2+ channels are re-expressed following myocardial infarction 
which subsequently results in pathological hypertrophy (Huang et al., 2000; Izumi et 
al., 2003). Within wt and Cav3.1
-/- mice, cardiac hypertrophy could be induced by 
pressure overload, which was achieved by aortic banding or exposure to angiotensin II. 
In stark contrast, pressure- and angiotensin II-induced hypertrophy was suppressed in 
Cav3.2
-/- mice. Following aortic banding, the thickness of ventricular walls and also the 
cross sectional diameter of myocytes was significantly increased in wt mice but not in 
Cav3.2
-/- mice. As there were no apparent differences in blood pressure between wt 
and CaV3.2 mice, stong evidence that CaV3.2 channels contribute to pathological 
cardiac remodelling was therefore provided (Chiang et al., 2009).  
 
A final physiological role for atrial T-type Ca2+ channels is in the secretion of atrial 
natriuretic factor (ANF). ANF is a hormone which inhibits the release of renin, 
aldosterone and vasopressin. In addition to the diuretic and natriuretic effects on the 
kidney, ANF has vasodilatory effects (Inagami. 1989). Ca2+ currents recorded from 
atrial and ventricular myocytes freshly dissociated from 8-day old rats have been 
shown to be facilitated by both L-type (CaV1.2) and T-type (CaV3.1 and CaV3.2) Ca
2+ 
channels. The predominant current species within atrial myocytes was LVA. 
Concurrently, ANF secretion evoked in 8-day old rats by small depolarisations was 
almost completely abolished by mibefradil (1µM). Evidence that ANF secretion by 
atrial myocytes is, at least partially, dependent on CaV3.x channels is thus provided. 
Consistent with previous reports, comparison of current density between young and 
adult rats revealed a progressive decline in functional T-type Ca2+ channels in atrial 
myocytes alongside a complete disappearance within ventricular myocytes 
(Leuranguer et al., 2000).  
 
1.4.3. Endocrine tissue  
The role of T-type Ca2+ channels in hormone secretion is not restricted to atrial cells 
but is also applicable to adrenal, pituitary and pancreatic tissues. Within rat and bovine 
adrenal glands, CaV3.2 channels are the primary CaV3.x isoform. This was shown by 
both in situ hybridisation and the high Ni2+-sensitivity of LVA currents recorded from 
22 
 
both glomerulosa (Schrier et al., 2001) and fasciculata (Mlinar et al., 1993) cells. In 
adrenal glomerulosa cells, which also express HVA CaV channels, rises in extracellular 
K+ concentrations can activate T-type Ca2+ channels leading to Ca2+-dependent APs and 
the synthesis and release of aldosterone. Similarly, in adrenal fasciculata cells, 
depolarisation induced by adrenocorticotropic hormone (ACTH) activates T-type Ca2+ 
channels leading to the synthesis and release of cortisol. It has correspondingly been 
suggested that CaV3.2 channels play important roles in stimulus-secretion activity, as 
reviewed (Perez-Reyes, 2003).  
 
Pituitary cells are capable of generating LTCS and spontaneous APs which result in 
growth hormone secretion (Tomic et al., 1999). The expression of all three CaV3.x 
isoforms has been shown in pituitary tissue, with CaV3.2 channels being predominant 
(Talley et al., 1999). The link between T-type Ca2+ channels, pacemaker activity and 
hormone secretion is similarly applicable to insulin secretion by pancreatic β-cells. 
Specifically, elevation of glucose levels increases ATP concentrations which results in 
the closure of ATP-gated K+ channels. This can lead to the activation of T-type Ca2+ 
channels and high frequency Ca2+-dependent spikes, as reviewed (Satin, 2000). 
Interestingly, the expression profiles of CaV3.x channels in pancreatic β-cells shows 
considerable species variation. For example, whilst T-type Ca2+ channel currents are 
prominent within human pancreatic β-cells (Barnett et al., 1995), T-type Ca2+ channel 
currents in the equivalent cells of mice are only detectable upon IL-1β pre-treatment 
(Wang et al., 1999).  
 
1.4.4. Blood vessels and VSMCs  
The expression of CaV3.1 and CaV3.2 channels has been demonstrated within a variety 
of blood vessels including the cerebral, mesenteric and renal microcirculations, as 
reviewed (Kuo et al., 2011). As previously detailed, differentiated VSMCs primarily 
express L-type CaV channels which facilitate the Ca
2+ influx required for VSMC 
contraction. In addition to prominent L-type HVA currents, LVA currents have also 
been detected within VSMCs isolated from veins, arteries and organs. Prior to the 
molecular cloning of CaV3.x channels it was difficult to confirm conclusively that LVA 
currents were mediated by T-type Ca2+ channels. This was largely due to the fact that 
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LVA currents recorded from VSMCs are tiny, necessitating the use of very high 
concentrations of charge carriers. Importantly, this can shift current-voltage activation 
profiles to more positive potentials, which can be misleading when identifying LVA 
channels (Perez-Reyes, 2003). As a further complication, HVA P-type (CaV2.1) Ca
2+ 
channel expression has also been identified in VSMCs isolated from rat aortic and renal 
preglomerular resistance vessels and in the rat thoracic aorta VSMC cell line (A7r5). P-
type Ca2+ channels inactivate at similar voltages to LVA currents and are also inhibited 
by mibefradil. Electrophysiological studies have further indicated that functional P-
type Ca2+ channels can contribute to depolarisation-induced contraction, particularly 
within renal afferent arterioles (Hansen et al., 2000).  
 
Subsequent studies have revealed that both CaV3.1 and CaV3.2 channels are expressed, 
in addition to CaV1.2 (L-type) channels, within renal blood vessels. In rats, regions of 
expression included pre- and post-glomerular resistance vessels and juxtamedullary 
efferent arterioles. Ca2+ imaging of rabbit afferent and rat juxtamedullary efferent 
arterioles revealed that exposure to high K+ concentrations induced rises in [Ca2+]i. This 
response could be partially inhibited by the T-type CCB mibefradil (100nM) or the L-
type selective CCB calciseptine (Hansen et al., 2001). It was further demonstrated that 
K+-induced contraction of rabbit afferent arterioles could be completely abolished by 
mibefradil (1µM), Ni2+ (1mM) and calciseptine (10pM). In contrast, no CaV channel 
expression was observed in cortical efferent arterioles. Furthermore, K+-induced rises 
in [Ca2+]i within rabbit cortical efferent arterioles were considerably smaller than those 
observed in other vessels, and unaltered by CCBs. These data indicate that CaV3.1, 
CaV3.2 and CaV1.2 channel expression is functionally important for the contraction of 
certain renal blood vessels (Hansen et al., 2001).  
 
The contribution of T- and L-type Ca2+ channels to vasomotor function has also been 
compared between segments of the large thoracic aortic and small mesenteric vessels. 
Within rat aorta, CaV3.1, CaV3.2 and CaV1.2 channels were abundantly expressed in 
equal amounts. Within rat mesenteric resistance vessels however, the expression of 
CaV3.1 and CaV3.2 channels was considerably greater than that of CaV1.2 channels (Ball 
et al., 2009). Vasomotor function was subsequently assessed using wire myograph 
recordings. Contraction was stimulated, in the presence or absence of various CCBs, by 
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exposure to increased K+ concentrations or to endothelin-1 (Et-1). In order to assess 
the contribution of ECs to the effects of CCBs, the contractile response of denuded 
vessels was also examined. Within intact segments, endothelial integrity was observed 
by inhibition of contractile responses (≥80%) upon application of the endothelium-
dependent vasodilators, bradykinin (BK) or acetylcholine (ACh), to human and rat 
vessels respectively. Regarding the CCBs applied, verapamil (1µM) and nifedipine 
(1µM) were used as selective L-type CCBs. Efonidipine (21nM) and mibefradil (1µM), 
referred to as combined CCBs, were applied with the purpose of inhibiting both L- and 
T-type Ca2+ channels (Ball et al., 2009). An important consideration is that previous 
studies have shown that when applied for similar time periods as used by Ball et al., 
(2009), mibefradil (1µM) selectively inhibits vascular T-type Ca2+ currents but is 
without effect on L-type Ca2+ currents (Brueggemann et al., 2005). Contrastingly, when 
applied as a mixture of its R(-) and S(+) enantiomers, efonidipine inhibits recombinant 
L- and T-type Ca2+ channels with similar potencies, without significant effect on other 
HVA channel subtypes (Furukawa et al., 2004). As such, the classification of combined 
CCB within the study accurately describes efonidipine, but arguably not mibefradil. As 
an interesting side note, the isolated R(-) enantiomer of efonidipine has been found to 
preferentially inhibit T-type over L-type Ca2+ channels (Furukawa et al., 2004). 
 
Pre-treatment with each of the four CCBs was found to inhibit Et-1-induced contractile 
responses to similar extents within intact (i.e. endothelium present) rat aortic 
segments. In comparison to L-type specific CCBs, efonidipine and mibefradil were 
significantly more effective at inhibiting the contractile responses of intact and 
denuded rat and human mesenteric microvessels. As the contribution of ECs to CCB 
responses was ruled out, VSMC Ca2+ channel expression is implicated. It was also 
shown within rat microvessels that efonidipine produced further inhibition of 
contractile responses, proceeding maximal nifedipine- or verapamil-mediated 
inhibition. Collectively, these findings show that T-type Ca2+ channels contribute 
considerably to the vascular responses of small mesenteric blood vessels, and also to a 
lesser extent within the aorta (Ball et al., 2009).  
 
Alternative studies have confirmed that CaV channels expressed by VSMCs contribute 
to vasomotor function. Within isolated rat mesenteric terminal arterioles, CaV3.1, 
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CaV3.2 and CaV1.2 channels were shown to be expressed by VSMCs. CaV3.2 expression 
was also apparent within adjacent ECs. Ratiometric Ca2+ imaging revealed that 
potassium chloride (KCl) microinjection led to increases in VSMC [Ca2+]i, observed in 
areas localised and remote to the site of injection. Both localised and remote increases 
in [Ca2+]i were inhibited by bath application of nifedipine and the T-type selective CCBs, 
R(-)-efonidipine and NNC55-0396 (NNC). Remote [Ca2+]i responses could also be 
inhibited by the gap-junction un-couplers carbenoxolone and palmitoleic acid. Since 
both nifedipine and NNC were equally capable of reducing the [Ca2+]i response, it is 
suggested that functional coupling between L- and T-type Ca2+ channels occurs within 
VSMCs. Of key significance is that when CCBs were applied away from the site of KCl 
microinjection, no modification of localised or remote [Ca2+]i response were observed. 
This study therefore concluded that whilst L- and T-type Ca2+ channels contribute to 
local electromechanical coupling, they are not critical for the conduction of 
vasoconstrictor responses (Braunstein et al., 2009).  
 
Expression of CaV3.1, CaV3.2, CaV1.2, and CaV1.3 channels has also been detected in 
adult rat basilar and middle cerebral arteries and their branches. CaV3.1 and CaV1.2 
channels were expressed in the greatest abundance. Notably, the expression of CaV3.2 
channels was considerably greater in arterial branches compared to major cerebral 
arteries. Electron microscopy revealed that CaV1.2 channels were localised to the cell 
membranes of SMCs and absent from ECs. In contrast, CaV3.1 and CaV3.2 channels 
were localised in SMCs and ECs where they exhibited both membranous and 
cytoplasmic patterns of distribution. In addition to L-type Ca2+ currents, patch-clamp 
electrophysiology of isolated SMCs identified nifedipine- and nimodipine-insensitive 
Ca2+ currents which also displayed characteristic T-type Ca2+ current kinetics. These 
Ca2+ currents accounted for approximately 20% of the total Ca2+ current in SMCs 
isolated from main arteries and approximately 45% of total current in SMCs isolated 
from branches. It was additionally shown that nifedipine-insensitive currents could be 
inhibited by mibefradil, NNC and efonidipine, strongly indicating the involvement of T-
type Ca2+ channels (Kuo et al., 2010). 
 
Within main cerebral arteries, contractile responses were shown to be solely mediated 
by L-type Ca2+ channels, as nifedipine completely abolished vasoconstriction. In 
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contrast, nifedipine-insensitive vasoconstriction was observed within branches, the 
extent of which increased with decreasing arteriole diameter. It was correspondingly 
suggested that nifedipine-insensitive Ca2+ currents play a larger role in vasoconstriction 
within smaller vessels of the cerebrovascular circulation (Kuo et al., 2010). It is 
important to consider that the nifedipine-insensitive currents, described by Kuo et al. 
(2010), are not explicitly referred to as T-type Ca2+ currents. This is due to the fact that 
they activated at voltages more characteristic of HVA channels. Subsequent studies 
have similarly reported nifedipine-insensitive Ca2+ currents within cerebral arteries 
which, compared to L-type Ca2+ currents, show more hyperpolarised I-V relationships 
and have faster activation and inactivation kinetics. Interestingly, these currents were 
blocked by low Ni2+ (50µM) concentrations, thereby implicating a specific contribution 
of CaV3.2 channels. The nifedipine-insensitive Ca
2+ currents appeared likely to be 
facilitated by T-type Ca2+ channels. However, when compared to the typical biophysical 
profile of T-type Ca2+ channels, activation and inactivation occurred at more positive 
potentials. It was thus suggested that T-type Ca2+ channel splice variants may be 
expressed within the vasculature (Harraz & Welsh, 2013). This suggestion has been 
confirmed by studies which have identified vascular-specific T-type Ca2+ channel spice 
variants, which arguably fit better within the HVA category (Kuo et al., 2011; Kuo et al., 
2014).   
 
Many recent advances in our understanding about the specific contribution of CaV3.1 
and CaV3.2 channel isoforms to normal and pathological cardiovascular functions has 
come from studies using global CaV3.1
-/- and CaV3.2
-/- KO mice. Of specific 
consideration is that both CaV3.1
-/- and CaV3.2
-/- mice exhibit neurological deficits, as 
reviewed (Cheong & Shin, 2013). A further problem associated with KO models is that 
compensatory mechanisms can occur. As such, it is important that results are 
compared against the effects of appropriate pharmacological inhibitors where 
possible. The CaV3.1
-/- KO mouse was developed by deleting the N-terminus of the α1G 
subunit (Kim et al., 2001), whereas the CaV3.2
-/- KO mouse involved deletion of the S5 
segment within DI of the α1H subunit (Chen et al., 2003a).  
 
Opposing results regarding the role of CaV3.1 channels in the maintenance of vascular 
tone within different regions of the vasculature have been described. For example, 
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within intrarenal arteries, contraction induced by the α1 adrenoceptor agonist 
phenylephrine was significantly greater in CaV3.1
-/- mice. In contrast, phenylephrine-
induced contraction within mesenteric arteries was significantly reduced in CaV3.1
-/- 
mice. Importantly, no differences in K+-induced contraction of intrarenal and 
mesenteric vessels was observed between CaV3.1
-/- and wt mice. It has therefore been 
proposed that CaV3.1 channels are involved in vascular responses to endogenous 
phenylephrine, and can also be involved in both contraction and relaxation. Further 
investigations are required to establish whether factors such as vessel diameter, 
oxidative state or NO availability, account for the disparate effects of CaV3.1 channel 
expression within different vessels (Hansen, 2015). 
 
Early studies conducted on CaV3.2
-/- mice revealed that, when compared to wt mice, 
coronary arteries were constitutively constricted and exhibited large areas of fibrosis. 
Whilst typical contractile responses were preserved in isolated coronary arterioles, 
ACh- or nitroprusside-induced relaxation was considerably reduced. In addition, low 
Ni2+ concentrations prevented relaxation, further indicating that CaV3.2 channels play 
an important physiological role within vasorelaxation of coronary arteries (Chen et al., 
2003a).  
 
It has been suggested that the role of CaV3.2 channels in the process of vasodilation 
may result from their regulation by NO. Treatment of rat middle cerebral arteries with 
the nitric oxide synthase (NOS) inhibitor, NG-nitro-L-arginine methyl ester (L-NAME), 
has been shown to produce vasoconstriction. L-NAME-induced contraction could be 
partially inhibited by mibefradil (100nM) and NNC (300nM), implicating a role for T-
type Ca2+ channels (McNeish et al., 2010). Interestingly, incubation of cerebral vessels 
with L-NAME increased the expression of CaV3.1 channels within isolated VSMCs, and 
was accompanied by a redistribution of CaV3.1 channels from the cytoplasm to the 
membrane. Unfortunately, patterns of CaV3.2 expression were not determined within 
cerebral arterioles. Furthermore, whilst CaV3.1 and CaV3.2 staining was generally 
absent from cremaster muscle arterioles, treatment with L-NAME significantly 
increased the expression of both CaV3.1 and CaV3.2 channels (Howitt et al., 2013). The 
contribution of L- and T-type Ca2+ channels to myogenic vascular tone were next 
examined by manipulating intraluminal pressure in the presence or absence of 
28 
 
nifedipine, NNC or mibefradil. A key strength of this study was that NNC and mibefradil 
were always applied following nifedipine treatment, thus ruling out any potential 
effects of mibefradil or NNC on L-type Ca2+ channels. Acute treatment of basilar 
arteries with L-NAME increased the contribution of T-type, and decreased the 
contribution of L-type, Ca2+ channels to cerebral artery tone. Significantly, these effects 
were attenuated in both CaV3.1
-/- and CaV3.2
-/- mice. These findings collectively show 
that both CaV3.1 and CaV3.2 contribute to vascular tone during NO deficiency (Howitt 
et al., 2013). An alternative study found that 5,6-epoxyeicosatrienoic acid (5,6-EET) 
potently inhibited recombinant human CaV3.1, CaV3.2 and CaV3.3 (Cazade et al., 2014). 
Furthermore, 5,6-EET was also shown to have vasodilatory effects on pre-constricted 
mesenteric arteries. In addition, the vasodilatory effects of 5,6-EET were impaired in 
CaV3.2
-/-, but not CaV3.1
-/- mice (Cazade et al., 2014). Collectively, these studies 
indicate that CaV3.2 channels specifically play an important role in the process of 
vasodilation.  
 
 
1.5. The role of T-type Ca2+ channels in proliferation  
Due to their overlapping voltage-dependencies of activation and inactivation, T-type 
Ca2+ channels can facilitate a window current at or around resting Vm, as shown by 
Figure 1.4. This tonic Ca2+ influx can be a key determinant of [Ca2+]i (Chemin et al., 
2000). The issue of whether T-type Ca
2+ channels expressed by VSMCs facilitate a 
window current has been debated (Perez-Reyes ,2003). This is primarily due to the fact 
that the resting Vm of pressurised arterioles has been shown to be between 
approximately -55mV and -40mV (Hirst & Edwards, 1989). At these potentials T-type 
Ca2+ channels are generally inactivated. A likely resolution for this issue was provided 
when vascular-specific CaV3.1 splice variants, which both activate and inactivate at 
more depolarised potentials, were identified (Kuo et al., 2014). It remains feasible, 
therefore, that T-type Ca2+ channel splice variants expressed by VSMCs may facilitate a 
window current. 
 
Central to the current investigation are observations that within VSMCs a co-ordinated 
elevation in [Ca2+]i is required for cell cycle progression (Husain et al., 1997). In relation 
to this, the expression of T-type Ca2+ channels in primary cultures of rat aortic VSMCs is 
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restricted to the proliferative phases of the cell-cycle. Specifically, immunohistological 
and electrophysiological techniques revealed that within the G0 phase T-type Ca
2+ 
channel expression was absent and Ca2+ currents were solely mediated by L-type Ca2+ 
channels. Within the proliferative G1 and S phases a significant increase in T-type Ca
2+ 
currents was observed alongside a dramatic reduction in L-type Ca2+ currents (Kuga et 
al., 1996). As described below, subsequent studies have revealed an intimate link 
between T-type Ca2+ channel expression, VSMC proliferation and vascular remodelling, 
within both developmental and pathological situations.  
 
The ductus arteriosus (DA) is a vascular shunt within the foetal circulatory system 
which predominantly expresses CaV3.1 in addition to CaV3.2 channels. Postpartum, 
VSMC proliferation and migration mediates intimal cushion formation and rapid 
closure of the DA (Yokoyama et al., 2006). CaV3.1 channels were shown to mediate this 
remodelling process, as oxygenation induced an up-regulation of CaV3.1 channels in 
proliferating VSMCs of the neonatal rat DA. Concurrently, CaV3.1 up-regulation 
increased VSMC migration whilst down-regulation decreased VSMC migration. 
Pharmacological T-type Ca2+ channel inhibition using (R)-efonidipine produced similar 
anti-migratory and anti-proliferative effects on VSMCs. Furthermore, when R(-
)efonidipine was administered in vivo a significant delay in the closure of the DA was 
observed (Akaike et al., 2009).  
 
Neointima formation is a common undesirable consequence of vascular intervention 
that involves increased VSMC proliferation and migration, resulting in restenosis. Early 
studies demonstrated that oral administration of mibefradil significantly reduced 
neointima formation in rats subjected to carotid balloon injury. This indicated a 
causative role for T-type Ca2+ channels in pathologically elevated VSMC proliferation 
(Schmitt et al., 1996). Regarding KO studies, Tzeng et al. (2012) demonstrated that 
carotid artery wire injury induced neointima formation in both wt and Cav3.2
-/- mice. 
Significanlty, however, neointima formation was not observed in Cav3.1
-/- mice, which 
importantly displayed no other vascular abnormalities. Immunohistological processing 
revealed that neointima formation within wt mice was due to increased VSMC 
proliferation. Furthermore, CaV3.1 mRNA was up-regulated in response to wire injury 
in wt mice prior to neointima formation, suggesting that CaV3.1 up-regulation was 
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crucial for the development of this pathogenic phenotype. Such evidence strongly 
supports a role for T-type Ca2+ channels in pathological vascular remodelling and VSMC 
proliferation (Tzeng et al., 2012).  
 
In vitro studies have also implicated T-type Ca2+ channels in the control of VSMC 
proliferation. Freshly isolated VSMCs typically exhibit a contractile phenotype and have 
correspondingly been shown, within isolated rat aortic VSMCs, to predominantly 
express L-type Ca2+ channels. Upon subsequent culture, VSMCs were found to revert 
to a proliferative phenotype. This switch in phenotype was characterised by an 
increase in LVA currents, alongside a corresponding decrease in HVA currents and loss 
of contractile activity (Richard et al., 1992). In a rabbit model of neointima formation, 
balloon-induced arterial injury caused a rapid dedifferentiation of medial VSMCs. 
Proliferation assays conducted on cultured VSMCs demonstrated that mibefradil only 
exerted anti-proliferative effects on dedifferentiated, and not contractile, VSMCs 
(Louis et al., 2006). Furthermore, it has been shown that down-regulation of CaV3.1 
using small interfering RNA (siRNA) significantly reduced the proliferation of cultured 
human pulmonary artery smooth muscle cells (HPASMCs). Importantly, mibefradil was 
also found to reduce HPASMC proliferation whilst the specific L-type Ca2+ channel 
inhibitor diltiazem was without effect (Rodman et al., 2005).  
 
Cancer  
The link between T-type Ca2+ channel expression and cellular proliferation is not 
restricted to VSMCs. Indeed, stable transfection of HEK293 cells with CaV3.2 channels 
has been shown to produce functional currents with corresponding increases in 
cellular proliferation (Wang et al., 2002b). The first connection between T-type Ca2+ 
channels and cancer was discovered in T-cell leukaemia cell lines; namely Jurkat, Molt-
4 and HSB. LVA currents displaying characteristic T-type Ca2+ channel kinetics such as 
rapid activation and inactivation, were recorded from all three cell lines (Densmore et 
al., 1992). It has since been shown that both mibefradil and CaV3.1-targeted siRNA are 
anti-proliferative in both human and mouse neuroblastoma cell lines, U87MG and 
N1E-115 respectively. Furthermore, mibefradil was shown to reduce significantly 
CaV3.1 and CaV3.2 expression levels in a manner similar to growth serum deprivation, 
thus supporting the notion that T-type Ca2+ channel expression is restricted to the 
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proliferative phases of the cell-cycle. Over-expression of CaV3.2 channels in U87MG 
and N1E-115 cells increased intracellular Ca2+ influx stimulated by modest 
depolarisation and concurrently doubled their rates of proliferation. As the observed 
Ca2+ influx was inhibited by mibefradil, but not by the specific L-type CCB verapamil, T-
type Ca2+ channels are conclusively implicated in the aberrant proliferation of 
cancerous cells (Panner et al., 2005). Similar findings have been reported in 
retinoblastoma, C6 glioma, prostate and breast cancer lines (Panner & Wurster, 2006).  
 
Further evidence linking T-type Ca2+ channel expression, elevations in basal [Ca2+]i and 
increased proliferative rates, has been provided by studies conducted in cancerous cell 
lines. Within differentiated human prostate cancer epithelial cells (LNCaP), up-
regulated CaV3.2 channel expression has been shown to result in increased basal [Ca
2+]i 
(Mariot et al., 2002). Similarly, electrophysiological investigations in human 
neuroblastoma cells (SK-N-MC) revealed functional expression of T-type Ca2+channels. 
Peak T-type Ca2+ channel current amplitude was increased upon treatment with the 
glycoprotein, erythropoietin (Epo), which was accompanied by a corresponding 
increase in basal [Ca2+]i. Elevations in [Ca
2+]i were found to be dependent on Ca
2+ influx 
through T-type CaV channels as opposed to Ca
2+ release from internal stores (Assandri 
et al., 1999).  
 
Within all cell types, Ca2+ influx at various stages of the cell-cycle, such as the G1/S 
transition phase, is fundamental for cell-cycle progression and subsequent 
proliferation. Specifically, at the G1/S restriction point a concerted input of increased 
[Ca2+]i, growth factor stimulation and nutrient availability is required. Dysregulation of 
the G1/S restriction point is believed to underpin the mitogen-independent cellular 
proliferation observed in cancerous pathologies. It has correspondingly been proposed 
that elevated CaV3.1 and CaV3.2 Ca
2+ channel expression provides the “all or nothing” 
event that is central to the transition from graded and regulated proliferation in 
physiological conditions to the irreversible linear sequence of cellular proliferation 
characteristic of cancerous cells (Gray et al., 2013).  
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1.6. The thioredoxin (Trx) system 
Cell-surface proteins, or those within the extracellular environment, are subject to 
oxidising conditions and are rich in stabilising disulphides (S2). In contrast, the 
intracellular environment is maintained in a reduced state and intracellular proteins 
contain many free thiol or sulfhydryl (SH) groups. Thioredoxin (Trx) serves as a major 
intracellular disulphide reductase. As such, Trx functions as an antioxidant which can 
counterbalance oxidative stress when up-regulated or over-expressed (Nakamura et 
al., 1997). The Trx system is ubiquitously expressed within mammalian cells and plays a 
key role in the maintenance of cellular redox balance. The system is composed of Trx, 
thioredoxin reductase (TrxR), nicotinamide adenine dinucleotide phosphate (NADPH), 
and vitamin D3 up-regulated protein (VDUP). TrxR reduces Trx to its active form using 
electrons donated from NADPH, whilst VDUP serves as the endogenous negative 
regulator. Due to the rapidly reversible nature of thiol-disulphide exchange reactions, 
Trx also plays a key role in the dynamic control of enzymes dependent on structural 
and catalytic thiol groups (Arner & Holmgren, 2000).   
 
1.6.1. Structure- function relationships of the Trx system  
For Trx to exert the majority of its biological effects the active site disulphide of 
oxidised Trx (oTrx) must be reduced by TrxR to generate an active site dithiol ((SH)2) 
group. As such, the functions of Trx are dependent on its redox-state and 
correspondingly the activity of TrxR. TrxR belongs to the pyridine nucleotide disulfide 
oxidoreductase family, which also includes glutathione reductase (GR) and 
trypanothione reductase (TryR). Mammalian TrxR is a homodimeric protein made up of 
two 55kDa subunits, arranged head to tail. Key structural features of mammalian TrxR 
include; flavin adenine dinucleotide (FAD) and NADPH binding domains, an interface 
domain and two separate active sites. The N-terminal CVNVGC active site motif is also 
found within GR and TryR, whilst the second Gly-Cys-Sec-Gly selenocysteine (Sec) 
active site motif is unique to TrxR. Electrons are initially transferred from NADPH to the 
N-terminal active site of TrxR, then to the Sec TrxR active site and finally to the Trx 
disulphide substrates. Interestingly, TrxR isolated from lower organisms, such as 
bacteria and plants, has a significantly lower molecular weight (Mr~35kDa per subunit), 
does not contain the Sec active site and has a lower substrate specificity, as reviewed 
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(Arner, 2009; Holmgren & Lu, 2010). Following the reduction of Trx by TrxR, dithiol-
exchange reactions between reduced Trx (rTrx) and target proteins can occur, as 
summarised by Figure 1.5. 
 
NADPH + H+
NADP+
TrxR(S2)
TrxR(SH)2
Trx(SH)2
Trx(S)2
protein(S)2
protein(SH)2  
Figure 1.5. The activities of Trx rely upon reversible dithiol-exchange reactions 
Schematic diagram showing the reversible redox reactions (green arrows) utilised by 
the Trx system. The initial source of electrons is provided by the conversion of 
nicotinamide adenine dinucleotide phosphate (NADPH) to NADP+. Electrons are then 
transferred to oxidised thioredoxin reductase (TrxR(S2)) which is reduced to TrxR(SH2). 
Oxidised thioredoxin (Trx(S2)) is correspondingly reduced by TrxR(SH2) to produce 
Trx(SH2), which ultimately catalyses the reduction of disulphide bonds within many 
target proteins, highlighted by the grey box. Diagram adapted from Holmgren & Lu 
(2010). (Holmgren & Lu 2010) 
 
 
Trx is a 12kDa protein which is expressed by a vast array of organisms ranging from 
bacteria to humans. Trx isolated from Escherichia coli (E.coli) provides the most 
characterised form, with early reports showing it to be composed of 108 amino acid 
residues. This same study also identified that the functional group of Trx involved two 
cysteine residues at positions 32 and 35 (Cys32 and Cys35), separated by a glycine (Gly) 
and a proline (Pro) residue (Holmgren, 1968). When compared to E.coli Trx, the 
sequence homology of Trx isolated from different species is variable (27-69%), 
although the Cys-Gly-Pro-Cys active site sequence is highly conserved. The overall 3-
dimensional (3D) structure of Trx, referred to as the Trx fold, is also common to all 
forms. As shown by Figure 1.6, the Trx fold is composed of four α-helices surrounded 
by a central core of five β-strands. The active site of Trx is located at the end of the β2-
strand and the beginning of the α2-helix (Holmgren, 1995).  
 
The high-resolution solution structure of Trx has been successfully resolved using NMR 
spectroscopy, thereby enabling comparisons between oTrx and rTrx and also between 
mammalian and bacterial forms. Regarding E.coli Trx, only minor structural differences 
between oTrx and rTrx were observed. The backbone structures were virtually 
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identical although a local conformational change involving Cys32 and Cys35 residues 
within the disulphide active site was observed. Specifically regarding rTrx, the side 
chain of the Cys32 residue was tilted towards the solvent and away from Cys35, to 
accommodate for the increased distance between the sulphur (S) atoms upon 
reduction of the disulphide. Different patterns of hydrogen bonding also indicated that 
rTrx has more conformational substrates compared to oTrx, which could contribute to 
their differences in functional activity (Jeng et al., 1994).  
 
α1
α2
α4
β1
β2
β5
Cys32
Cys35
N
C
α3
β3
β4
 
Figure 1.6. Schematic diagram of the crystal structure of oTrx 
The central core of five β-strands (green arrows) are surrounded by four α-helicies 
(blue cylinders), as numbered. The N-terminus (N) is found at the start of β1 with the 
C-terminus (C) at the end of the α4-helix. The redox-active site cysteine residues (Cys32 
and Cys35, red circles) are located on a protrusion between the β2-strand and the α2-
helix. Diagram adapted from Holmgren (1995) and Hwang et al. (2015). (Holmgren 
1995; Hwang et al., 2015) 
 
Mammalian Trx (12kDa) has been shown to be composed of 110 amino acids (Luthman 
& Holmgren, 1982). The crystal structure of human Trx (hTrx) has also been 
determined. A key difference between hTrx and prokaryotic forms is that, in addition 
to active site Cys32 and Cys35 residues, hTrx also contains three non-canonical Cys 
residues, at positions 62, 69, and 73. In agreement with findings from E.coli, the 
structures of human oTrx and rTrx exhibit only subtle differences involving the 
conserved active site. A striking difference between hTrx and E.coli Trx however, is that 
the crystal structure of both oxidised and reduced forms of hTrx were dimeric. 
35 
 
Specifically, substitution of active site Cys residues to serine residues (C32S/C35S) had 
no effect on hTrx dimerisation. Trx dimers were also observed when the equivalent 
mutation was conducted on Cys73 (C73S), although C73S dimers were linked by 
hydrogen bonds, as opposed to stronger disulphide bonds linking dimeric wt and 
C32S/C35S hTrx. As dimeric Trx is not a substrate for TrxR, inter-molecule covalent 
bond formation via Cys73 residues may provide a mechanism for the regulation of Trx 
inactivation (Weichsel et al., 1996).  
 
Whilst much work has been conducted to elucidate the function of active site Cys 
residues, the functional importance of non-canonical Cys residues is only recently 
emerging. Importantly, oTrx generally refers to Cys32 and Cys35 residues being in their 
disulphide form and does not take into account the redox state of non-canonical Cys 
residues (Weichsel et al., 1996). With respect to this, the crystal structure of fully 
oxidised hTrx has recently been determined (Hwang et al., 2015). Significantly, fully 
oxidised hTrx was comprised of only 3 α-helices, surrounding the typical core of 5 β-
strands. While the active site disulphide bond between Cys32 and Cys35 was identical to 
that previously described (Weichsel et al., 1996), an additional disulphide bond 
between Cys62 and Cys69 was also identified. This bond disrupted the structure of the 
α3 helix, thereby producing a bulging loop and resultantly exposed hydrophobic 
residues to the solvent. This modification is predicted to prevent reduction of Trx by 
TrxR. Confirmation that inter-molecular disulphide bonds occurring via hTrx Cys73 
residues mediate hTrx homodimer formation was also provided. It is consequently 
suggested that compared to prokaryotic Trx, hTrx responds to and regulates its 
environment in a much more complex way, involving all five cysteine residues (Cys32, 
Cys35, Cys62, Cys69 and Cys73). The contribution of non-canonical Cys residues, in 
addition to active site Cys residues, to the diverse biological activities of hTrx are 
therefore of important consideration (Hwang et al., 2015).  
 
The primary endogenous negative regulator of Trx activity is VDUP, also referred to as 
Trx binding protein-2 (TBP2) or Trx interacting protein-1 (TXNIP). VDUP is a 50kDa 
protein which selectively inhibits the disulphide reductase activities of rTrx, as 
reviewed (Yoshihara et al., 2014). As VDUP does not interact with oTrx it has been 
suggested that it may inactivate Trx by forming disulphide bonds with active site Cys 
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residues of rTrx. In agreement with this, two Cys residues within the VDUP protein 
(Cys63 and Cys247) have been identified as being crucial for Trx binding. It was further 
shown that VDUP and rTrx undergo thiol-exchange reactions involving Cys247 of 
oxidised VDUP and Cys32 of rTrx. This results in the formation of a stable mixed 
disulphide which inhibits Trx activity. Conversely, these findings also indicate that in 
addition to the activities of Trx as a disulphide reductase molecule, Trx could also 
participate in redox signalling by forming stable mixed disulphides with other signalling 
molecules (Patwari et al., 2006).  
 
1.6.2. The intracellular functions of Trx as a disulphide reductase molecule  
The physiological functions of Trx are extremely wide-ranging, and as such, thorough 
discussion is beyond the scope of this introduction. However, within the intracellular 
environment Trx plays a key role in numerous physiological processes including, but is 
not limited to, DNA synthesis, cell growth, apoptosis, inflammatory responses and 
redox balance control. These functions generally, although not always, require the 
reducing capabilities of Trx which are dictated by the active site Cys32 and Cys35 
residues, as summarised in Figure 1.7.  Whilst new roles for Trx are constantly 
emerging, the intracellular functions of this protein are broadly categorised into two 
main groups. Firstly, as an electron carrier for biosynthetic enzymes and secondly in 
the protection of cytosolic proteins from oxidative formation of intra- or inter-
molecular disulphide bonds, as reviewed (Arner & Holmgren, 2000). 
 
Regarding the molecular mechanisms of the oxidoreductase actions of Trx, Cys 
residues within the classical Cys-Gly-Pro-Cys active site sequence undergo reversible 
dithiol-disulphide reactions. It is proposed that the hydrophobic surface area of rTrx 
binds to and subsequently makes a complex with the substrate protein. The thiolate (S -
) group of Cys32 then acts as a nucleophile which attacks the target protein resulting in 
a covalently-linked mixed disulphide transition state. Finally, the now deprotonated 
thiolate group of the Cys35 residue generates a dithiol in the target protein, thereby 
leaving Trx is its disulphide form. Considerable conformational changes within the Trx 
molecule are observed during protein binding and also within electron transfer steps, 
as shown in Figure 1.7 and reviewed in detail (Holmgren, 1995; Holmgren & Lu, 2010). 
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Figure 1.7.  Proposed mechanism of Trx-mediated protein disulphide reduction 
Schematic diagram showing electron transfer steps as represented by the black 
arrows. A, Reduced thioredoxin (Trx(SH)2) binds to the oxidised target protein and the 
thiolate group of  the Cys32 residue then acts as a nucleophile. B, This results in the 
transient formation of a mixed disulphide between Trx and the target protein, 
followed by nucleophilic attack of the deprotonated Cys35 residue. C, The target 
protein is subsequently reduced and oxidised Trx(S2) is generated. Note, Trx undergoes 
conformational changes as the reaction proceeds. Diagram based on E.coli Trx, 
adapted from Holmgren (1995). (Holmgren 1995) 
 
Some of the key physiological functions of Trx are conserved between lower and 
higher organisms. For example, by virtue of its disulphide reductase capabilities rTrx is 
a hydrogen donor for ribonucleotide reductase. This enzyme provides 
deoxyribonucleotides and is essential for DNA synthesis in both lower and higher 
organisms (Holmgren, 1989). Many of the antioxidant properties of Trx are also 
conserved across species. Within both mammalian and many bacterial cells there are 
two major thiol-dependent antioxidant systems, namely the Trx and glutaredoxin (Grx) 
systems. The antioxidant actions of Trx are generally achieved by electron transfer to  
peroxiredoxins (Prxs) and methionine sulfoxide reductases (MSRs). Prxs are key players 
in both the removal of ROS and in the defence against oxidative stress. Regarding the 
mechanism for this, Prxs also contain two Cys residues within their active site which 
are reduced and subsequently activated by rTrx. Thiol groups within the Prxs then act 
to remove ROS such as hydroxyl (OH-) superoxide (O2
-) and hydrogen peroxide (H2O2) 
(Lu & Holmgren, 2014). The H2O2 scavenging mechanism of Prx has been shown to be 
extremely fast within both human and yeast cells (Cox et al., 2009; Ogusucu et al., 
2007). MSRs are also antioxidant enzymes which receive electrons donated by the Trx 
system. Under conditions of oxidative stress, free and protein-bound methionine is 
oxidised to produce methionine sulfoxide, which is accompanied by a corresponding 
loss in antioxidant function. When reduced by rTrx, MSR-A and MSR-B can repair 
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methionine sulfoxide and thus indirectly participate in ROS removal (Lu & Holmgren, 
2014).  
 
As implied by the greater structural complexity of mammalian forms of Trx, its 
physiological roles are more varied and extensive when compared to bacteria. A key 
example of the additional functions of mammalian Trx is within the activation or 
inactivation of a variety of transcription factors. Indeed, Trx has been shown to be 
crucial for redox-mediated regulation of the nuclear transcription factor-κβ (NF-κβ). 
This is particularly important as NF-κβ activity influences the expression of numerous 
inflammatory genes (Hayashi et al., 1993). Interestingly, Trx can also form complexes 
with other proteins and correspondingly acts as a structural component of some 
enzymes. Trx-protein binding has been shown to be redox-dependent as rTrx, but not 
oTrx, binds with high affinity to T7 DNA polymerase forming a 1:1 complex and 
increasing enzyme activity (Huber et al., 1987). Within mammalian cells, rTrx but not 
oTrx has also been found to make inhibitory complexes with apoptosis signalling kinase 
1 (ASK1). As such, apoptosis can be stimulated when Trx becomes oxidised (Saitoh et 
al., 1998). The activity of a large number of other transcription factors including redox 
effector factor (Ref-1), phosphatase and tensin homolog (PTEN) and hypoxia inducible 
factor-α (HIF-α), and various other proteins such as p53 and oestrogen receptors, are 
regulated by Trx in a redox-dependent manner. The redox state of Trx is therefore 
believed to be central to its extensive biological activities within the intracellular 
environment, as reviewed extensively (Arner & Holmgren, 2000; Holmgren, 1979; 
Holmgren & Lu, 2010; Lu & Holmgren, 2014). 
 
1.6.3. Emerging roles for Trx as an extracellular signalling molecule  
In addition to its extensively characterised intracellular roles, Trx can also be released 
from cells and therefore act as an extracellular signalling molecule. An early study 
examined human T-lymphotropic virus type I (HTLV-I) transformed T-lymphocytes and 
found that these cells secreted a protein originally termed adult T-cell leukaemia-
derived factor (ADF). ADF was found to up-regulate interleukin-2 (IL-2) receptors and 
also had co-cytokine activity (Wakasugi et al., 1990). Further investigation revealed 
that ADF was actually extracellular Trx (Gasdaska et al., 1994). Subsequent studies 
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have reported that Trx is secreted into the extracellular environment by both normal 
and neoplastic cells in response to inflammation or oxidative stress (Rubartelli et al., 
1992; Rubartelli et al., 1995). Extracellular Trx has been found to have chemotactic 
properties similar to the chemokine IL-8 inducing the migration of T lymphocytes, 
monocytes and polymorphonuclear leukocytes when applied at ng/ml concentrations 
(Bertini et al., 1999). Within fibroblasts, Trx has also been shown to directly enhance 
the release of cytokines (Yoshida et al., 1999). Whilst the mechanism of Trx secretion is 
not fully established, a key study conducted on activated lymphocytes has 
demonstrated that it occurs via a leaderless secretory pathway independent of the 
classical endoplasmic reticulum-Golgi route (Rubartelli et al., 1992). A similar pattern 
of Trx secretion has been described in MCF-7 (breast cancer), HT-29 (colon carcinoma), 
U937 (histiocytic lymphoma), and IM9 (multiple myeloma) cells. It is noteworthy that 
Trx secretion was unaltered by treatment with brefeldin A, which disrupts the ER-Golgi 
mechanism, and was also independent of cell lysis (Tanudji et al., 2003). 
 
An important consideration is whether the redox state of Trx influences its secretion or 
indeed its extracellular functions, as shown for its numerous intracellular physiological 
roles. Mutation of the Trx active site Cys residues (C32S/C35S) has been shown to 
prevent its chemotactic activity, suggesting extracellular Trx to be rTrx (Bertini et al., 
1999). However, this observation contradicts with findings that Trx is secreted in 
response to oxidative stress (Nakamura et al., 2006); indicating that extracellular Trx is 
likely oTrx (Arner & Holmgren, 2000). In support of this suggestion, the effects of 
cellular redox status on Trx secretion was explored by Kondo et al. (1994), who 
conducted an extensive study using the T-lymphocyte cell lines, ATL2 and Jurkat. 
Measurement of Trx levels from culture supernatants and cell lysates confirmed that 
oxidative stress, achieved by treatment with H2O2, increased both intracellular and 
extracellular Trx levels. Importantly, whilst having no effect on intracellular Trx, 
treatment with the reducing agent and antioxidant N-acetylcysteine (NAC) caused a 
significant reduction in extracellular Trx. This provided strong evidence that cellular 
redox-status regulates Trx secretion (Kondo et al., 2004).  
 
Jurkat cells were also transfected with either recombinant wt Trx or mutant 
(C32S/C35S) Trx. Stimulation of Jurkat cells with H2O2 rapidly stimulated Trx secretion 
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from cells transfected with wt Trx, however not in cells transfected with the C32S/C35S 
Trx. This strongly suggested that an intact redox-active site is essential for Trx secretion 
(Kondo et al., 2004). Interestingly, it was also observed that application of exogenous 
rTrx to Jurkat cell culture media decreased Trx secretion, but not intracellular levels. It 
is subsequently suggested that Trx regulates its own release (Kondo et al., 2004). In 
continuation of this proposal, application of fluorescently-labelled wt Trx to the 
extracellular environment resulted in cellular Trx uptake. Specifically, time-dependent 
increases in Trx levels within cytosolic and plasma membrane fractions were observed. 
As no cellular uptake was observed when mutant Trx (C32S/C35S) was applied, 
evidence that the redox-active site of Trx determines both its secretion and cellular 
uptake is provided (Kondo et al., 2004).  
 
In contrast with these findings, an alternative study conducted on Chinese hamster 
ovary (CHO) cells indicated that Trx secretion can occur independently of the cell’s 
redox state (Tanudji et al., 2003). CHO cells transiently transfected with hTrx were 
found to slowly and efficiently secrete hTrx. Acute treatment with NAC did not alter 
Trx secretion, although treatment with NAC for 12hrs did decrease both intracellular 
and extracellular Trx levels. As mutation of hTrx Cys35 (active site) or Cys73 residues 
(dimerisation site) did not alter secretion, evidence that intact active sites or 
dimerisation sites are not required for Trx secretion was provided (Tanudji et al., 
2003). Further evidence that the functions of extracellular Trx are, at least not entirely, 
dependent on its redox active site, are provided by studies investigating non-typical 
Trx structural forms. In addition to its standard 12kDa form, hTrx secreted from human 
platelets and cytotrophoblast cell lines was shown to also be comprised of a 10kDa 
derivative of the 12kDa Trx (Di et al., 1998). This truncated Trx form, subsequently 
termed Trx80, has been shown to be an extracellular product of Trx cleavage, as 
reviewed (Holmgren & Lu, 2010).  
 
Despite the fact that Trx80 lacks disulphide reductase activity it has been shown to act 
as a mitogenic cytokine on human peripheral blood mononuclear cells (PBMCs). In 
PBMCs, Trx80 also stimulated the release of interleukin-2 (IL-2) whilst wt Trx was 
without effect (Pekkari et al., 2001). Trx80 has also been referred to as eosinophil 
cytotoxicity-enhancing factor (ECEF). Exogenous Trx80 has also been found to increase 
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dramatically the expression of the human immunodeficiency virus (HIV) in human 
macrophages. In stark contrast, exogenous human rTrx potently inhibited the 
expression of HIV by human macrophage cells (Newman et al., 1994). It has also been 
suggested that post-translational modification of non-canonical Cys residues in hTrx 
influences its extracellular functions (Tao et al., 2004). A further consideration is that 
TrxR has also been shown to be present at the surface of some cells and within the 
extracellular environment (Soderberg et al., 2000; Zhang et al., 2013). 
Correspondingly, the redox state of secreted Trx does not necessarily correspond with 
its redox state in the extracellular environment. Collectively, these studies emphasise 
that the physiological roles of Trx within the extracellular environment are not entirely 
dependent on its redox active site. 
 
 
1.7. Clinical implications of Trx expression in proliferative disorders 
Regarding clinical situations, increased levels of circulating Trx are detected within 
numerous pathological conditions, including but not limited to; a variety of cancers 
(Baker et al., 2013), acute myocardial infarction (AMI) (Miyamoto et al., 2003), 
abdominal aortic aneurysm (Martinez-Pinna et al., 2010), atherosclerosis (Okuda et al., 
2001), rheumatoid arthritis (Yoshida et al., 1999) and HIV (Nakamura et al., 1996). 
Elevated Trx levels are also detected in the blood plasma of patients subject to 
cardiopulmonary bypass operations (Nakamura et al., 1998). Whilst elevations in Trx 
may initially serve to counterbalance oxidative stress, Trx over-expression in cancer 
patients is associated with aggressive tumour growth, increased proliferation, 
decreased apoptosis, and reduced patient survival (Raffel et al., 2003).  
 
1.7.1. Cardiovascular disorders 
Oxidative stress is believed to be a key factor in the development of atherosclerosis 
which can ultimately lead to myocardial infarction (MI). A hallmark feature of 
atherosclerosis is atheromatous plaque formation resulting from elevated VSMC 
proliferation and increased platelet aggregation (Chistiakov et al., 2015). Within non-
atherosclerotic human coronary vessels, Trx expression has been shown to be localised 
within medial VSMCs. In contrast, within atherosclerotic coronary vessels, Trx was 
42 
 
additionally present throughout the vessel wall and surrounding infiltrating 
macrophages (Okuda et al., 2001). An alternative clinical study was conducted on three 
groups of patients suffering from acute MI (AMI), coronary artery occlusion with stable 
exertional angina (SEA) or chest pain syndrome (CPS) without arterial stenosis or 
spasm. Plasma Trx levels were considerably elevated in the AMI group when compared 
to the SEA and CPS groups. Increased levels of extracellular Trx within the AMI group 
positively correlated with increased platelet aggregation and negatively correlated 
with left ventricular ejection fraction. These changes, although reduced, were still 
apparent four weeks post-AMI. Whilst oral administration of statins did not alter 
plasma Trx levels, it did significantly decrease the degree of small platelet aggregates 
within the AMI group. Therefore, the application of statins, which are capable of 
reducing oxidative stress, could improve the prognosis of AMI patients (Miyamoto et 
al., 2003). A more recent study measured plasma Trx levels from MI patients 1, 2 and 3 
days post-event. Significantly, patients who died 24hrs post-MI had the highest plasma 
Trx levels. Patients with coronary risk factors are subject to prolonged oxidative stress; 
as such, increased serum Trx levels may initially appear as a compensatory antioxidant 
mechanism. However, as increased Trx did not counteract oxidative stress or 
inflammatory responses post-MI; in fact, increased serum Trx actually provides a 
negative indicator of MI severity and outcome (Mongardon et al., 2013). Increased 
levels of Trx have also been directly implicated in the differentiation and proliferation 
of SMCs, leading to pathological cardiac remodelling following AMI in rats (Suresh et 
al., 2015). Cardiovascular remodelling can also occur in hypertensive patients. 
However, in contrast with findings reported for atherosclerosis and AMI, increased 
levels of oxidative stress were accompanied by reductions in Trx expression within the 
aorta, heart and kidney of spontaneously hypertensive rats (Tanito et al., 2004). 
 
A further complication of atherosclerosis involving the differentiation of VSMCs is the 
development of abdominal aortic aneurysm (AAA). Increased levels of plasma Trx have 
also been reported in patients suffering from AAA. Discontinuous patterns of growth 
and periods of acute expansion exhibited in AAA can result in fatal vessel rupture. 
Vessel diameter, a surrogate marker of growth rate, is therefore used to assess AAA 
severity and as a surgical indication. Using two cohort populations, AAA patients were 
shown to have significantly higher circulating Trx levels when compared to control 
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patients. The degree of Trx elevation correlated with increased AAA vessel diameter. 
Immunohistochemical processing of surgically removed thrombi revealed that Trx was 
produced and released by the luminal, as opposed to the abluminal, layer of the 
thrombus. Thrombus formation within AAA also leads to the production of ROS. 
Correspondingly, aspirin treatment was found to decrease circulating Trx levels in AAA 
patients. Importantly, these findings show that oxidative stress increases serum Trx 
levels, which provides an important biomarker for the severity and progression of AAA 
(Martinez et al., 1999). In direct agreement with these findings, serum Trx levels are 
elevated in patients following acute ischemic stroke (AIS). High Trx levels were also 
shown to be an effective diagnostic and prognostic marker for AIS (Qi et al., 2015). 
Plasma Trx levels have also been measured in patients suffering from chronic heart 
failure (CHF). Urinary β2-microglobulin-creatinine ratios (UBCR) were additionally 
measured as a marker for renal tubular damage. Significant elevations in plasma UBCR 
and Trx levels were recorded in CHF patients suffering from cardiac events when 
compared to cardiac event-free patients. In agreement with findings from other 
cardiovascular disorders, the extent of Trx elevation correlated with poor CHF outcome 
(Otaki et al., 2014).  
 
The link between increased extracellular Trx levels and cardiovascular disorder severity 
is commonly associated with pathological oxidative stress. It is suggested that the 
antioxidant functions of up-regulated Trx may provide a compensatory mechanism in 
response to increased ROS generation, as reviewed (Billiet & Rouis, 2008; Burke-
Gaffney et al., 2005). Interestingly, many of the cardiovascular pathologies associated 
with increased oxidative stress and elevated Trx also involve VSMC dedifferentiation, 
increased proliferation and cardiovascular remodelling, as discussed in section 1.2. As 
such, the pathophysiological significance of elevated extracellular Trx may additionally 
concern the mitogenic functions of Trx. Evidence linking the Trx system to the 
phenotypic switching of VSMCs and vascular remodelling is provided by a retrospective 
study which reported that patients with T2DM had significantly elevated levels of 
circulating VDUP. Interestingly, increased VDUP levels correlated with carotid artery 
neointima thickness (Zhao et al., 2015). Direct evidence of the pro-proliferative nature 
of Trx in VSMCs is provided by a study showing that Trx over-expression significantly 
increased DNA synthesis in VSMCs, a key marker of proliferation. In contrast, VDUP 
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over-expression reduced Trx activity and inhibited mitogen-stimulated VSMC 
proliferation (Schulze et al., 2002). Furthermore, it has also been shown that VDUP can 
inhibit Trx-induced protein synthesis in cardiomyocytes. Cells with elevated VDUP were 
also shown to develop less hypertrophy following aortic constriction. Importantly, this 
study emphasised that in addition to its role as an antioxidant, Trx serves as a signalling 
molecule which participates in the development of pressure-induced cardiac 
hypertrophy (Yoshioka et al., 2004). The role of Trx as an extracellular signalling 
molecule and the dependency of these effects on the redox-state of Trx are discussed 
extensively in Chapter 5.   
 
1.7.2. Cancers 
Malignant disorders characterised by aberrant cellular proliferation demonstrate 
increased extracellular Trx levels. It is believed that Trx upregulation can initially act to 
counterbalance oxidative stress induced by carcinogenic agents and thereby serve a 
protective role. Contrastingly, within established malignancies the pro-proliferative 
effects of Trx on cancerous cells considerably outweighs its initial beneficial 
antioxidant functions. As discussed in sections 1.6.2 and 1.6.3, due to the range of 
biological targets of Trx, potential mechanisms of Trx-mediated growth stimulation are 
numerous. This includes activating transcription factors, providing essential reducing 
equivalents for DNA synthesis and increasing cellular-sensitivity to growth factors and 
cytokines, as reviewed (Burke-Gaffney et al., 2005). Specifically within tumour cells, Trx 
has been shown to enhance tumorigenesis by increasing the levels and activity of HIF-
1α and also protein products of hypoxia-responsive genes, such as vascular endothelial 
growth factor (VEGF) and NOS (Welsh et al., 2002). Trx can also inhibit the tumour 
suppressor gene PTEN, which involves binding of the Trx Cys32 residue with the PTEN 
Cys212 residue. This results in a steric influence of Trx on the PTEN active site, and 
enhances tumorigenesis. A further important mechanism of tumorigenesis is that Trx 
has also been found to inhibit apoptosis by influencing polyamine-induced apoptosis 
pathways (Husbeck et al., 2003) and also through its regulation of ASK1 (Powis et al., 
2000; Saitoh et al., 1998). Given that many chemotherapy drugs act to promote cancer 
cell apoptosis, increased Trx levels could account for reduced effectiveness of these 
treatment strategies (Burke-Gaffney et al., 2005).  
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The range of cancers associated with increased blood plasma and cellular Trx levels is 
constantly expanding. The current list includes, but is not limited to, pancreatic cancer 
(Nakamura et al., 2000); lung cancer (Kahlos et al., 2001; Kakolyris et al., 2001; Soini et 
al., 2001); cervical cancer (Fujii et al., 1991) and hepatocellular carcinoma (Kawahara 
et al., 1996; Nakamura et al., 1992). Increased Trx levels have also been described in 
human primary gastric carcinomas, where elevated Trx was directly shown to promote 
tumour cell proliferation and inhibit apoptosis (Grogan et al., 2000). A further key 
study examined Trx levels in human primary and metastatic colorectal cancers and 
found them to be significantly elevated when compared to normal colonic mucosa. 
Follow up studies further revealed that increased levels of Trx correlated with 
decreased patient survival. Crucially, it was also suggested that elevations in Trx levels 
occur relatively late in colorectal carcinogenesis, providing an effective biomarker of 
patient prognosis (Raffel et al., 2003).  
 
In light of the wealth of evidence associating Trx with cancerous cell growth, the Trx 
inhibitors PX-12 and AuF are currently being explored clinically as anti-cancer agents 
(Ramanathan et al., 2011; Roder & Thomson, 2015). Importantly, cancer patients 
showed significantly elevated plasma Trx levels when compared to healthy controls, 
which were subsequently reduced following PX-12 treatment. In addition to the 
human studies, it was also reported that PX-12 decreased circulating Trx in non-
tumour bearing mice, observed 2 and 24 hours post-treatment. Interestingly, the 
authors postulate that this was due to rapid cellular uptake of modified Trx, although 
decreased Trx secretion could also contribute to this observation (Baker et al., 2013). 
 
1.8.  Aims and hypothesis: 
Recent findings have shown that extracellular Trx can regulate not only recombinantly-
expressed CaV3.2 channels (Boycott et al., 2013) but also TRPC1 and TRPC-5 channels 
(Xu et al., 2008). These observations may explain the, as of yet, undetermined 
functional significance of coincident upregulation of T-type Ca2+ channels and Trx in 
proliferative disorders. This thesis has therefore explored the hypothesis that Trx can 
regulate T-type Ca2+ channels and, in so doing, modulate VSMC proliferation. The 
specific aims of this study were to initially assess the effects of T-type Ca2+ expression 
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and pharmacological Trx inhibition on both VSMC proliferation and Ca2+ handling. An 
additional aim was to characterise the mechanism and isoform sensitivity of Trx-
mediated T-type Ca2+ channel regulation in detail. 
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Chapter 2 -Methods and materials 
2.1. Cell culture  
 
All cells were maintained in a humidified incubator at 37°C, CO2 (5%): air (95%), and all 
culture reagents were purchased from Gibco, Thermo Fisher Scientific, (Paisley, UK), 
unless otherwise stated.  
2.1.1.  A7r5 cells 
Rat aortic smooth muscle cells (A7r5; ECACC, Public Health England, Porton Down, UK) 
were cultured in complete growth media consisting of Dulbecco’s modified eagle 
medium (DMEM) supplemented with antibiotic/antimycotic (1%) and foetal bovine 
serum (FBS, 10%, Biosera, UK). Cells were passaged on a weekly basis from 75cm3 
culture flasks by trypsinisation; media was removed and cells washed with Dulbecco’s 
phosphate buffered saline (PBS) before trypsin-EDTA (2mL, 0.05%) was applied and 
incubated with cells (3mins, 37°C). Cell detachment was verified under a microscope 
before cells were suspended in complete growth media (10ml), transferred to a 50ml 
Falcon tube and centrifuged (400xg, 6mins). The trypsin containing supernatant was 
discarded and the cell pellet re-suspended in complete growth media (20ml). From this 
suspension, fresh 75cm3 culture flasks were seeded at 1:10 or 1:20 dilutions, and the 
remaining cell suspension was plated into various culture vessels for subsequent 
experiments. 
 
Two batches of A7r5 cells purchased from the same supplier were used within the 
project: initial A7r5 cells referred to as “old” A7r5 cells had been sub-cultured at 90-
100% confluency and stored by the group for a number of years. The “old” A7r5 cells 
were used between passage (p) 14-17 and exhibited phenotypic variation with 
increasing p number. This was hypothesised to be due to a reduction in T-type Ca2+ 
channel expression due to culture at relatively high confluency, as previously described 
within primary cultures of rat thoracic aortic smooth muscle cells (Richard et al., 1992). 
In an attempt to maximise T-type Ca2+ channel expression, a new batch of A7r5 cells 
were purchased, sub-cultured at 70-80% confluency and used between p1-12. 
Increased T-type Ca2+ channel expression was validated using real-time reverse 
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transcriptase polymerase chain reaction (qRT-PCR, as described in section 2.2). The 
“new” A7r5 cells were used for all subsequent experiments.  
 
2.1.2. wt HEK293 and recombinant HEK293/CaV3.1 and HEK293/CaV3.2 cells 
Wild-type (wt) human embryonic kidney 293 (HEK293) cells (ECACC, Public Health 
England, Porton Down, UK) were cultured in complete growth media consisting of 
minimum essential medium (MEM) supplemented with antibiotic/antimycotic (1%), 
non-essential amino acids (1%), gentamicin (0.1%) and FBS (10%, Biosera, UK). HEK293 
cells stably expressing either rat CaV3.1 or human CaV3.2 (HEK293/CaV3.1 and 
HEK293/CaV3.2 cells respectively, originally a gift from Dr. E. Perez-Reyes, University of 
Virginia, Charlottesville, VA, USA) were cultured in the same media additionally 
supplemented with G-418 (400µg/ml) as the selection antibiotic. For comparison, 
HEK293 cells stably transfected by Dr Jason Scragg in-house with the CaV3.2-containing 
mammalian expression vector to generate HEK293/CaV3.2/clone P cells, were also 
used occasionally. In addition to HEK293 cells transfected with the Cav3.2(H191Q) 
construct (a gift from Dr. E.Perez-Reyes) whereby the histidine (H) residue at position 
191 of the Cav3.2 channel had been mutated to a glutamine (Q) residue 
(HEK293/CaV3.2(H191Q) cells). HEK293/CaV3.2/clone P and HEK293/CaV3.2(H191Q))  
cells were cultured in the same media as used for other recombinant cells. All cells 
were passaged weekly at 90-100% confluence as previously described (2.1.1). Fresh 
culture flasks were seeded at 1:40 dilutions for WT HEK293 and HEK293/CaV3.2/clone 
P and HEK293/CaV3.2(H191Q) cells and 1:80 dilutions for HEK293/CaV3.1 and 
HEK293/CaV3.2 cells. All HEK293 cells were used between p 1-12.  
 
2.2. Real-time polymerase chain reaction (qRT-PCR)  
To quantify native CaV3.1 and CaV3.2 channel expression in “new” A7r5 cells, and 
enable comparison with “old” A7r5s as previously determined (Duckles et al., 2015); 
CaV3.1 and CaV3.2 mRNA levels were measured using qRT-PCR. This technique is 
superior to standard PCR as it enables real-time detection and accurate quantification 
of the amplified gene of interest (amplicon), typically through the inclusion of 
fluorescently-labelled, sequence-specific primers, measured by fluorescence detectors 
within specialised thermal cyclers. Initial amplification cycles, whilst producing 
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exponential increases in amplicon level, do not produce enough fluorescence to be 
detected. The cycle number which yields enough amplicon accumulation to enable 
fluorescence detection is referred to as the threshold cycle (CT) and is used to calculate 
the amount of template initially present.  
 
2.2.1. Cell culture and RNA extraction 
A7r5 cells were plated at 1:10 or 1:20 dilutions and cultured in T75 flasks for 7 days 
(70-80% confluent respectively), cells were then trypsinised as described (section 
2.1.1) and re-suspended in ice-cold PBS and centrifuged (400xg, 6mins, x2). The 
supernatant was discarded and cell pellets triturated with 100μL of RNAlater® 
(Ambion, Cambridge, UK) and transferred to microcentrifuge tubes which were 
refrigerated (4°C) for 24hrs then stored at -80°C.  
 
When required, samples were thawed, washed and centrifuged with PBS (400xg, 
6mins, x3) and all supernatant was discarded. Due to the highly unstable nature of 
RNA, all surfaces were thoroughly cleaned with ethanol (70%) and then RNAase AWAY 
(Molecular Bio Products, CA, USA); RNA extraction was conducted using the Aurum 
total RNA mini kit (Bio-Rad, Hemel Hempstead, UK) following manufacturer’s 
instructions. Briefly, PBS (1ml) was added and cells were triturated and centrifuged 
(12,000xg, 30secs). Supernatant was discarded and lysis buffer and ethanol was then 
added in equal volume (350µL). After thorough mixing the suspension was transferred 
to an RNA binding column and low-stringency wash solution (700µL) was added prior 
to centrifugation (12,000xg, 30secs). All flow-through was discarded and RNAase-free 
DNAase I (80µL) was applied to the membrane stack at the bottom of each column and 
incubated at room temperature (RT, 15mins). High-stringency wash solution (700µL) 
was then added and the binding column centrifuged (12,000xg, 1min, x3), which was 
repeated with low-stringency wash solution (700µL). Flow-through was discarded and 
elution buffer (80µL, pre-warmed to 70°C) was added to the membrane stack and 
incubated at RT (1min). The column was then centrifuged (12,000xg, 2min) to elute 
total RNA, which was used immediately or stored at -80°C.  
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2.2.2. cDNA generation and qRT-PCR protocol  
All surfaces were thoroughly cleaned with ethanol (70%) and RNAase AWAY then cDNA 
templates were generated from extracted RNA samples using the iScript cDNA 
synthesis kit (Bio-Rad; Hemel Hempstead, UK), according to manufacturer’s 
instructions. Briefly, RNA samples and reagents were allowed to thaw over ice. iScript 
reaction mix (4µL), iScript reverse transcriptase enzyme (1µL) and RNase/DNase-free 
H2O (12.5µL, Gibco; Thermo Fisher Scientific, Paisley, UK) were added to each RNA 
sample (2.5µL) contained within a PCR tube, which was transferred to the 3Prime 
thermal cycler (Techne, Staffordshire, UK). Samples were heated to 25°C (5mins), 42°C 
(30mins), 42°C (30mins), and held at 4°C (5mins). Samples were then centrifuged 
(12,000xg, 30secs) and immediately stored at -20°C. 
 
qRT-PCR was conducted using Taqman probes for rat Cav3.1, rat Cav3.2 and the 
endogenous housekeepers rat hypoxanthine phosphoribosyltransferase (HPRT1), and 
rat large ribosomal subunit (17S), (all supplied Applied Biosystems (ABI), UK). The 
relevant Taqman Primer (0.5µL) was mixed with RNase/DNase-free H2O (8.5µL, Gibco; 
Paisley, UK), Taqman Universal PCR Master Mix (10µL, ABI) and the cDNA template 
(1µL) within individual wells on a 96-well PCR plate (ABI, Cambridge, UK. The plate was 
sealed with an optical adhesive cover and qRT-PCR was carried out using a 7500 real-
time PCR system (ABI). The reaction profile was set to 50°C (2mins), 95°C (10mins), 
95°C (5secs) for 60 cycles, and 60°C (1min) before holding at 4°C. All samples were 
measured in triplicate. 
 
2.2.3. Data analysis- comparative CT method for relative quantification 
Data were analysed using the 7500 software (ABI) and relative gene expression was 
calculated using the 2-∆∆CT method using HPRT1 as the endogenous control. Using this 
method the amount of target, normalised to the endogenous control and relative to a 
calibrator is calculated by the formula: 
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RQ = 2-∆CT 
 RQ = relative quantification value. 
 CT = threshold cycle number for a particular sample and refers to a particular 
target (e.g. CaV3.1 or HPRT1). 
 ∆CT = difference between CT values for target (CaV3.1 or CaV3.2) and reference 
(HPRT1) 
Finally, the relative expression of CaV3.1 or CaV3.2 in relation to the housekeeper was 
expressed by multiplying 2-∆CT by 100. All measurements were made in triplicate wells 
with the mean value used as n=1. Paired or un-paired Student’s t-tests were conducted 
(GraphPad Software, Inc), as described in section 2.11.  
 
2.3. Immunohistochemistry  
To assess the subcellular localisation of CaV3.1 and CaV3.2 channels in the cell lines 
used for the current project, immunohistochemistry was conducted. All primary and 
secondary antibodies were purchased from NeuroMab (UC Davis, NIH NeuroMab 
Facility, CA, USA). As recommended, antibody concentrations were optimised prior to 
experiments. Following trypsinisation (2.1), HEK293/CaV3.1, HEK293/CaV3.2 and 
HEK293/CaV3.2/clone P cells were plated at 1:10 dilutions, whereas A7r5 cells were 
plated at a 1:5 dilution, onto poly-L-lysine coated sterile glass coverslips (22x22mm, 
thickness 0). Coverslips were held within 6-well plates containing the relevant 
complete growth media (2ml per well). Cells were then incubated for 3 days before 
media was removed and coverslips were washed with ice-cold PBS (5mins, x3).  
Paraformaldehyde (1ml per well, 4% in PBS, Sigma-Aldrich, UK) was applied for 40mins 
at 4°C. The fixative was removed and coverslips were incubated in PBS containing 
Triton®X-100 (0.1%, Sigma-Aldrich, UK) and bovine serum albumin (BSA, 10%, Sigma-
Aldrich, UK) for 20mins at RT (1ml per well). This was to both permeabilise cells and 
block non-specific staining respectively. Cells were then washed with Triton®X-100 
(0.1% in PBS, 1ml per well, 5mins, x3), before a final wash with BSA (1% in PBS, 1ml per 
well, 5mins). Primary (1°) antibodies were made up to the appropriate dilutions using 
PBS + BSA (1%). Coverslips were then incubated with either anti-CaV3.1 (1:100, mouse, 
clone N178A/9) or anti-CaV3.2 (1:1000, mouse, clone N55/10) for 12hrs at 4°C. To 
minimise usage, for all 1° antibody incubations coverslips were inverted on ParafilmM® 
(Sigma-Aldrich, UK), using 100µL of 1° antibody per coverslip.   
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Two fluorophore-bound secondary (2°) antibodies were used to detect anti-CaV3.1 or 
anti-CaV3.2 1° antibodies. Coverslips were first washed with BSA (1% in PBS, 1ml per 
well, 5mins, x3). AlexaFluor555 goat anti-mouse IgG1 (red) or AlexaFluor488 goat anti-
mouse IgG1 (green) were then diluted to 1:1000 in PBS + BSA (1%). 2° antibodies were 
applied to coverslips for 1hr at RT (1ml per well), protected from light. Finally cells 
were washed with PBS (1ml per well, 5mins, 3x) before a final wash with double-
distilled H2O (ddH2O, 1ml per well, 5mins). Coverslips were allowed to air-dry, then 
mounted onto microscope slides using VectashieldR mounting media containing 4',6-
Diamidino-2-Phenylindole Dihydrochloride (DAPI, Vector Laboratories; Peterborough, 
UK), to label total DNA. Coverslips were finally sealed round the edges with nail varnish 
and refrigerated (40C) in the dark.  
 
2.3.1. Image acquisition and analysis 
Slides were removed from the fridge and allowed to warm to RT for 30mins before 
viewing with a light microscope (Nikon Eclipse E600, COOL LED pE illumination system, 
x40 magnification, used throughout). For each coverslip, 5 fields of view were 
randomly selected and the appropriate LEDs and filter sets used to detect different 
fluorophores. DAPI was visualised using the blue channel (400nm), AlexaFluor488 using 
the green channel (470nm) and AlexaFluor555 using the red channel (GYR). Images 
were captured via an integrating analogue CCD camera (JVC KYF 55B) attached to an 
Acquis image-capture system (Synoptics; Cambridge, UK). To examine co-localisation, 
Images were merged post-acquisition and were adjusted for brightness and contrast 
using Corel photo paint.  
 
2.4. MTT viability assays  
In order to assess whether the thioredoxin inhibitors Auranofin (AuF) and PX-12 would 
affect cell viability, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) assays were conducted on A7r5, wt HEK293 and HEK293/CaV3.2 cells. The MTT 
assay is based on the principle that only active mitochondria are able to cleave MTTs 
tetrazolium ring and convert the pale yellow soluble substrate to the partially soluble, 
dark blue formazan product. The degree of colorimetric absorbance at 570nm is thus 
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directly proportional to the number of living cells present (Mosmann, 1983). 96-well 
plates were coated with poly-L-lysine (100µL) which was removed before plates were 
allowed to dry for 30mins. Cells were plated in complete growth media, at the 
appropriate cell density to achieve confluence 24, 48 or 72 hours post-drug treatment. 
Cells were incubated overnight and media was replaced with complete growth media 
(100µL) ± AuF (1nM-3µM) or PX-12 (300nM-300µM). The 96-well plate layout shown 
within Figure 2.1 enabled 8 treatment and 2 control groups to be analysed, as the 
outer wells were prone to evaporation and plate reader inaccuracy.  
 
 
Figure 2.1. 96-well plate layout used for MTT assay 
Red line, omitted from analysis, blue line, control wells. 
 
Following drug treatment (24, 48 or 72 hours), MTT (11µL, 5mg/ml, Sigma-Aldrich) was 
added to each well and cells were incubated for 3 hours (37°C). A solubilising solution 
of propan-1-ol (Sigma-Aldrich) and 1M HCl (1:25) was added to each well (111µL), to 
lyse cell contents and standardise media coloration. Cell suspensions were thoroughly 
triturated and absorbance was measured at 570nm using a spectrophotometer 
(Glomax multi-detection system; Promega, UK). Absorbance values were normalised to 
control values and averages taken for each condition. The mean value of 8 wells was 
used as n=1. All experiments were repeated three times over different passage 
numbers. Data were analysed using one-way ANOVA and Dunnett’s post-hoc tests 
(GraphPad Software, Inc), as described in section 2.11. 
 
 
2.5. Proliferation assays - direct cell counting 
The direct cell counting protocol used for proliferation assays was based on 
longstanding published methods (Porter et al., 2002). Cells were trypsinised as detailed 
(2.1.1), and after centrifugation the cell pellet was re-suspended in complete growth 
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media (1ml), and cell number was counted using the T10 automated cell counter (Bio-
Rad; Hemel Hempstead, UK). Cells were plated into 24-well plates at appropriate 
densities estimated to not exceed 100% confluency on the final day of the assay; 
1x104.ml-1 or 2x104.ml-1 for A7r5 cells and HEK293 cells respectively. Due to poor 
adherence of WT HEK293, HEK293/CaV3.1 and HEK293/CaV3.2 cells, 24-well plates 
were coated with poly-L-lysine, allowed to dry for 30mins prior to plating. Cells were 
incubated in the relevant complete growth media for 9 hours to enable optimum cell 
adherence, washed with PBS (1ml per well), and incubated in serum free media (SFM, 
0% FBS) for 12 hours to encourage cell cycle synchronisation. Day 0 counts were taken, 
and media changed to complete growth media ± various drugs as listed in Table 2.1. 
Cells were incubated for 3 days and counted either daily or on day three alone. 
 
All cell counts were made in triplicate (i.e. from three wells) including day 0 counts. 
Media was retained from a single well from each condition to enable floating cell 
quantification, which was added to the non-viable cell count. Adherent cells were 
washed with PBS (1ml) and trypsinised (200µL trypsin-EDTA per well). Cells were 
triturated and transferred to micro-centrifuge tubes (1.5ml) along with complete 
growth media (800µL per well), to inhibit further trypsin dissociation. Cells were 
centrifuged (400xg for 6mins) and 950µL of supernatant was removed. Cell 
suspensions were then mixed with equal amounts of Trypan blue (50µL, Sigma-Aldrich, 
UK), to stain unviable cells and counted using the automated cell counter. For low 
concentration cell suspensions (i.e. floating cells and day 0) counts were performed 
using a haemocytometer. Un-paired Student’s t-tests were conducted (GraphPad 
Software, Inc), as described in section 2.11.  
55 
 
Drug and 
vehicle 
Working 
conc’ 
Purpose of application  
Auranofin  
(DMSO) 
300nM 
100nM 
A gold containing compound initially characterised as an 
anti-rheumatic drug (Finkelstein et al., 1976) which was 
later shown to Inhibit thioredoxin reductase (TrxR), the 
enzyme responsible for the reduction and subsequent 
activation of thioredoxin (Trx) with a Ki of 4nM when 
measured in the presence of 50µM Trx (Gromer et al., 
1998).  
PX-12 
(DMSO) 
1µM Trx inhibitor originally named IV-2 (1-methylpropyl 2-
mercaptoimidazolyl disulfide) which inhibits Trx via 
irreversible thioalkylation of Cys73. At higher concentrations 
reversible thioalkylation of Cys32 and Cys35 also (Ki=31µM) 
occurs (Kirkpatrick et al., 1998). 
NNC 55-0396  
(ddH20) 
1µM, 
3µM 
T-type selective Ca2+ channel blocker (CCB), which shows no 
inhibition of high voltage activated (HVA) currents at 
100µM (Li et al., 2005). 
ML218 
(DMSO) 
3µM A recently developed compound, shown by high-
throughput screening technique, to be T-type selective at 
10µM (Xiang et al., 2011). 
Mibefradil  
(ddH20) 
1µM, 
3µM 
Within VSMCs mibefradil (≤ 1µM) selectively inhibits T-type 
Ca2+ currents (Brueggemann et al., 2005). It has also been 
shown its metabolite can also activate L-type Ca2+   
channels when applied at higher concentrations (Li et al., 
2005).  
Nifedipine 
(DMSO) 
2µM Nifedipine (300nM) has been shown to selectively inhibit L-
type Ca2+ currents in arterial smooth muscle, enabling T-
type Ca2+ current isolation (Abd El-Rahman et al., 2013).  
Table 2.1. Drugs used in proliferation assays and Ca2+ microfluorimetry 
 All purchased from Sigma-Aldrich, UK, except Auranofin and PX-12 (Tocris biosciences; 
Bristol, UK and ML218 (kindly gifted from Craig Lindsley, Vanderbilt University, 
Tennessee, USA) 
 
 
2.6. Proliferation assays - EdU incorporation assay 
As an alternative to the direct cell counting proliferation assay, the Click-iT® EdU assay 
(Invitrogen Molecular Probes; Thermo Fisher Scientific, Paisley, UK) was employed to 
examine the effects of PX-12 on WT HEK293 and HEK293/CaV3.1 cell proliferation. EdU 
(5-ethynyl-2´-deoxyuridine) is a nucleoside analog of thymidine which becomes 
incorporated into newly synthesised DNA, and is detected by utilisation of the 
principles of click chemistry i.e. it involves a copper-catalyzed covalent reaction 
between an alkyne (EdU incorporated into DNA) and an azide (Alexa Fluor detection 
reagent). This newly developed assay can be used as a replacement for the standard 
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BrdU (5-bromo-2’-deoxyuridine) nucleoside incorporation assay with the main 
advantage that the small size of the azide allows detection without denaturing DNA, 
circumventing potential effects on cell morphology and nuclear counterstaining 
associated with BrdU. As the assay utilises bio-orthogonal moieties, high detection 
sensitivities and low background signals are achieved.  
 
2.6.1. Cell culture and EdU incubation 
EdU incorporation assays were performed according to manufacturer’s instructions.  
As recommended EdU concentration/incubation time (5 or 10µM, 1-48 hours) and 
plating density (1-4x104.ml-1) was optimised prior to experiments. Following 
trypsinisation, cell number was determined as described (2.5) and wt HEK293 and 
HEK293/CaV3.2 cells were plated at 4x10
4.ml-1 onto poly-L-lysine coated sterile glass 
coverslips (22x22mm, thickness 0) within 6-well plates containing the relevant 
complete growth media (2ml per well). Cells were allowed to adhere for 24 hours, 
washed with PBS (2ml per well) and incubated in SFM (2ml per well) for 12 hours to 
encourage cell cycle synchronisation. Media was then changed to complete growth 
media ± PX-12 (1µM) and/or NNC55-0396 (3µM). After 12 or 32 hours, EdU (5µM) was 
added by half changing the growth media, PX-12 and NNC concentrations were 
maintained. Cells were incubated for a further 12 hours.  
 
2.6.2. Cell fixation, permeabilization and EdU detection 
Following EdU incubation, media was removed and coverslips were washed with PBS 
(2ml per well) before paraformaldehyde (3.7% in PBS, Sigma-Aldrich, UK) was applied 
for 15mins at RT. The fixative was removed and coverslips were washed with PBS 
containing bovine serum albumin (BSA, x2, Sigma-Aldrich, UK) before PBS containing 
Triton®X-100 (0.5%, Sigma-Aldrich, UK) was added for 20mins at RT to permeabilise 
cells. Next coverslips were washed with PBS containing BSA (3%, x2) before EdU 
detection cocktail (50µL) was added to each coverslip. The EdU detection cocktail 
contained CuSO4, Alexa fluor-555 azide and proprietary reaction buffers and additives 
and was made fresh each day. Coverslips were incubated for 30mins at RT and 
protected from light. The detection cocktail was then removed and coverslips washed 
with PBS containing BSA (3%, x2) and also then with ddH2O. Coverslips were allowed to 
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air-dry, then mounted onto microscope slides using VectashieldR mounting media 
containing DAPI, (Vector Laboratories; Peterborough, UK) to label total DNA, and 
finally sealed round the edges with nail varnish. All slides were refrigerated (40C) in the 
dark.  
 
2.6.3. Image acquisition and analysis 
Images were acquired as detailed (2.3.1). For each coverslip, 5 fields of view were 
randomly selected and visualised under the blue channel (400nm) for DAPI and the red 
channel (GYR) for EdU. DAPI and EdU images were merged post-acquisition using Corel 
photo paint in order to examine co-localisation. DAPI is a well characterised nuclear 
stain which binds to DNA and so was used to label the total number of nuclei. As DNA 
synthesis, fundamental for proliferation, occurs within the nucleus; EdU incorporation 
labelled the nuclei of cells which had synthesised DNA within the 12hour incubation 
period. Therefore EdU labelling reliably co-localised with DAPI staining. In order to 
compare DNA synthesis between control and drug treated conditions, the number of 
EdU-labelled nuclei (EdU+) was expressed as a percentage of the DAPI-labelled nuclei 
(DAPI+) for each image.  
 
An attempt was made to custom build an automated analysis pipeline using an open 
source programme CellProfiler (www.cellprofiler.org). However, due to inaccuracies in 
results when compared to counting the nuclei by eye (manual counting), it was 
decided that for the current project manual counting was the best option (discussed in 
Chapter 4). Using Corel photo paint, EdU+ nuclei were outlined and counted and the 
resultant outline was then superimposed onto the corresponding DAPI image. The 
percentage of EdU+/DAPI+ nuclei was calculated for each of the five images in each 
condition and an average taken (to count as n=1).  Data were normalised to the control 
condition and analysed by one-way ANOVA with Dunnets’ post-hoc comparison test or 
un-paired Student’s t-tests (GraphPad Software, Inc), as described in section 2.11.  
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2.7. Ca2+ microfluorimetry 
Ca2+ microfluorimetry uses fluorescent indicators to measure intracellular Ca2+ 
concentration ([Ca2+]i) within cell populations. In the current project, Fura-2-AM (4µM, 
Invitrogen Molecular Probes; Thermo Fisher Scientific, Paisley, UK) was used to load 
A7r5, wt HEK293, HEK293/CaV3.1 and HEK293/CaV3.2 cells with the ratiometric 
fluorophore Fura-2. As the conjugated acetoxymethyl (AM) ester group confers a high 
degree of lipophilicity it is readily taken up by cells. Intracellular esterases then break 
down the AM group, thereby preventing the charged Fura-2 from leaving the cell, 
enabling the use of low incubation concentrations.  Fura-2 is a dual excitation 
fluorophore which emits light at 510nm in response to excitation at 340nm and 
380nm. With increasing Ca2+ binding; emission intensity (510nm) increases in response 
to excitation at 340nm, whilst correspondingly decreasing in response to excitation at 
380nm, as detailed in Figure 2.2. The ratiometric nature of Fura-2 compensates for 
potential differences in dye loading, cell thickness and instrument sensitivity 
(Grynkiewicz et al., 1985). 
 
 
Figure 2.2. Fluorescence excitation spectra of Fura-2 
As measured in solutions containing 0–39.8 µM free Ca2+ (diagram adapted from 
www.thermofisher.com).  
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2.7.1. Cell culture  
Following trypsinisation (as described in 2.1.1) cells were plated at various dilutions 
onto circular sterile glass coverslips (10mm, thickness 0) within 24-well plates 
containing the relevant complete growth media (1ml per well). Cells were then 
incubated for 1-4 days until they were ~ 50-70% confluent. Coverslips were transferred 
to 35mm Petri dishes and incubated with Fura 2-AM (4µM) diluted in control buffer 
(see Table 2.2) at RT for 40mins.  After washing with control buffer (2ml, x3), coverslips 
were incubated for 15mins with control buffer to allow AM group de-esterification. 
After fragmentation, coverslip segments were transferred to a perfusion chamber 
mounted over an epi-fluorescence microscope. Buffers were perfused from one of six 
reservoirs, connected to a 6-way Hamilton tap (Hamilton GB Ltd; UK), via Tygon tubing 
(0.83mm internal diameter, Merck; UK). A suction tube connected to a peristaltic 
pump (Gilson, Minipulse 3, Anachem) provided the outlet. Cell populations were 
identified and emission intensity at 510nm was recorded in response to synchronised 
excitation at 380nm and 340nm (ME-SE Photometry system, Cairn Research, 
Faversham, UK). The ratio of absorbance (340:380nm) at 1Hz, directly proportional to 
[Ca2+]i, was visualised via a computer using Acquisition Engine 1.6.1 software (Cairn 
Research, UK). 
 
Chemical  Concentration (mM) 
 
Control perfusate  High [K+] perfusate Ca2+ free perfusate 
NaCl 135 120 135 
KCl 5 20 5 
HEPES 5 5 5 
Glucose 10 10 10 
Sucrose 29 29 29 
MgCl2  1.2 1.2 1.2 
CaCl2   2.5 2.5 - 
EGTA - - 1 
Table 2.2. Ca2+ microfluorimetry perfusate compositions, all adjusted to pH = 7.4 
using NaOH. 
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2.7.2. Depolarisation induced intracellular Ca2+ oscillation protocol - A7r5 cells 
To study the effects of Trx inhibition, “old” A7r5 cells were incubated with auranofin 
(AuF, 2µM) dissolved in control buffer (RT, 25mins) post Fura-2 incubation. Baseline 
[Ca2+]i  measured in control buffer, replicating physiological resting state conditions, 
was stabilized before switching to a perfusion buffer containing a modestly elevated 
[K+] (20mM, control 5mM), as shown within Table 2.2. The modest [K+] elevation was 
designed to induce a small degree of depolarisation of ~35mV as calculated by the 
Nernst equation detailed in Figure 2.3, with the aim of preferentially activating T-type 
Ca2+ channels recruited by small voltage increases. In control situations, this stimulus 
reliably produced rapid oscillations in [Ca2+]i comparable to spontaneous oscillations 
observed in “new” A7r5 cells. After any response to the depolarising stimuli had 
reached a plateau, the perfusion buffer was switched back to control and baseline 
[Ca2+]i re-established. In some conditions, dithiothreitol (DTT, 1mM; Sigma-Aldrich, 
UK), dissolved in control buffer, was then applied prior to repeating the depolarisation 
protocol for a second time.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Schematic representation of the Nernst equation  
As used to calculate the degree of depolarisation induced by switching extracellular 
[K+] from 5mM to 20mM 
  
     
  
  
     
     
     
  
 
Where: 
   = K
+ equilibrium potential  
      = extracellular K
+ concentration (5 or 20mM) 
      = intracellular K
+ concentration (140mM) 
R = gas constant, T = temperature, z = valency of ion, F = Faraday constant 
                                  
  
   = 58mV  
 
   = 58 x log10 (5/140) = -84mV 
 
   = 58 x log10 (20/140) = -49mV 
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The effects of various Ca2+ channels blockers (CCBs) on [Ca2+]i, as used in the 
proliferation studies as detailed in Table 2.1 were also examined. The same initial 
depolarisation protocol was applied as detailed above; however CCBs were then 
perfused firstly in control and then in the high [K+] buffer. This enabled comparison 
between the first and second depolarisation responses. The perfusion buffer was then 
switched back to the control buffer and baseline [Ca2+]i re-established.  
 
2.7.3. Window current protocol 
As T-type Ca2+ channels are activated at low voltages there is commonly a small 
population open at or around the resting membrane potential. These facilitate tonic 
Ca2+ influx, often referred to as window current, believed to be important for 
proliferation. In order to measure and compare any window current within A7r5, wt 
HEK293, HEK293/CaV3.1 and HEK293/CaV3.2 cells, baseline [Ca
2+]i in control buffer was 
established before switching to a Ca2+ free perfusate (CF, replaced with 1 mM EGTA). 
Any changes in [Ca2+]i were allowed to stabilise before the perfusate was switched 
back to the control buffer. When investigating the effects of CCBs (Table 2.1), drugs 
were diluted and applied firstly in control and then in CF perfusate.  
 
2.7.4. Data analysis  
All data analysis was conducted using Graphing (an in-house program) and GraphPad 
Prism version 6 (GraphPad Software, Inc). As detailed in Figure 2.4 regarding the 
induced depolarisation experiments, the amplitude of the response (Δ[Ca2+]i) was 
measured by deducting the baseline Fura-2 ratio (in control buffer, A1), from the Fura-
2 ratio measured at the response plateau (A2). For drug treatments, baseline ratio was 
measured from drug + control buffer perfusion. To calculate the frequency of Ca2+ 
oscillations observed in response to depolarisation, the number of spikes was counted 
and divided by the duration of the high [K+] perfusion (T2-T1).  
 
Regarding window current experiments, the response to removal of extracellular Ca2+ 
was calculated by deducting the baseline Fura-2 ratio in CF buffer (A2) from the 
baseline Fura-2 ratio in control buffer (A1) as detailed within Figure 2.4. For drug 
treatment conditions, baseline ratio was measured from drug + control buffer 
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perfusion. All data was analysed using paired or un-paired Students t-tests or one-way 
ANOVA with Dunnett’s post-hoc comparison tests, as appropriate (section 2.11). 
 
A1
A2
T1 T2
240secs
0.2 ru
 
 
A1
A2
120secs
0.1 ru
 
Figure 2.4. Example control Ca2+ microfluorimetry traces 
Illustrating analysis parameters used for induced depolarisation protocols; A, response 
amplitude (A2-A1) and B, firing frequency in A7r5 cells (no° spikes/(T2-T1)) and C, 
window current protocols in A7r5 and HEK293 cells (A1-A2). Red lines show high K+ 
stimulus, purple line shows Ca2+ free perfusate. Scale bars showing time in seconds 
(horizontal bars) and ratio units (ru,) i.e. the ratio of absorbance (340:380, vertical 
bars).  
 
 
2.8. Electrophysiology  
In order to assess whether Trx directly modulated voltage-gated Ca2+ (CaV) channels 
within A7r5 HEK293/CaV3.1 and HEK293/CaV3.2 cells, patch-clamp electrophysiology 
(whole-cell configuration) was implemented. All recordings were made in the presence 
of tetraethylammonium chloride (TEA) and CsCl (both Sigma-Aldrich, UK) to block 
voltage-gated K+ channels and non-selective cation channels respectively.  
 
A B 
C 
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2.8.1. Cell culture 
Following trypsinisation (as detailed 2.1.1), cells were plated at various dilutions (1:10-
1:80) onto poly-L-lysine coated sterile glass coverslips (22x22mm, thickness 0) or 
circular sterile glass coverslips (10mm, thickness 0) in 6 or 24-well plates, containing 
2ml or 1ml of the relevant complete growth media per well, for recombinant HEK293 
or A7r5 cells respectively. Cells were incubated overnight before media was replaced 
with antibiotic-free growth media (FBS, 10%, no added antibiotic/antimycotic, 
gentamicin, or G-418), which was found to increase the success rate of stable 
recordings. Cells were then incubated for a further 1-3 days prior to recording. 
Coverslips were transferred into 35mm petri dishes and fragmented, enabling small 
sections to be transferred into the recording chamber.  
 
2.8.2. Electrophysiology rig set up  
The recording chamber was mounted over a light microscope (Olympus CK40) and 
perfused by one of four reservoirs connected to a 4 way Hamilton tap (Hamilton GB 
Ltd) via Tygon tubing (0.83mm internal diameter, Merck, UK). A suction tube 
connected to a vacuum pump (JUN-AIR, Redditch, UK) provided the outlet. Patch-
pipettes with a resistance of 3-7 MΩ were made from borosilicate glass capillary tubes 
(0.86mm internal diameter; Harvard Apparatus, Cambridge, UK) using an electrode 
puller (PP-83; Narishige, London, UK). Patch-pipettes were filled with intracellular 
solution as detailed in Table 2.3 ensuring no air bubbles were present. The patch-
pipette was then attached securely to the electrode holder so that the silver/silver 
chloride (Ag/AgCl2) recording electrode was connected to the headstage and was also 
in contact with the intracellular solution. The Ag/AgCl2 chloride ground electrode 
connected to the headstage was placed in the recording chamber in contact with the 
extracellular solution (Table 2.3). The headstage positioning was controlled by a 
micromanipulator (Patch star (PS-700C), Scientifica, East Sussex, UK) enabling precise 
manoeuvre of the patch-pipette over three axes (x, y and z) to allow its delicate 
placement against cell membranes.  
 
The electrode holder contained a side-arm air outlet attached to Tygon tubing 
facilitating manual suction required to rupture the cell membrane and achieve the 
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whole-cell configuration. This could be connected to a syringe with a three-way tap to 
maintain suction. To reduce electrical noise, all apparatus was contained within a 
Faraday cage and individual electrical items were grounded to a common earth point. 
Patch-clamp recordings were made using an Axopatch 200A amplifier/Digidata 1200 
interface (Axon Instruments; Foster City, CA, USA) controlled by Clampex 9.0 software 
(Molecular Devices; Foster City, CA, USA). Signals were sampled at 10 kHz and low-pass 
filtered at 2 kHz.  
 
Chemical Concentration (mM) 
 
ICaT* extracellular ICaL * extracellular Intracellular 
NaCl 95 95 - 
CsCl 5 5 120 
MgCl2 0.6 0.6 2 
TEA 20 20 20 
HEPES 5 5 10 
glucose 10 10 - 
sucrose 20 20 - 
CaCl2 15 - - 
BaCl2 - 15 - 
EGTA - - 10 
Na - ATP - - 2 
Mg- ATP - - 2.5 
Table 2.3. Composition of solutions used for electrophysiology 
Extracellular solutions were adjusted to pH 7.4 using NaOH, whilst the intracellular 
solution was adjusted to pH 7.2 using CsOH. ICaT = T-type Ca2+ current. ICaL= L-type 
Ca2+ current. All chemicals supplied by Sigma-Aldrich, UK. 
 
2.8.3. Whole-cell recording configuration  
All electrophysiological recordings were made in the whole-cell configuration. Upon 
placement of the patch-pipette against the cell membrane, gentle suction was applied 
until a mechanically and electrically tight seal (≥1GΩ resistance) was formed between 
the patch-pipette and cell membrane. Membrane potential was set to the required 
voltage (-80mV for T-type Ca2+ currents (ICaT)) and pipette capacity transients were 
minimised using amplifier controls. Suction was then gradually increased until the cell 
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membrane ruptured, which was detected as a sudden increase in slower capacitance 
transients which were subsequently minimised using the whole-cell capacitance and 
series resistance controls.  
 
2.8.4. Single step (SS) voltage protocols  
T-type Ca2+ channels exhibit marked differences when compared to other members of 
the CaV family such as L-type Ca
2+ channels (CaV1.1-1.4).  Specifically they have lower 
voltage thresholds for activation (-70mV vs. -40mV), they inactivate rapidly, have 
transient kinetics and exhibit slower rates of deactivation leading to prominent tail 
currents after a depolarising pulse (Perez-Reyes, 1999). Correspondingly, when 
recording ICaT cells were maintained at a holding potential of -80mV (to ensure 
channels were in their closed state) and step depolarisations to -20mV (voltage for 
peak ICaT activation) were applied for 200ms (sufficient time to observe activation and 
inactivation), before return to the holding potential (-80mV). Repeated depolarising 
steps were made at 0.1 Hz. 
 
Contrastingly, when recording L-type Ca2+ currents (ICaL) cells were maintained at a 
holding potential of -50mV and step depolarisations to +20mV  (voltage for peak ICaL 
activation) were applied initially for 200ms, before returning to the holding potential (-
50mV). Over this period, no inactivation was observed, however the depolarising pulse 
duration was reduced to 100ms to minimise current rundown. Repeated depolarising 
steps were made at 0.1 Hz. Ba2+ (15mM) was used as the charge carrier for ICaL 
recordings to circumvent Ca2+ dependent inactivation associated with L-type Ca2+ 
channels and augment current amplitudes.  
 
The two individual SS protocols detailed above were designed to maximally activate T- 
or L-type Ca2+ channels. Whilst these protocols are ideal for recording currents from 
recombinant expression systems, it is important to note that contamination of ICaT or 
ICaL may have occurred within A7r5 cells which natively express both subtypes of Ca2+ 
channel. CaV1.2 channels have been previously shown to begin activating ~-20mV, 
when expressed recombinantly (Scragg et al., 2007). Furthermore, recombinant CaV1.3 
channels have been shown to have considerably lower activation thresholds compared 
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to CaV1.2 channels (Lipscombe et al., 2004). As such, the global Ca
2+ influx in A7r5 cells 
evoked using the T-type SS protocol (-80mV to -20mV) may be a combination of ICaL 
and ICaT. Care was therefore taken when interpreting results from A7r5 cell T-type SS 
recordings, and nifedipine was applied to eliminate the contribution of ICaL where 
possible.  
 
2.8.5. Current-voltage (IV) relationship protocol and data analysis 
To assess potential effects of compounds of interest on current amplitudes in response 
to a range of voltages, current-voltage (IV) relationship protocols were also 
implemented. Cells were maintained at a holding potential of -80mV and a series of 
80ms depolarising steps from -100 to +40mV in 10mV increments were made, with a 
return to -80mV between each step. 
 
All data analysis was performed offline using Clampfit 9.0 (Molecular Devices) and 
GraphPad Prism version 6 (GraphPad Software, Inc). For single-step protocols, 
statistical analysis was initially conducted using raw peak current amplitude values. For 
effective visual representation, peak amplitude in the presence of a drug was 
expressed as a % of peak amplitude under control conditions for each cell. For 
consistency, final statistical analysis was conducted on data in this format Data were 
analysed using paired or un-paired Students t-tests or one-way ANOVA with Dunnett’s 
post-hoc comparison tests, as appropriate (detailed in section 2.11). 
 
2.9. Thioredoxin assays  
As the classical function of Trx is to reduce intracellular proteins via cysteine thiol-
disulphide exchange the standard way to measure Trx activity is using insulin disulfide 
reduction assays (Holmgren, 1979). A commercially available Trx assay was purchased 
(FkTRX-02-V2, IMCO Corporation Ltd AB; Stockholm, Sweden), which is based on the 
reduction of insulin by Trx. As shown by the three equations within Figure 2.5, the 
eosin-labelled insulin fluorescence signal at 545nm (after excitation at 520nm) 
increases upon reduction, and is applied in relative excess in addition to thioredoxin 
reductase (TrxR) and nicotinamide adenine dinucleotides phosphate (NADPH) 
(Montano et al., 2014). These assays were performed with the aim of measuring 
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endogenous Trx activity within cell lines and to potentially examine the effects of Trx 
inhibitors on this activity.  
 
 
Figure 2.5.  Schematic depiction of Trx activity assay reactions. 
  Showing, 1, the reduction of oxidised thioredoxin (Trx-S2) to its reduced dithiol form 
(Trx-(SH)2) by thioredoxin reductase (TrxR) with nicotinamide adenine dinucleotide 
phosphate (NADPH) as a cofactor. 2, Trx-(SH)2 reduces insulin disulfide (insulin-S2) to its 
dithiol form (insulin-(SH)2) and Trx-S2 with 3, a corresponding increase in fluorescence 
(derived from (Montano et al., 2014))  
 
2.9.2. Cell sample preparation  
To assess the effects of chronic application of Trx inhibitors on endogenous Trx activity 
levels, A7r5, WT HEK293 and HEK293/CaV3.1 cells were cultured in T75 flasks (as 
detailed 2.1.1) in the appropriate complete growth media (20mL) for three days before 
media was replaced with media ± AuF (300nM) or PX-12 (1µM). Cells were then 
cultured for a further 3 days before they were trypsinised and cell number determined 
(as described 2.5). Cells were then suspended in PBS (10mL) and centrifuged (1000xg, 
10mins, x2). All supernatant was removed and the cell pellet re-suspended in TE buffer 
(500µL, pH 7.3, Qiagen, UK) and divided into 2 samples. To lyse cells, samples were 
sonicated (XL-2000; Misonic, NY, USA) for 5 seconds and centrifuged (10,000xg, 4°C, 
20mins) to remove cellular debris. The supernatant was retained and frozen (-80°C) for 
subsequent Trx analysis.  
 
To assess the effects of acute exposure to higher PX-12 concentrations HEK293/CaV3.1 
and HEK293/CaV3.2 cells were cultured in T25 flasks (6ml total volume, 1:10 dilution) in 
the relevant complete growth media for 3 days before media was replaced for 
complete growth media ± PX-12 (10-300µM, 6mL) and incubated for 10mins prior to 
trypsinisation. Samples were then processed as detailed above. 
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2.9.3. Bicinchoninic acid (BCA) assay  
Before conducting Trx assays, it was important to quantify the total protein content of 
each sample in order to standardise the amount loaded using the bicinchoninic acid 
(BCA) protein assay (Thermo Scientific; Rockford, USA). This assay involves protein 
mediated reduction of Cu2+ which is chelated by BCA producing a deep purple colour, 
the intensity of which is proportional to the amount of protein present, and can be 
measured colorimetrically (Smith et al., 1985). The assay was conducted according to 
manufacturers’ instructions. Briefly, 10µL BSA protein standards (0, 250, 500, 750, 
1000, 1250, 1500, 1750 and 2000µg/ml) and either 2.5 or 10µL of cell sample was 
loaded onto a 96 well plate and total volume was made up to 200µL with working 
reagent. Plates were incubated for 30mins and absorbance was measured at 570nm 
(Glomax multi-detection system; Promega, UK). A calibration curve was generated 
from the BSA standards using GraphPad Prism version 6 (GraphPad Software, Inc) and 
the absorbance values of the cell sample fitted to calculate total protein.  
 
2.9.4. Assay protocol and data analysis  
Briefly, cell samples were allowed to equilibrate to RT and 15µg total protein was 
loaded into each well. Half of the wells contained TrxR (100nM), which was omitted 
from the other half to enable measurement of background fluorescence. Volume 
(100µL per well) was standardised with assay buffer. For calibration, reference wells 
containing known Trx concentrations (0-244ng) were included. To facilitate the 
reduction of Trx, β-NADPH (5µL per well) was added and plates incubated for 30mins 
prior to fluorescent substrate (20µL per well) addtion. Emission was recorded at 
545nm after excitation at 520nm (Varioskan Flash; Thermo Scientific, UK) over a 60 
minute period (1Hz). All test, background and reference samples were performed in 
triplicate.   
 
All data analysis was conducted offline using GraphPad Prism version 6 (GraphPad 
Software, Inc). Average values per minute were taken and emission intensity was 
plotted against time for each sample. The 10min time point which showed the most 
linear increase in fluorescence was selected (25-35 ± 10 mins) and linear regression 
was conducted to generate a fitted line for each sample. The slope of the background 
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reference sample (0ng Trx) was subtracted from the other reference sample slopes 
(taken from the calculated fit) and a calibration curve was generated. Linear regression 
analysis was then conducted to obtain the Trx standard line equation, and R2 values 
were noted. To calculate Trx concentrations within the cell samples the background 
slope values were deducted from the corresponding test sample slope. This resulting 
slope value was then used to calculate Trx concentration from the standard line 
equation generated from the Trx standards.   
  
2.10. Preparation of reduced thioredoxin (rTRX) 
In order to assess directly the effects of rTrx it was necessary to convert Trx to its 
reduced and active form. To do this, Trx (200µL, 1mg/ml; Sigma-Aldrich, UK), dissolved 
in binding buffer (10mM HEPES, 1mM EDTA, 50mM NaCl, pH, 7.0) was incubated with 
DTT (1mM) at RT (30mins). This solution was then transferred to a strong anion 
exchange spin column (Pierce mini; Life technologies, UK) which was pre-washed with 
binding buffer (400µL) and centrifuged (2000xg, 5mins). The column was then washed 
and centrifuged with binding buffer (400µL, 2000xg, 5mins, x3) with the flow-through 
discarded each time to completely remove any DTT. Elution buffer (250µL, 10mM 
HEPES, 1mM EDTA, 1mM NaCl, pH, 7.0) was added and the column centrifuged 
(2000xg, 5mins) enabling collection of rTrx. BCA assays were conducted (as described 
2.9.3) to determine rTrx concentrations and rTrx was used immediately to minimise 
oxidation.  The effects of oxidised Trx (oTrx), i.e. non-reduced Trx were also examined.  
 
 
2.11. Statistical analysis  
Prior to the selection of statistical analysis, where sample sizes allowed, D'Agostino-
Pearson normality tests were conducted, to ensure that parametric tests were 
appropriate. Unless otherwise stated, Student’s t-tests were subsequently conducted 
when examining differences between two groups, whilst one-way ANOVA with 
multiple comparison tests were used to examine three or more groups. Regarding 
ANOVA, Dunnett’s post-hoc comparison tests were chosen when comparing the mean 
of a control condition with the mean of every other condition. In contrast, Tukey’s 
post-hoc comparison tests were used to compare the mean of each condition with the 
mean of every other condition. As a final option, Bonferroni’s post-hoc comparison 
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tests were used when comparing a selected set of means.  When assessing the effects 
of different experimental conditions on the same cell(s) i.e. matched groups, paired 
Student’s t-tests or repeated-measures one-way ANOVA were used. When 
experimental groups comprised of different populations of cells, un-paired Student’s t-
tests or ordinary one-way ANOVA tests were conducted. All statistical analysis 
described within this thesis was conducted using GraphPad Prism version 6 (GraphPad 
Software, Inc), p values <0.05 were considered statistically significant. 
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Chapter 3 -The role of T-type Ca2+ channels in cellular 
proliferation and [Ca2+]i mobilisation. 
3.1. Introduction  
The current project has been conducted using the commercially-available VSMC cell 
line, A7r5 cells in addition to HEK293 cells stably expressing recombinant CaV3.1 or 
CaV3.2 channels. A7r5 cells were originally derived from rat thoracic aorta (Kimes & 
Brandt, 1976) and have been widely used as a convenient and relatively well 
characterised in vitro VSMC model, particularly for studying mechanisms of Ca2+ 
regulation (Carre et al., 2015; Erac et al., 2014; Simard et al., 2015; Sperti & Colucci, 
1991). HEK293 cells contain all the essential biochemical machinery required for post-
translational modifications, they have enabled functional expression of a huge range of 
recombinant proteins such as ion channels, and have been used extensively over the 
past 35 years as both transient and stable expression systems. Originally derived from 
epithelial cells of the human embryonic kidney, HEK293 cells are small in size and have 
minimal processes which make them ideal for patch-clamp electrophysiology (Thomas 
& Smart, 2005). 
 
Previous projects conducted by the Peers group investigating the effects of novel T-
type Ca2+ channel regulators CO and H2S on VSMC proliferation, have utilised the same 
cell lines as reported here (Duckles et al., 2015; Elies et al., 2015). As variations in ion 
channel expression can occur with prolonged cell culture (Richard et al., 1992), it was 
important to re-validate T-type Ca2+ channel expression and dissect the contribution of 
individual CaV channel isoforms to proliferation and Ca
2+ handling. Mibefradil is a 
widely used T-type Ca2+ channel blocker (CCB), although when applied at high 
concentrations also  inhibits  L-type Ca2+ currents (Mishra & Hermsmeyer, 1994). 
Nifedipine belongs to a family of drugs called dihydropyridines (DHPs), which are 
highly selective L-type CCBs. The high selectivity arises as the pore forming α1C subunit 
of L-type Ca2+ channels has a unique high affinity DHP binding site involving IIIS6 and 
IVS6 transmembrane segments (Peterson et al., 1996).  
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3.2. Results  
3.2.1. Characterisation of CaV channels in A7r5 cells 
Two batches of A7r5 cells were used within the current project: “old” A7r5 cells were 
sub-cultured to 100% confluency and had been used within the group for many years 
whilst the “new” A7r5 cells were sub-cultured at lower confluence, in an attempt to 
maximise T-type Ca2+ channel expression (Richard et al., 1992). To quantify CaV3.1 and 
CaV3.2 mRNA expression and allow for comparison between the two batches of cells, 
real-time polymerase chain reaction (rtPCR) was conducted. When using this 
technique, it is important to select a housekeeping gene which is expressed at similar 
levels to the target gene(s) of interest. It was determined that the large ribosomal 
subunit (17S) was expressed at higher levels than both hypoxanthine 
phosphoribosyltransferase (HPRT1) and the target genes CaV3.1 and CaV3.2; reflected 
by the lower threshold cycle (CT) values. As the average CT value for HPRT1 was similar 
to that of CaV3.1, it was confirmed to be an appropriate housekeeper gene and was 
used for all subsequent analysis (Figure 3.1). Both batches of A7r5 cells expressed 
CaV3.1 mRNA at significantly higher levels than CaV3.2 mRNA. CaV3.1 and CaV3.2 mRNA 
expression was much higher in the “new” A7r5 cells sub-cultured at low confluence 
(70-80%) compared to the “old” A7r5 cells sub-cultured at greater confluence (90-
100%), as detailed in Figure 3.1. Consequently, the “new” A7r5 cells were used for all 
subsequent experiments unless otherwise stated. Note, rtPCR on the “old” A7r5 cells 
was conducted by Dr Hayley Duckles using an identical protocol and data are included 
with permission (Duckles et al., 2015).  
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Figure 3.1. CaV3.1 and CaV3.2 mRNA is expressed by A7r5 cells 
A, Bar graph showing the average (mean ± s.e.m) threshold cycle (CT) values for the 
target genes CaV3.1 and CaV3.2, and the housekeeping genes hypoxanthine 
phosphoribosyltransferase (HPRT1) and large ribosomal subunit (17S) within A7r5 cells 
(n=8). B, Bar graph showing relative mRNA expression of CaV3.1 (upper y-axis) and 
CaV3.2 (lower y-axis), channel expression is plotted as (mean ± s.e.m) % expression of 
HPRT1, for “old” A7r5 cells sub-cultured at 90-100% confluence (n=7, experiments 
conducted by Dr H. Duckles). C, As B except with “new”A7r5 cells sub-cultured at 70-
80% confluence (n=8, note larger axis). A7r5 cell lysates were measured in triplicate 
wells with the mean value used as n=1. All data were analysed using unpaired students 
t-tests, *p≤0.05, ****p ≤0.0001.  
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In order to assess the sub-cellular distribution of CaV3.1 and CaV3.2 channels, 
immunofluorescence was conducted on “new” A7r5 cells. On all occasions, DAPI (4',6-
diamidino-2-phenylindole) was co-applied to label cell nuclei. Initial attempts to detect 
the CaV3.1 and CaV3.2 antibodies within A7r5 cells using the Alexa Fluor 488 secondary 
antibody (detected in green) were unsuccessful due to prominent background 
fluorescence, apparent upon omission of either the primary or secondary antibodies 
(Error! Reference source not found.). NAD(P)H is a common source of 
autofluorescence detected within cytosolic, mitochondrial and nuclear regions. Within 
bovine coronary artery smooth muscle cells, NAD(P)H-mediated autofluorescence has 
been observed, with peaks of excitation and emission around 340nm and 450nm 
respectively (Gao & Wolin, 2008). Resultantly, Alexa Fluor 555 (detected in red) was 
used as the secondary antibody within A7r5 cells, as no background fluorescence was 
observed at these wavelengths (Error! Reference source not found.). Low levels of 
immuno-reactivity (IR) to both CaV3.1 and CaV3.2 antibodies were detected within 
some A7r5 cells. CaV3.2 channels were found to be localised around nuclear regions 
(Error! Reference source not found.), whereas CaV3.1 channels appeared to have a 
more generalised distribution throughout A7r5 cells (Error! Reference source not 
found.). Both CaV3.1 and CaV3.2 primary antibodies were found to be highly specific, as 
they showed no cross-reactivity with the opposing isoform, i.e. no CaV3.2 IR was 
apparent within HEK293/CaV3.1 cells and vice versa (Error! Reference source not 
found. and 0, discussed in further detail within section 3.2.4). 
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Figure 3.2. Background fluorescence is detected in “new” A7r5 cells at 488nm 
Control images for dual-label immunofluorescence using anti-CaV3.1 (1:100) and anti-
CaV3.2 (1:1000) primary antibodies, with Alexa Fluor-488 secondary antibody (1:1000, 
left panel, green images), and DAPI to label cell nuclei (right panel, blue images). 
Fluorescence is observed within A7r5 cells when; A, the Alexa Fluor 488 secondary 
antibody is applied alone, B, when the CaV3.1 primary antibody is applied alone (i.e. no 
secondary) and C, when the CaV3.2 primary antibody is applied alone (i.e. no 
secondary). All scale bars 50µm.  
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Figure 3.3. No background fluorescence is detected in “new” A7r5 cells at 555nm 
Control images for dual-label immunofluorescence using anti-CaV3.1 (1:100) and anti-
CaV3.2 (1:1000) primary antibodies, with Alexa Fluor-555 secondary antibody (1:500, 
left panel, red images), and DAPI to label cell nuclei (right panel, blue images). No 
fluorescence is observed within A7r5 cells when; A, the Alexa Fluor 555 secondary 
antibody is applied alone, B, when the CaV3.1 primary antibody is applied alone (i.e. no 
secondary) and C, when the CaV3.2 primary antibody is applied alone (i.e. no 
secondary). All scale bars 50µm.  
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Figure 3.4. Sub-cellular distribution of CaV3.1 channels within “new” A7r5 cells 
Dual-label immunofluorescence using anti-CaV3.1 (1:100) with Alexa Fluor-555 
secondary antibody (1:500, left panels, red images) and DAPI to label cell nuclei (centre 
panel, blue images), merged CaV3.1 and DAPI images (right panels). A, A7r5 cells show 
low levels of diffuse CaV3.1 immuno-reactivity (IR), regions of interest (white box) are 
magnified in (i). All scale bars 50µm.   
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Figure 3.5. Sub-cellular distribution of CaV3.2 channels within “new” A7r5 cells 
Dual-label immunofluorescence using anti-CaV3.2 (1:1000) with Alexa Fluor-555 
secondary antibody (1:500, left panels, red images) and DAPI to label cell nuclei (centre 
panels, detected in blue), merged CaV3.1 and DAPI images (right panels). A, A7r5 cells 
show low levels of CaV3.2 immuno-reactivity (IR) localised within and around cell 
nuclei, regions of interest (white box) are magnified in (i). All scale bars 50µm.  
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Due to a wide variety of factors such as post-translational modification and dynamic 
membrane trafficking, mRNA expression does not necessarily equate to functional ion 
channel expression. For example, increased T-type Ca2+ channel current-density 
observed in response to chronic insulin stimulation within rat pituitary derived GH3 
cells was shown to be due to increases in dynamic endosomal recycling and trafficking 
of CaV3.1 to the surface membrane and not alterations in mRNA levels or promoter 
activity (Toledo et al., 2012). We therefore employed patch-clamp electrophysiology to 
assess functional T-type and L-type Ca2+ channel expression within A7r5 cells. 
 
As illustrated by Figure 3.2, both the T- and L-type SS protocols evoked Ca2+ currents 
within some A7r5 cells. Whilst the SS protocols were designed to maximally activate T- 
or L-type Ca2+ channels it was possible that these voltage protocols were not entirely 
subtype selective (Chapter 2). As such, quotations marks are used when describing 
currents evoked using the SS protocols in A7r5 cells. The distribution of Ca2+ currents 
was highly heterogeneous; some A7r5 cells expressed either “T-type” or “L-type” Ca2+ 
currents in isolation, some cells expressed both types of current and many cells had no 
detectable CaV current. As approximate values, 75% of cells expressed both “T-” and 
“L-type” Ca2+ currents, 10% expressed “L-type” Ca2+ currents alone, 5% expressed “T-
type” Ca2+ currents in isolation and 5% showed no detectable CaV current. It would 
have been advantageous to provide a more accurate quantification, however, on many 
occasions recordings did not last long enough to run both single-step protocols. In 
addition, to ensure effective voltage-clamp, only small A7r5 cells were recorded from 
which would have introduced a selection bias and decreased the validity of any 
quantification. Regarding current-voltage (I-V) relationships, cells exhibiting 
predominantly “L-type” Ca2+ currents showed maximal activation at +20mV. By 
contrast, cells exhibiting predominantly “T-type” Ca2+ currents displayed maximal 
activation at -20mV and cells with mixed populations showed maximal activation at 
0mV.  
 
 
80 
 
A(i)
-80mV
-20mV
-50mV
+20mV
iiiii “T-type” “L-type”
B(i) iiiii
C(i) ii
 
Figure 3.2. T-type and L-type Ca2+ channel currents are heterogeneously expressed 
within “new” A7r5 cells 
Whole-cell patch-clamp recordings from 3 representative “new” A7r5 cells using Ca2+ 
(15mM), as the charge carrier. A, Cell with both T- and L-type Ca2+ currents. B, Cell with 
predominant “L-type” Ca2+ current. C, Cell with predominant “T-type” Ca2+ current. (i), 
Current-voltage relationships with red line showing voltage producing maximal 
current, (ii), “T-type" Ca2+ current traces evoked from single step(SS)-depolarisations 
to -20mV from a holding potential of -80mV, (iii), “L-type” Ca2+ current traces evoked 
from SS-depolarisations to +20mV from a holding potential of -50mV. All scale bars 
50pA (vertical), 50ms (horizontal). Due to the potential activation of L-type mediated 
Ca2+ current using the T-type SS protocol and vice versa, “T-type” and “L-type” currents 
are labelled with quotation marks.   
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For single step (SS) voltage protocols, “T-type” Ca2+ currents were stimulated by 
repetitive depolarisations (0.1Hz) to -20mV (200ms) from a holding potential (Vh) of -
80mV. This evoked Ca2+ currents showing rapid activation and inactivation, the 
characteristic shape of T-type Ca2+ channel currents. “L-type” Ca2+ channel currents 
were stimulated by SS voltage protocols to +20mV (200ms, 0.1Hz) from a Vh of -50mV. 
When using Ca2+ as the charge carrier this produced currents with rapid activation and 
both a slowly inactivating and a sustained component. L-type Ca2+ currents are 
generally characterised by their sustained shape resulting from their very small degree 
of voltage-dependent inactivation. It should be noted however, that the kinetics and 
resultant current shape is highly dependent on the L-type Ca2+ channel isoform, splice 
variant and auxiliary subunits expressed. These factors can dictate varying degrees of 
Ca2+-dependent inactivation which may account for the slowly inactivating component 
observed, as reviewed within (Lipscombe et al., 2004). 
 
Interestingly, the amplitude of currents recorded in response to L-type SS protocols 
were of smaller amplitude than those recorded at the equivalent voltage (+20mV) in I-
V protocols, also illustrated in Figure 3.2. This further raises the possibility that 
summation of L- and T-type Ca2+ currents was occurring. In order to determine 
whether the currents evoked by the two SS protocols were mediated solely by the 
channel of interest, we examined the effects of specific T- and L-type Ca2+ channel 
blockers (CCBs). Currents evoked using the T-type SS voltage protocol were inhibited 
by the selective T-type CCB NNC55-0396 (3µM, NNC) in a partially reversible manner, 
whilst the L-type selective CCB nifedipine (2µM) had no significant effect on T-type 
Ca2+ channel current amplitudes, when applied to a limited number of cells (Figure 
3.3). This suggested that only T-type Ca2+ channels were contributing to the Ca2+ influx 
using this SS protocol. Due to the heterogeneous patterns of T- and L-type Ca2+ current 
expression in A7r5 cells (Figure 3.2), the observation that some currents evoked using 
the T-type SS were nifedipine-insensitive does not necessarily translate to the whole 
A7r5 population 
  
For the L-type SS voltage protocols, Ba2+ (20mM) was examined as an alternative 
charge carrier. This significantly enhanced the amplitude of L-type Ca2+ currents and 
almost completely eliminated the slowly inactivating component, resulting in a 
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sustained current shape more characteristic of L-type Ca2+ currents (Figure 3.4). 
Reducing the stimulating voltage-pulse duration (100ms from 200ms) whilst using Ba2+ 
had the added advantage of reducing L-type Ca2+ current rundown (data not shown). 
Consequently, Ba2+ was used for all SS L-type recordings. Nifedipine (2µM) inhibited 
currents evoked by the L-type SS protocol in a partially reversible manner. Surprisingly, 
L-type Ca2+ currents were also inhibited by NNC (3µM), indicating either that NNC was 
not selective for T-type Ca2+ channels at 3µM or that some of the current recorded 
using the L-type SS was being facilitated by T-type Ca2+ channels.  
 
Together, these results show that A7r5 cells express functional T- and L-type Ca2+ 
channels, that both CaV3.1 and CaV3.2 mRNA is expressed with CaV3.1 in greater 
abundance and that CaV3.1 channels tend to be localised around the cell membrane, 
whereas CaV3.2 channels tend to be localised around nuclear regions.  
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Figure 3.3. A7r5 “T-type” Ca2+ currents are inhibited by NNC55-0396 
Whole-cell patch-clamp recordings from “new” A7r5 cells. Currents evoked by step-
depolarisations (200ms duration, 0.1Hz) from -80mV to -20mV. Due to potential 
activation of L-type mediated Ca2+ currents using this protocol “T-type” is labelled with 
quotation marks. A, Example time-series plot illustrating the effects of NNC55-0396 
(NNC, 3µM, black bar) applied via the perfusate on “T-type” Ca2+ current amplitude B, 
Corresponding current trace (from A) showing both the effects of NNC (black trace) on 
control amplitude (red trace) and the small degree of washout (blue trace), scale bar 
50pA (vertical), 50ms (horizontal). C, Bar chart illustrating (mean ± s.e.m) peak “T-
type” Ca2+ current amplitude (% of control) in the presence of NNC (black box) and 
after washout (white box), n=4. D-F, As (A-C), except with nifedipine (2µM) and no 
washout data. F, n=3.  
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Figure 3.4. Ba2+ augments the size and shape of A7r5 “L-type” Ca2+ currents 
Whole-cell patch-clamp recordings from “new” A7r5 cells. Currents evoked by step-
depolarisations (100ms duration, 0.1Hz) from -50mV to +20mV. Due to potential 
activation of T-type mediated Ca2+ currents using this protocol “L-type” is labelled with 
quotation marks. A, Example time-series plot illustrating the effects of switching to 
Ba2+ (20mM, black bar) from Ca2+ (15mM) as the charge carrier on L-type Ca2+ current 
amplitude. B, Corresponding L-type Ca2+ current trace (from A) showing effects of Ba2+ 
(black trace) on control amplitude and current shape (red trace), scale bar 100pA 
(vertical), 40ms (horizontal). C, Bar chart illustrating peak amplitude (mean ± s.e.m) of 
L-type Ca2+ currents using either Ca2+ (black box) or Ba2+ (grey box) as the charge 
carrier, n=7. Data were analysed using paired Student’s t-test, **p<0.01.  
 
 
 
 
 
 
 
 
 
85 
 
NNCnifedipine
%
 c
o
n
tr
o
l a
m
p
li
tu
d
e
NNCnifedipine wash
%
 c
o
n
tr
o
l a
m
p
li
tu
d
e
A D
B
C F
E
 
Figure 3.5. A7r5 “L-type” Ca2+ currents are inhibited by nifedipine and NNC55-0396 
Whole-cell patch-clamp recordings from “new” A7r5 cells. Currents evoked by step-
depolarisations (200ms duration, 0.1Hz) from -50mV to +20mV, using Ba2+ (20mM) as 
the charge carrier. Due to potential activation of T-type mediated Ca2+ currents using 
this protocol “L-type” is labelled with quotation marks. A, Example time-series plot 
illustrating the effects of nifedipine (nif, 2µM, black bar) applied via the perfusate 
(black bar) on L-type Ca2+ current amplitude, B, Corresponding L-type Ca2+ current 
trace (from A) showing both the effects of nif (black trace) on control amplitude (red 
trace) and the small degree of washout (blue trace), scale bar 50pA (vertical), 50ms 
(horizontal). C, Bar chart illustrating (mean ± s.e.m) peak L-type Ca2+ current amplitude 
(% of control amplitude) in the presence of nif (black box, n=12) and after washout 
(white box, n=6). D-F, As (A-C), except showing the effects of NNC (3µM). F, n=5, (no 
washout data). 
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3.2.2. The effects of subtype specific CCBs on A7r5 proliferation and Ca2+ handling  
We then examined what effects subtype specific CCBs would have on proliferation. As 
shown by the control growth profiles within Figure 3.6, both batches of A7r5 cells were 
proliferative, reflected by the significant increase in cell number between day 0 and 
day 3 (d0-d3). This also confirmed that a three day assay was a suitable time-course for 
proliferation assays. Both batches similarly exhibited slow rates of growth over the first 
day of the assay following serum deprivation (d0-d1) indicating that effective 
synchronisation of the cell cycle had been achieved.  
 
Upon comparing the average daily increases in A7r5 cell number within Figure 3.6 key 
differences between the two batches are apparent. Between d1-d2 only the “new” 
batch of A7r5 cells significantly increased in cell number whereas between d2-d3 only 
the “old” A7r5 cells significantly increased. This shows that the newer A7r5 cells began 
and ceased to proliferate more quickly. As T-type Ca2+ channel expression is associated 
with proliferation (Kuga et al., 1996; Rodman et al., 2005; Tzeng et al., 2012); the 
faster initiation may be due to the higher levels of T-type Ca2+ channel expression as 
detailed in Figure 3.1. The “new” A7r5 cells were larger in size (Figure 3.7) and 
correspondingly showed greater confluency on day three of the assay, despite a much 
lower average cell number compared to “old” A7r5 cells. Cultured cells do not 
proliferative within confluent cultures due to a well-defined process termed contact 
inhibition of proliferation (CIP), which is evident by a plateau in growth curves 
(McClatchey & Yap, 2012). With consideration to this, the greater confluence of the 
“new” A7r5 cells likely explains the faster decline in proliferation. In addition to their 
smaller size, the morphology of “new” A7r5 cells was flatter and less spindle-shaped 
when compared to the “old” A7r5 cells (Figure 3.7). A decline in the spindle-shaped 
“hill and valley” morphology within VSMCs has been previously reported alongside 
increased proliferative responses to serum. These morphological changes are 
associated with the switch from contractile to proliferative phenotypes (Faries et al., 
2001; Pandolfi et al., 2003). An alternative explanation for the morphological 
differences currently observed could be contamination of the “new” A7r5 cell culture 
with fibroblasts. Further studies using immunohistochemistry with antibodies directed 
again SMC markers such as smooth muscle myosin heavy chain, calponin-1 and 
smooth muscle α-actin (SMA) would address this possibility.   
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Figure 3.6. Different A7r5 batches exhibit contrasting growth profiles 
 Line graphs showing average A7r5 cell number (mean ± s.e.m) over three day 
proliferation assays. A, “Old” A7r5 cells proliferate between day 0 and day 3, with the 
greatest daily increase between day 2 and 3 (n=7). B, As (A) except with “new” A7r5 
cells showing greatest daily increase between day 1 and 2, (note different y axis, n=10). 
All cell counts were made in triplicate with the mean value counting as n=1. Data were 
analysed by one-way ANOVA followed by Bonferroni’s multiple comparison test, 
**p<0.01, ****p<0.0001.  
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Figure 3.7. “New” A7r5 cells are larger in size than “old” A7r5 cells 
Representative phase-bright images showing: A-B, “new” A7r5 and C-D, “old” A7r5 cell 
morphology. Scale bars 50µm.  
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Proliferation assays examining the effects of CCBs using the “old” A7r5 cells were 
previously conducted by Dr Hayley Duckles. Mibefradil was shown to cause a 
concentration-dependent decrease in proliferation without any significant effect on 
cell viability (1-5µM). Contrastingly, nifedipine was without significant effect on “old” 
A7r5 cell proliferation or viability (Figure 3.8, (Duckles et al., 2015). These data were 
used to select appropriate concentrations of mibefradil and nifedipine for subsequent 
proliferation assays.   
 
Similar observations were made when these experiments were repeated with “new” 
A7r5 cells (Figure 3.9). Mibefradil (3µM) significantly inhibited A7r5 proliferation 
without any effect on viability, whilst nifedipine (2µM) was without effect. The effects 
of the more recently developed T-type Ca2+ channel inhibitors ML218 and NNC were 
also examined over a range of concentrations. NNC caused a concentration-dependent 
reduction in A7r5 proliferation without effecting cell viability. At higher concentrations, 
NNC (10-30µM) was cytotoxic as reflected by the dramatic increase in average dead 
cell counts. ML218 also reduced proliferation in a concentration-dependent manner, 
with ML218 (30µM) showing the greatest reduction in average A7r5 cell number with 
no significant increase in cell death. As many of the drugs used were dissolved in 
DMSO, we also examined the potential effects of exposing cells to the vehicle alone. 
DMSO (1:1000) was the highest concentration used throughout the project, and as 
shown, had no effect on A7r5 proliferation (Figure 3.9). Together, these findings 
demonstrate that T-type Ca2+ channels regulate A7r5 proliferation and rule out the 
contribution of L-type Ca2+ channels. 
 
As intracellular Ca2+ (Ca2+i) plays an integral role in VSMC proliferation, it was 
important to assess the effects of CCBs on A7r5 Ca2+ handling. For “old” A7r5 
populations, a modest depolarising stimulus was applied with the aim of preferentially 
activating T-type, rather than L-type Ca2+ channels, achieved by switching to a 
perfusate containing a modestly elevated K+ concentration ([K+] 20mM, 5mM control). 
Under control conditions, the high K+ stimulus reliably induced a rapid increase in 
[Ca2+]i leading to sustained high frequency oscillations. Removal of the depolarising 
stimulus was accompanied by a rapid cessation of oscillations and gradual return of 
[Ca2+]i back to baseline levels (Figure 3.10 & Figure 3.11). 
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Figure 3.8. Mibefradil suppresses proliferation of “old” A7r5 cells 
Bar graphs showing the proliferative response (mean ± s.e.m) of A7r5 cells to 
increasing concentrations of specified drugs. Proliferation (plotted as bar graphs, 
corresponding to the left-hand y-axis) was monitored on day 0 (solid bars) and on day 
3 (open bars) in the absence or presence of either mibefradil (A, n=4) or nifedipine (B, 
n=3). The open circles show the corresponding non-viable cell count (plotted against 
corresponding right-hand y-axis). All cell counts were made in triplicate with the mean 
value representing n=1. Data were analysed via ratio repeated measures one-way 
ANOVA followed by Dunnett’s multiple comparison test using day 3 control (no drug) 
counts as control, **p<0.01,****p<0.0001. Data was taken with permission from 
Duckles et al. (2015). (Duckles et al., 2015) 
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Figure 3.9. T-type Ca2+ channel inhibitors reduce “new” A7r5 proliferation  
Bar graphs showing the proliferative response (mean ± s.e.m) of “new” A7r5 cells to 
specified drugs, as monitored on day 3. A, Effects of mibefradil (mib, 3µM) and 
nifedipine (nif, 2µM) both (n=9) and B, DMSO (1:1000, n=6) on A7r5 proliferation as 
monitored on day 3, data analysed using unpaired students t-tests. C, Proliferation 
with increasing concentrations of NNC55-0396 (plotted against the left-hand y-axis) 
monitored on day 0 and on day 3. The red circles show the corresponding non-viable 
cell count (plotted against the right-hand y-axis). Data were analysed via one-way 
ANOVA followed by Dunnett’s multiple comparison test (n=7 (n=2 for 10 and 30µM)). 
D, As (C), except with ML218 (n=4). All cell counts were made in triplicate with the 
mean value representing n=1, for all graphs *p≤0.05, **p≤0.01.  
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For all experiments, control responses were individually recorded to ensure that when 
the depolarising stimulus was reapplied to the same cell population there was no 
significant difference in the amplitude of responses (Figure 3.10 & Figure 3.11). 
  
A variety of CCBs were applied to “old” A7r5 cells prior to and during the 2nd 
depolarisation, and it was found that the selective T-type CCBs ML-218 (30µM) and 
mibefradil (1µM) significantly reduced the amplitude of the response to the 2nd 
depolarisation when compared to the corresponding 1st depolarisation (Figure 3.10). A  
Mibefradil (3µM) was also shown to produce a similar degree of inhibition. The L-type 
Ca2+ channel specific inhibitor nifedipine (2µM) also reduced the amplitude of the 2nd 
response (Figure 3.11). Collectively, these findings show that Ca2+ oscillations observed 
in response to depolarisation within “old” A7r5 cells are facilitated by both T-type and 
L-type Ca2+ channels.  
 
The effects of NNC were also examined, however, for these experiments a decline in 
the amplitude of response between the 1st and 2nd depolarisations was apparent 
alongside a dramatic reduction in Ca2+ oscillations within control situations (data not 
shown). This indicated a phenotypic variation within the “old” A7r5 cells and 
prevented reliable conclusions regarding NNC effects. New A7r5 cells, were resultantly 
purchased and shown to express significantly higher levels of CaV3.1 and CaV3.2 mRNA 
(Figure 3.1). These “new” A7r5 cells were used for the majority of subsequent 
experiments.  
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Figure 3.10. T-type CCBs reduce depolarisation-induced Ca2+ entry in “old” A7r5 cells 
Example Ca2+ microfluorimetry traces showing the effects of CCBs on Fura 2 ratio units 
(340:380), representing Δ [Ca2+]i in response to depolarisation. Black bars above traces 
show periods where perfusate containing elevated [K+] (20mM, control 5mM) was 
applied in order to depolarise cells. Red lines show the period of CCB application (as 
stated). A, Example control trace matched with, B, Example trace showing the effects 
of ML218 (30µM) applied between the 1st and 2nd depolarisations. C, Bar graph 
showing the (mean ± s.e.m) response amplitude to the 1st and 2nd depolarisations in 
control (blue bar, n=4) and ML218 (30µM, red bar, n=7) conditions. D-E, As (A-B), 
except showing the effects of mibefradil (1µM). F, As (C), except showing control (blue 
bar, n=9) and mibefradil (1µM, red bar, n=11). All data were analysed using paired 
Student’s t-tests, ****p≤0.0001. 
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Figure 3.11. T-type and L-type CCBs reduce depolarisation-induced Ca2+ entry in “old” 
A7r5 cells  
Example Ca2+ microfluorimetry traces showing the effects of CCBs on Fura 2 ratio units 
(340:380), representing Δ [Ca2+]i in response to depolarisation. Black bars above traces 
show periods where perfusate containing elevated [K+] (20mM, control 5mM) was 
applied in order to depolarise cells. Red lines show the period of CCB application (as 
stated). A, Example control trace matched with, B, Example trace showing the effects 
of mibefradil (3µM) applied between the 1st and 2nd depolarisations. C, Bar graph 
showing the (mean ± s.e.m) response amplitude to the 1st and 2nd depolarisations in 
control (blue bar, n=9) and mibefradil (3µM, red bar, n=11) conditions. D-E, As (A-B), 
except with nifedipine (2µM), F, As (C), except with nifedipine (2µM, control n=12, 
mibefradil n=11). All data were analysed using paired Student’s t-tests, ****p≤0.0001.  
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Upon examination of basal Ca2+ levels within the “new” A7r5 cells, spontaneous Ca2+ 
oscillations of variable frequencies were apparent under control conditions within 
some A7r5 populations as represented in Figure 3.12. These oscillations rapidly ceased 
upon removal of extracellular Ca2+ (Ca2+e) suggesting that they were mediated by Ca
2+ 
channel influx, presumably via channels present within the cell membrane. As T-type 
Ca2+ channels have well established roles in pacemaker activity within the sinoatrial 
node and various brain regions (Mesirca et al., 2014; Nelson et al., 2006), this 
spontaneous oscillatory activity may be attributable to increased levels of T-type Ca2+ 
channels.   
 
Further investigation revealed that removal of Ca2+e also caused a decrease in baseline 
Ca2+ levels within “new” A7r5 populations which did not exhibit spontaneous 
oscillations. This suggested that a small degree of Ca2+ influx was occurring under 
control conditions in the absence of oscillations. As T-type Ca2+ channels exhibit a 
characteristic overlap in activation and steady-state inactivation voltages, they can be 
open without fully inactivating at the cell’s resting membrane potential (Vm). This 
commonly facilitates tonic basal Ca2+ influx, referred to as a “window current”, as 
reviewed (Perez-Reyes, 2006). As no measurable window current was detectable 
within the “old” A7r5 cells (data not shown) which expressed significantly lower levels 
of T-type Ca2+ channels, it was likely that the recorded window current within the 
“new” A7r5 cells was mediated by these channels. In order to investigate this further, 
NNC (3µM) was applied to A7r5 populations and, as illustrated in Figure 3.13, such an 
exposure decreased basal Ca2+ levels. After pre-treatment with, and in the continued 
presence of NNC (3µM), the fall in ratio units (ru) in response to removal of Ca2+e was 
considerably lower when compared to control conditions. These findings clearly 
demonstrate that T-type Ca2+ channels contribute a window current within “new” A7r5 
cells.  
 
Following an identical protocol, the effects of nifedipine (2µM) were also assessed. 
Nifedipine was surprisingly found to have similar effects on “new” A7r5 cell basal 
[Ca2+]i as was observed for NNC. Removal of Ca
2+
e, after both pre-treatment and in the 
continued presence of nifedipine, caused a reduction in [Ca2+]i, which was significantly 
lower than observed in control conditions (Figure 3.13). This suggested that the 
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observed window currents were also partially facilitated by L-type Ca2+ channels. This 
was unexpected as these channels are activated at relatively high voltages and are 
therefore usually presumed to be closed at resting Vm. Whilst, electrophysiological 
recordings had shown that T-type Ca2+ currents were insensitive to nifedipine (Figure 
3.3), further investigation was conducted within recombinant HEK293/CaV3.1 cells to 
assess the potential non-specific effects of nifedipine on basal Ca2+ levels (Figure 3.17). 
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Figure 3.12. “New” A7r5 cells with higher T-type Ca2+ channel expression exhibit 
spontaneous Ca2+ oscillations 
Example Ca2+ microfluorimetry traces showing the Fura 2 ratio units (340:380), 
representing Δ [Ca2+]i,, under both control conditions and following the removal of 
extracellular Ca2+ (purple bar), and clearly showing different patterns of oscillatory 
activity within 3 different A7r5 populations (A-C).  
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Figure 3.13. NNC55-0396 and nifedipine inhibit the “new” A7r5 Ca2+ window current 
Example Ca2+ microfluorimetry traces showing Fura 2 ratio units (340:380), 
representing Δ [Ca2+]i, upon removal of extracellular Ca
2+  (CF, purple bar) under: A,D, 
control conditions, B, after pre-treatment and in the continuous presence of NNC55-
0396 (green bar, NNC, 3µM). E, As (B), except with nifedipine (orange bar, nif, 2µM). C, 
Bar graph showing (mean ± s.e.m) decrease in ratio units (340:380) in response to: CF 
in control conditions (black box, CF, n=44), during NNC pre-treatment (green box, 3µM, 
n=12), and during CF with NNC present (purple box, 3µM, n=12). F, As (C), except 
showing control conditions (black box, n=44), nif pre-treatment (orange box, 2µM, 
n=25), and CF with nif present (purple box, 2µM, n=25). Effects of CF between control 
and NNC or nif conditions were analysed using unpaired Student’s t-tests, *p≤0.05, 
**p≤0.01.  
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3.2.3. Effects of CaV3.1 and CaV3.2 expression on HEK293 cell proliferation and Ca
2+ 
handling 
In order to examine the effects of T-type Ca2+ channel expression on cellular 
proliferation and Ca2+ handling in isolation, and also to assess potential isoform 
differences, recombinant HEK293 cells stably transfected with either CaV3.1 or CaV3.2 
channels (HEK293/CaV3.1 and HEK293/CaV3.2 respectively) were employed. 
Proliferation assays, conducted over a three day period, revealed that both 
HEK293/CaV3.1 and HEK293/CaV3.2 cells proliferated at a significantly greater rate 
when compared to untransfected (control) HEK293 cells (wt HEK293), as shown by the 
differences in average cell number on day 3 (Figure 3.14). NNC was applied at a lower 
concentration (1µM)  than used for A7r5 proliferation assays as NNC (3µM) caused an 
increase in HEK293 non-viable cells counts on some occasions (data not shown). Figure 
3.15 demonstrates that NNC (1µM) caused a significant reduction in HEK293/CaV3.1 
and HEK293/CaV3.2 cell proliferation but was without effect on wt HEK293 cells. 
Despite this observed reduction, the average HEK293/CaV3.1 and HEK293/CaV3.2 cell 
numbers in NNC conditions remained elevated when compared to wt HEK293 cells 
under control conditions. As the IC50 of NNC within HEK293/CaV3.1 cells is 7µM (Li et 
al., 2005) it is likely that NNC (1µM) only partially inhibited T-type Ca2+ channels, which 
may explain why the proliferative rate of recombinant cells remains higher than for wt 
HEK293 cells. These data demonstrate that CaV3.1 or CaV3.2 expression increases 
HEK293 cell proliferation.  
 
The proliferative rate of a HEK293/CaV3.2 cell line generated within the Peers group by 
Dr Jason Scragg (HEK293/CaV3.2/clone P) was also examined and, as shown in Figure 
3.15, proliferated at a similar rate to wt HEK293 cells. Furthermore, no inhibition in 
HEK293/CaV3.2/clone P proliferation was observed with NNC (1µM). This 
demonstrates that CaV3.2 expression in itself does not augment proliferation and 
indicates that some form of post-translational modification, sub-cellular localisation 
and/or trafficking mechanism may be critical for development of the highly 
proliferative phenotype. NNC treatment was shown also shown to be without effect on 
viability for any of the cell lines examined (Figure 3.15).  
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Figure 3.14. Recombinant HEK293/CaV3.x cells proliferate at a greater rate compared 
to wild type HEK293 cells 
Bar graph showing the proliferative rates (mean ± s.e.m) of untransfected (control) 
HEK293 cells (WT HEK, n=8) and HEK293 cells stably expressing Cav3.1 and Cav3.2 
(HEK293/CaV3.1, n=12; and HEK293/CaV3.2, n=10, respectively), as counted on day 3. 
All cell counts were made in triplicate with the mean value counting as n=1. Data were 
analysed using one-way ANOVA with Dunnett’s post-hoc comparison test, **p≤0.01, 
****p≤0.0001.  
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Figure 3.15. NNC55-0396 reduces elevated HEK293/CaV3.x cell proliferation 
Bar graphs showing the proliferative responses (mean ± s.e.m) of recombinant 
HEK293/CaV3.x and wt HEK293 cells in the presence of NNC55-0396 (NNC, 1µM) or 
DMSO (1:1000) as counted on day 3; day 0 counts also shown (plotted against the left-
hand y-axis), red circles show the corresponding non-viable cell count (plotted against 
the right-hand y-axis). A, wt HEK293 cells (n=5). B, HEK293/CaV3.1 cells (n=4). C, 
HEK293/CaV3.2 cells (n=4). D, HEK293/CaV3.2/clone P cells (n=6). All cell counts were 
made in triplicate with the mean value counting as n=1. All data were analysed via 
one-way ANOVA followed by Dunnett’s multiple comparison test *p≤0.05, **p≤0.01.  
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3.2.4. Sub-cellular localisation of CaV3.1 and CaV3.2 within recombinant HEK293 cells 
Immunohistochemistry using monoclonal antibodies directed against CaV3.1 or CaV3.2 
was conducted on recombinant HEK293 cells in order to both validate antibody 
specificity and enable comparison of the sub-cellular localisation of T-type Ca2+ 
channels within HEK293/CaV3.1, HEK293/CaV3.2 and HEK293/CaV3.2/clone P cell lines. 
DAPI was co-applied to label cell nuclei. Both the CaV3.1 and CaV3.2 antibodies were 
shown to be highly specific (Error! Reference source not found. and 0 respectively) as 
they showed no cross reactivity with the opposing isoform; i.e. no staining was 
detected when the CaV3.1 antibody was applied to HEK293/CaV3.2 cells and vice versa. 
In addition, no fluorescence was observed when either the primary or secondary 
antibodies were omitted, thus ruling out auto-fluorescence and non-specific labelling 
as confounding factors. 
 
Within HEK293/CaV3.1 cells, CaV3.1 channels were found to be widely distributed 
throughout most cells (0). Dense clusters of CaV3.1 immuno-reactivity (CaV3.1-IR) were 
commonly apparent and adjacent to cell nuclei, i.e. displaying perinuclear distribution. 
In addition, punctate regions of CaV3.1-IR were often observed localised in or around 
the plasma membrane (0). A small number of cells (highlighted by white circle) that did 
not express CaV3.1 were also apparent, labelled by DAPI but showing no CaV3.1-IR. As 
illustrated within 0, a virtually identical pattern of CaV3.2 immuno-reactivity (CaV3.2-IR) 
was observed in HEK293/CaV3.2 cells with dense perinuclear and punctate regions of 
CaV3.2-IR reliably detected. Contrastingly, although CaV3.2-IR was prominent 
throughout HEK293/CaV3.2/Clone P cells the distribution was comparatively diffuse, 
and no clustering of CaV3.2 channels was identifiable (0). This observation may explain 
why HEK293/CaV3.2/Clone P did not show an elevated proliferative rate; suggesting 
that sub-cellular localisation and/or compartmentalisation of CaV3.2 channels may be 
critical for the development of the highly proliferative phenotype. 
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Figure 3.20. CaV3.1 antibody is highly specific 
Dual-label immunofluorescence using anti CaV3.1 (1:100) with Alexa Fluor-488 
secondary antibody (1:1000, left panels, green images) and DAPI to label cell nuclei 
(right panel, blue images). Negative controls showing no CaV3.1 immunoreactivity (IR) 
is detected within; A, HEK293/CaV3.1 cells when the primary (1°) anti-CaV3.1 antibody 
is omitted, B, within HEK293/CaV3.1 cells when the secondary (2°) antibody is omitted 
and C, within HEK293/CaV3.2 cells when both anti-CaV3.1 (1°) and 2° antibodies are 
applied. All images shown are typical representations of findings from a minimum of 
three repeats.  
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Figure 3.21. Sub-cellular localisation of CaV3.1 channels within HEK293/CaV3.1 cells 
Dual-label immunofluorescence using anti-CaV3.1 (1:100) and Alexa Fluor-488 
secondary antibody (1:1000, left panels, green images) and DAPI to label cell nuclei 
(centre panel, blue images), merged CaV3.1 and DAPI images (right panels). A, 
HEK293/CaV3.1 cells show extensive CaV3.1 immunoreactivity (IR) with highly 
pronounced clusters adjacent to nuclei and punctate regions of CaV3.1-IR around the 
plasma membranes; regions of interest (white box) are magnified in (i) where white 
arrows highlight punctate CaV3.1-IR within the plasma membrane. All images shown 
are typical representations of findings from a minimum of three repeats. All scale bars 
50µm.  
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Figure 3.22. CaV3.2 antibody is highly specific 
Dual-label immunofluorescence using anti-CaV3.2 (1:1000) and Alexa Fluor-488 
secondary antibody (1:1000, left panels, green images) and DAPI to label cell nuclei 
(right panel, blue images). Negative controls showing no CaV3.2 immunoreactivity (IR) 
detected within; A, HEK293/CaV3.2 cells when the primary (1°) anti-CaV3.2 antibody is 
omitted, B, within HEK293/CaV3.2 cells when the secondary (2°) antibody is omitted 
and C, within HEK293/CaV3.1 cells, when both anti-CaV3.2 (1°) and 2° antibodies are 
applied. All images shown are typical representations of findings from a minimum of 
three repeats. All scale bars 50µm.  
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Figure 3.23. Sub-cellular localisation of CaV3.2 channels within HEK293/CaV3.2 cells 
Dual-label immunofluorescence using anti-CaV3.2 (1:1000) and Alexa Fluor-488 
secondary antibody (1:1000, left panels, green images) and DAPI to label cell nuclei 
(centre panel, blue images), merged CaV3.2 and DAPI images (right panels). A, 
HEK293/CaV3.2 cells show extensive CaV3.2 immunoreactivity (IR) with highly 
pronounced clusters adjacent to nuclei and punctate regions of CaV3.2-IR around 
plasma membranes; regions of interest (white box) are magnified in (i) where white 
arrows highlight punctate CaV3.2-IR within the plasma membrane. All images shown 
are typical representations of findings from a minimum of three repeats. All scale bars 
50µm.  
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Figure 3.24. Sub-cellular localisation of CaV3.2 channels within HEK293/CaV3.2/Clone 
P cells 
Dual-label immunofluorescence using anti-CaV3.2 (1:1000) and Alexa Fluor-488 
secondary antibody (1:1000, left panels, green images) and DAPI to label cell nuclei 
(centre panel, blue images), merged CaV3.2 and DAPI images (right panels). A, 
HEK293/CaV3.2 cells show extensive and diffuse CaV3.2 immunoreactivity (IR); regions 
of interest (white box) are magnified in (i). All images shown are typical 
representations of findings from a minimum of three repeats. All scale bars 50µm. 
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3.2.5. T-type Ca2+ channels facilitate the window current in recombinant HEK293 cells.  
Ca2+ microfluorimetry was then used to assess the effects T-type Ca2+ channel 
expression on basal Ca2+i levels. Removal of extracellular Ca
2+ (Ca2+e) was achieved by 
switching the standard perfusate to one where EGTA was substituted for Ca2+ (CF). For 
cells facilitating tonic Ca2+ influx (window current) this produced a measurable fall in 
[Ca2+]i, represented by a decrease in the Fura-2 ratio (340:380). Figure 3.16 shows that 
HEK293/CaV3.1 cells conduct a significantly larger window current compared to wt 
HEK293 cells. As the decrease in response to CF for HEK293/CaV3.1 cells is significantly 
reduced after both pre-treatment and in the continual presence of NNC (3µM), which 
is without effect on wt HEK293 cells, it is apparent that CaV3.1 expression increases 
basal [Ca2+]i levels within HEK293 cells. The small fall in [Ca
2+]i in wt HEK293 cells also 
suggests that other routes of Ca2+ entry may be present in these cells, but these were 
dominated by the much larger responses in transfected cells.  
 
The aforementioned CF protocol was also used to demonstrate that nifedipine was 
without effect on the HEK293/CaV3.1 window current, as shown in Figure 3.17, ruling 
out potential non-specific effects of nifedipine on the T-type mediated window 
current. This provides supporting evidence to the observation that the decrease in 
basal Ca2+ observed with nifedipine in A7r5 cells, as shown in Figure 3.13, is due to L-
type Ca2+ channels partially mediating the A7r5 window current rather than non-
specific effects of nifedipine. Previous work conducted by Dr Hayley Duckles showed 
that HEK293/CaV3.2 cells also mediate a window current of significantly larger 
amplitude than that observed in wt HEK293 cells. Figure 3.18, reproduced with 
permission from Duckles et al. (2013), additionally demonstrates that NNC (3µM) 
caused a significant reduction in basal [Ca2+]i in HEK293/CaV3.2 cells but not in wt 
HEK293 cells. Collectively, these data demonstrate that CaV3.1 or CaV3.2 expression 
increases tonic Ca2+ influx within HEK293 cells.  
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Figure 3.16. CaV3.1 expression influences basal [Ca
2+]i in HEK293 cells 
Example Ca2+ microfluorimetry traces illustrating Δ[Ca2+]i (ratio of absorbance), upon 
removal of extracellular Ca2+ (CF, purple line, replaced with 1 mM EGTA) for A, 
HEK293/CaV3.1 cells and B, wt HEK293 cells. Also shown are the effects of NNC55-0396 
(NNC, 3µM, blue line) before and during CF application for C, HEK293/CaV3.1 cells and 
D, wt HEK293 cells. E, Bar chart showing the (mean ± s.e.m) Δ[Ca2+]i  in response to CF 
exposure in control conditions for wt HEK293 cells (blue bars, n=6) and HEK293/CaV3.1 
cells (red bars, n=11), and also in the presence of  NNC55-0396 (3µM, CF+NNC) for wt 
HEK293 cells (n=6) and HEK293/CaV3.1 cells (red bars, n=7). All scale bars 0.1 ru 
(vertical), 120 seconds (horizontal). Data were analysed via one-way ANOVA followed 
by Tukey’s multiple comparison test, ***P<0.001. 
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Figure 3.17. Nifedipine has no effect on the CaV3.1-mediated window current 
Example Ca2+ microfluorimetry traces showing Fura 2 ratio units (340:380) 
representing the Δ[Ca2+]i upon removal of extracellular Ca
2+ (purple bar) under A, 
control conditions and B, after both pre-treatment and in continuous presence of 
nifedipine (nif, 2µM). C, Bar graph showing the (mean ± s.e.m) decrease in ratio units 
(340:380) in response to removal of extracellular Ca2+ in control conditions (black bar, 
n=6) and during nif (2µM) pre-treatment (pink bar, n=7). Scale bars 0.05 ru (vertical), 
120 seconds (horizontal). Data analysed using unpaired Student’s t-tests, **p≤0.01.  
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Figure 3.18. CaV3.2 expression influences basal [Ca
2+]i in HEK293 cells 
Example Ca2+ microfluorimetry traces illustrating the Δ[Ca2+]i (ratio of absorbance), 
upon removal of extracellular Ca2+ (CF, grey bar, replaced with 1 mM EGTA) for; A, 
HEK293/CaV3.2 cells and D, wt HEK293 cells. C, Bar graph illustrating (mean ± s.e.m) 
basal [Ca2+]i levels recorded in HEK293/CaV3.2 cells (open bars, n=6) and wt HEK293 
cells (shaded bars, n=6) in the presence and absence of extracellular Ca2+ as indicated. 
B, Example trace showing, effects of NNC55 0396 (NNC, 3μM, grey bar) on 
HEK293/CaV3.2 cells and E, wt HEK293 cells. F, Bar graph illustrating (mean ± s.e.m.) 
basal [Ca2+]i levels recorded in HEK293/CaV3.2 cells (open bars, n=8) and wt HEK293 
cells (shaded bars, n=8) before (con), during (NNC) and after (wash) exposure to NNC 
as indicated. Data were analysed via paired or unpaired Student’s t-tests as 
appropriate, and compared with appropriate controls, *P<0.05; **P<0.01, ***P<0.001. 
All scale bars 0.1ru (vertical), 100ms (horizontal). Figure reproduced with permission 
from Duckles et al. (2013).  
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3.3. Discussion  
3.3.1. A7r5 cells express functional T- and L-type Ca2+ channels  
A7r5 cells used throughout the current project as an in vitro VSMC model were shown 
to express T-type Ca2+ channels and rtPCR revealed that CaV3.1 mRNA was the primary 
isoform expressed, but CaV3.2 mRNA was also detected. A number of previous studies 
using molecular biology techniques have demonstrated both CaV3.1 and CaV3.2 
expression in rat, mouse and human VSMCs, throughout a range of vascular beds 
including rat renal, cerebral, mesenteric and cremaster arteries as reviewed recently 
by (Hansen, 2015). The “new” A7r5 cells cultured at lower confluence expressed 
considerably more CaV3.1 and CaV3.2 mRNA when compared to “old” A7r5 cells 
cultured at 90-100% confluence. This observation supports the findings of Richard et 
al. (1992) who used electrophysiological and pharmacological means to characterise 
the functional expression of low-voltage activated (LVA, i.e. T-type) channels and high-
voltage activated (HVA, i.e. L-type) Ca2+ channels within primary cultures of rat 
thoracic aortic smooth muscle cells. An inhibitory effect of confluency on functional 
LVA channel activity was reported as LVA current expression declined dramatically, 
alongside a smaller decrease in HVA currents, when primary cultures were allowed to 
reach 100% confluence prior to passage (Richard et al., 1992). Results presented here 
are consistent with these findings. 
 
Immunofluorescence revealed differential staining patterns for both CaV3.1 and CaV3.2 
channels in “new” A7r5 cells. Low levels of CaV3.2 immuno-reactivity (IR) was 
detected; localised within and around cell nuclei which were co-labelled by DAPI. 
Contrastingly, A7r5 cell nuclei were typically devoid of CaV3.1-IR, with low levels of 
diffuse CaV3.1-IR apparent within the cell body. Similar observations have been 
previously reported in cultured A7r5 cells, where diffuse cytoplasmic CaV3.1-IR was 
described, alongside CaV3.2-IR limited within some A7r5 nuclei (Brueggemann et al., 
2005). A similar study conducted with human pulmonary artery smooth muscle cells 
(HPASMCs) detected LVA currents alongside HVA currents using patch-clamp 
electrophysiology. Whilst both CaV3.1 and CaV3.2 mRNA was detected using rtPCR, 
immunohistochemistry indicated that only CaV3.1 channels were transcribed to give 
detectable protein levels within HPASMCs. The authors speculate that the lack of 
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CaV3.2 translation may be concerned with low expression levels, poor antibody 
sensitivity or post-transcriptional control of expression dependent on translational 
efficiency. They also discuss how temporal control as opposed to constitutive 
expression of CaV3.1 and CaV3.2 channels may be important for the control of 
proliferation (Rodman et al., 2005).  
 
Patch-clamp electrophysiology confirmed that A7r5 cells expressed functional T-type 
Ca2+ currents which, shown on some occasions to be inhibited by NNC (82%) and 
resistant to nifedipine. Upon development, NNC was shown in CaV3.1-expressing 
HEK293 cells to have an IC50 of 7µM (Li et al., 2005). In native cells such as bovine and 
rat embryo adrenal chromaffin cells  however, the IC50 of NNC on LVA T-type Ca
2+ 
currents was shown experimentally to be much lower at approximately 2µM 
(Fernandez-Morales et al., 2015). The average degree of inhibition currently observed 
with NNC applied at a single concentration of 3µM (82%) is therefore consistent with 
previous reports. This single concentration was examined as it is the NNC 
concentration used for proliferation assays. The contribution L-type Ca2+ currents to 
the global Ca2+ current evoked using the T-type SS protocol was also raised as a 
possibility. Future experiments requiring the isolation of T-type Ca2+ currents from 
A7r5 cells would be conducted in the continuous presence of nifedipine.  
 
L-type Ca2+ currents were also recorded in A7r5 cells which were both inhibited by 
nifedipine (average of 75%) and of significantly larger amplitude when using Ba2+ as 
the charge carrier. In extracellular solutions containing physiological ionic 
concentrations, L-type Ca2+ channels are highly selective for Ca2+ over more abundant 
cations such as K+ and Na+ due to the presence of a selectivity filter composed of four 
glutamate amino acid residues, this being highly conserved amongst CaV channels 
(Yang et al., 1993). A key feature of L-type Ca2+  channels however, is that when Ba2+ is 
substituted for Ca2+ they conduct Ba2+ much more easily (Almers & McCleskey, 1984). 
For example, it was demonstrated with recombinant CaV1.2-expressing HEK293 cells 
that currents were doubled in amplitude when recorded using Ba2+ as the charge 
carrier as compared to Ca2+ (Li et al., 2010). Contrastingly, upon substitution of 
extracellular Ca2+ with Ba2+ T-type Ca2+ channels are generally equally permeable, yet 
in the presence of Mg2+ CaV3.1 currents have actually been shown to conduct Ca
2+ 
preferentially (Serrano et al., 2000). Evidence that the currents evoked using the SS 
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protocol using the relatively higher holding and test potentials were primarily 
mediated by L-type Ca2+ channels is therefore provided.   
 
3.3.2. Potential expression of HVA T-type Ca2+channel splice variants 
As a point of interest, the potential contribution of other HVA Ca2+ channels was also 
raised as a possibility. The IC50 of nifedipine has previously been shown to be 55nM in 
CaV1.2-expressing HEK293 cells (Scragg et al., 2007), therefore it was surprising that 
complete inhibition of L-type currents using 2µM nifedipine in the current 
investigation was not observed. In addition, NNC also caused partial inhibition of L-
type Ca2+ currents, a finding which conflicts with the developers’ original publication 
showing that NNC had no effect on HVA currents when applied at 100µM to pancreatic 
INS-1 cells, which express P/Q, N and R-type in addition to L-type HVA channels (Li et 
al., 2005). Furthermore, currents evoked at +20mV within IV protocols were of 
considerably larger amplitude than those produced using a SS protocol to the 
equivalent voltage, suggesting potential summation of currents facilitated by different 
CaV subtypes was occurring.  
 
This possibility could be addressed by future experiments using protocols similar to 
those described in a study conducted by Harraz & Welsh, (2013). T- and L-type Ca2+ 
currents were effectively isolated in primary cultures of cerebral VSMCs. When using 
physiological Ca2+ concentrations, L- and T-type components were not clearly 
distinguishable as individual components on IV traces. However, when Ba2+ was 
substituted for Ca2+ a small rightward shift in the voltage for maximal activation was 
observed, likely due to the selective enhancement of L-type Ca2+ currents. The 
contribution of T-type Ca2+ channels to the whole-cell Ba2+ current was dissected by 
selectively inhibiting L-type currents using nifedipine (200nM). The nifedipine-
insensitive components showed relatively more hyperpolarised I-V relationships, faster 
activation and inactivation kinetics and were abolished by NNC (1µM). In agreement 
with current observations, application of NNC without prior nifedipine treatment 
significantly attenuated both T- and L-type mediated components. The off-target 
effects of NNC, emphasise the importance of applying L-type blockers prior to T-type 
Ca2+  channel inhibitors (Harraz & Welsh, 2013).  
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Interestingly, the activation and inactivation voltages of the isolated T-type Ca2+ 
currents were right-shifted when compared to the typical biophysical profiles of T-type 
Ca2+ channels. This was attributed to the use of Ba2+ as the charge carrier as replacing 
Ca2+ with Ba2+ also produced depolarising shifts in IV relationships when recording 
recombinant CaV3.1 or CaV3.2 mediated currents (Harraz & Welsh, 2013). In contrast 
with this explanation a growing amount of information is emerging that show tissue-
specific splice variants of CaV3.1 and CaV3.2 are common within VSMCs, which arguably 
fit better, functionally, within the HVA category. This alternative splicing generally 
occurs in exons 25 and 26, within the III-IV linker region of the α1G gene, producing 
shifts in activation and inactivation voltages to more depolarised potentials. Within the 
vasculature, expression of multiple T-type splice variants has been demonstrated 
thereby producing overlaps in T- and L-type Ca2+ channel activation voltages (Kuo et 
al., 2011; Kuo et al., 2014). Consequently, an interesting further investigation would be 
to explore whether CaV3.1 and CaV3.2 splice variants are expressed within A7r5 cells.  
It would also be useful to assess the extent of off-target NNC effects in recombinant 
HEK293 expressing a range of L-type CaV isoforms.    
 
3.3.3. T-type Ca2+ channels regulate A7r5 proliferation.   
Proliferation of all A7r5 cells used within the current project was partially inhibited by 
mibefradil and yet insensitive to nifedipine. A7r5 cells showing relatively higher CaV3.1 
and CaV3.2 expression profiles proliferated faster than “old” A7r5 cells, and were 
inhibited by the newer more specific T-type Ca2+ channel inhibitors (NNC and ML218) 
to greater extents than mibefradil. These observations collectively demonstrate that 
A7r5 cell proliferation is regulated by T-type Ca2+ channels and also rule out the 
contribution of L-type Ca2+ channels. Many similar observations have been reported 
within the vasculature; for example, Rodman et al. (2005) reported that selective 
blockade of CaV3.1 using small interfering RNA (siRNA) completely inhibited human 
pulmonary artery smooth muscle cell (HPASMC) proliferation and prevented entry into 
the cell cycle in response to stimulation with 5% serum. In addition, mibefradil 
completely prevented entry into the cell cycle whilst the L-type specific inhibitor 
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diltiazem was without effect when applied at 3 times the IC50 concentration (Rodman 
et al., 2005).  
 
One of the pivotal studies implicating T-type Ca2+ channels in the control of VSMC 
proliferation was conducted by Kuga et al. (1996) who demonstrated using both 
immunohistological and electrophysiological techniques that functional T-type 
expression was restricted to proliferative G1 and S phases of the cell cycle in rat aortic 
VSMCs. In addition to in vitro studies, a number of in vivo studies have implicated a 
role for T-type Ca2+ channels in the control of VSMC proliferation as a feature of both 
development and pathological vascular remodelling. Neointima formation is a 
common undesirable aspect of vascular disease, and also a consequence of vascular 
intervention, involving increased VSMC proliferation and migration, resulting in 
restenosis. Tzeng et al. (2012), demonstrated that carotid artery wire injury induced 
neointima formation in WT mice but not, crucially, in Cav3.1
-/- knockout mice, which 
demonstrated no other vascular abnormalities. Immunohistological processing 
demonstrated that this neointima formation was due to VSMC proliferation. In WT 
mice, Cav3.1 mRNA was up-regulated in response to wire injury prior to neointima 
formation, suggesting that up-regulation of Cav3.1 was crucial for the development of 
this pathogenic phenotype (Tzeng et al., 2012). 
 
3.3.4. T- and L-type Ca2+ channels regulate basal and oscillatory Ca2+ levels within A7r5 
cells 
Oscillations in [Ca2+]i are a widely discussed phenomenon reported in a variety of 
VSMC beds, and have been shown to be regulated by both voltage-dependent and 
voltage-independent mechanisms. Oscillations are thought to be observed as a result 
of signal integration of Ca2+ waves which, enabled by gap junctions, propagate through 
VSMCs over significant lengths of arteries without decrement. This activity has been 
shown to underlie spontaneous rhythmical contractions of blood vessels, a process 
collectively referred to as vasomotion, involving cyclical vasoconstriction and 
vasodilation, reviewed extensively by (Haddock & Hill, 2005)  
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Spontaneous oscillations in intracellular Ca2+ ([Ca2+]i) of varying frequencies were 
observed within some A7r5 populations. As these were abolished following the 
removal of external Ca2+, they are thus shown to be dependent on Ca2+ entry through 
the cell membrane, most likely through CaV channels. Similarly, a proportion of A7r5 
cells have been previously shown to exhibit spontaneous [Ca2+]i oscillations, which 
were dependent on external Ca2+ and abolished by cobalt (Co2+), applied for the 
purpose of blocking CaV channels (Otun et al., 1992). A more recent study utilised 
confocal microscopy to demonstrate that spontaneous Ca2+ oscillations occurred in 
79% of A7r5 cells within both cytoplasmic and nuclear compartments. Interestingly, 
the occurrence of spontaneous oscillations was correlated with greater amounts of 
sarcoplasmic reticulum. Whilst cytoplasmic and nuclear oscillations were of variable 
amplitudes they followed identical time-courses. Complete substitution of extracellular 
Ca2+, or application of the CCBs diltiazem and nimodipine, not only rapidly abolished 
spontaneous cytoplasmic [Ca2+]i oscillations but also gradually inhibited nuclear [Ca2+]i 
oscillations over a 10min period, thereby showing that [Ca2+]i oscillations were 
mediated by CaV channels (Fedoryak et al., 2004). In the current investigation a similar 
but more reliable pattern of [Ca2+]i oscillations was reproduced in “old” A7r5 cells 
through modest membrane depolarisation, achieved by slightly elevating external K+ 
(20 vs. 5mM). As the response to K+ was significantly and similarly inhibited by ML218, 
mibefradil and nifedipine, the induced [Ca2+]i oscillations were dependent on both T- 
and L-type Ca2+ channels.  
 
Arginine vasopressin (AVP) is a vasoconstrictor hormone important for vasomotion and 
has been shown in vitro to induce [Ca2+]i oscillations in VSMCs (Brueggemann et al., 
2005; Otun et al., 1992). Caution must be taken however as many of the studies used 
relatively high AVP concentrations which can induce changes in [Ca2+]i through a 
variety of different mechanisms including, but not limited to, IP3 production, 
membrane hyperpolarisation and activation of non-specific cation channels (Otun et 
al., 1992). Application of physiologically relevant concentrations of AVP (picomolar 
range) however has been shown to induce reliable oscillations in A7r5 populations, 
which were inhibited by mibefradil in a concentration-dependent manner at 
concentrations the authors reported to have no effect on L-type Ca2+ currents. The 
contribution of endogenously expressed CaV3.1 channels on the oscillatory activity was 
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confirmed as CaV3.2 over-expression had no effect on basal or oscillatory patterns of 
[Ca2+]i (Brueggemann et al., 2005). A conclusive role for the involvement of CaV3.1 is 
provided by a study which expressed CaV3.1 channels within the neuronal NG108-15 
cell line. This produced an increase in spontaneous Ca2+ oscillations corresponding with 
membrane potential oscillations (MPOs) and also an increase in basal [Ca2+]i, shown to 
be mediated by a T-type Ca2+ window current (Chevalier et al., 2008). The potential 
involvement of Ca2+ release from intracellular stores was also ruled out. Whilst any 
potential evidence for a role of [Ca2+]i oscillations in proliferation is unclear, they 
provide an interesting phenotype involving both T- and L-type Ca2+ channels, which can 
be utilised for assessing the effects of novel signalling molecules on A7r5 Ca2+ handling 
under relatively physiological conditions. 
 
A further key difference between the A7r5 cells expressing relatively higher T-type Ca2+ 
channels levels compared to the “old” A7r5 cells, in addition to the spontaneous 
nature of [Ca2+]i oscillations, was that basal Ca
2+ influx was apparent under resting 
conditions. Basal Ca2+ influx was detected by a fall in baseline [Ca2+]i upon substitution 
of extracellular Ca2+ with EGTA, suggesting the presence of a window current within 
some A7r5 populations. As the fall in response to Ca2+ removal was partially inhibited 
by both NNC and nifedipine it is suggested that the A7r5 window current is facilitated 
by both T- and L-type Ca2+ channels. Due to a characteristic overlap in activation and 
steady-state inactivation voltages, T-type Ca2+ channels can open without fully 
inactivating. This commonly facilitates basal Ca2+ influx at resting Vm, referred to as 
window current, and reviewed elsewhere e.g. (Perez-Reyes, 2006). The intimate link 
between T-type Ca2+ channel-mediated window currents regulating [Ca2+]i and the 
resulting control of proliferation is well summarised (Capiod, 2011). This review 
additionally considers the potential contributions of store-operated Ca2+ entry to cell 
cycle regulation. Inhibition of the T-type Ca2+ channel-mediated window current can 
therefore be directly linked to the anti-proliferative effects of T-type Ca2+ channel 
inhibition previously reported in a wide variety of cells including: A7r5 cells (Duckles et 
al., 2015), HPASMCs (Rodman et al., 2005), mesangial cells of the kidney (Cove-Smith 
et al., 2013) and a range of different cancers including leukaemia and glioblastoma 
(Huang et al., 2015; Zhang et al., 2012), further discussed in section 3.3.3.  
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Current findings also revealed that L-type Ca2+ channels also partially facilitated the 
basal Ca2+ influx observed in A7r5 cells. Potential non-specific effects of nifedipine on 
T-type Ca2+ channels were considered unlikely as basal Ca2+ influx within recombinant 
HEK293/CaV3.1 cells was unaltered by this agent. Previous studies have described L-
type Ca2+ channel-mediated window currents at the single channel level within canine 
cardiac Purkinje cells (Shorofsky & January, 1992), and also using [Ca2+]i imaging within 
equine tracheal myocytes (Fleischmann et al., 1994).  A more recent study conducted 
in mouse VSMCs demonstrated that in addition to their role in voltage-dependent 
contraction, L-type Ca2+ channels also mediate the window current which controls 
basal [Ca2+]i and correspondingly basal contraction of VSMCs at physiological Vm 
(Fransen et al., 2012). This was demonstrated through the simultaneous measurement 
of isometric tension and [Ca2+]i  in mouse aortic segments, which were correlated with 
Vm. To replicate voltage-clamp protocols, Vm was manipulated via modification of 
extracellular [K+] to achieve depolarisation and repolarisation within physiological Vm 
ranges (-77 to -51mV) (Fransen et al., 2012).  
 
As discussed in relation to T-type Ca2+ channels, a rapidly expanding body of work is 
currently emerging that shows not only tissue, but also cell and developmental stage 
specific CaV splice variants are common, which can impart atypical voltage-
dependencies. A relevant example of this is provided by a study which demonstrated 
that expression of a CaV1.2 splice-variant previously isolated from VSMCs in HEK293 
cells produced currents with more hyperpolarised activation profiles and with larger 
window currents at resting Vm, when compared to the standard full-length clone (Liao 
et al., 2007). Consistent with current observations demonstrating that nifedipine has 
no effect on A7r5 cell proliferation, the potential physiological relevance of L-type Ca2+ 
channel-mediated window currents within VSMCs is therefore likely concerned with 
contractile activity and not proliferation. A potential explanation as to how T-type Ca2+ 
channel-mediated window current selectively influences proliferation could be that 
different CaV isoforms may have restricted subcellular distributions. This suggestion is 
further discussed in section 3.3.5.  
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3.3.5. Recombinant expression of CaV3.1 and CaV3.2 increases cellular proliferation and 
window current.  
In direct support of observations made in A7r5 cells, expression of either recombinant 
CaV3.1 or CaV3.2 channels significantly increased basal Ca
2+ influx and proliferation 
which could be partially inhibited by NNC. Further evidence is therefore provided that 
T-type Ca2+ channels regulate [Ca2+]i and subsequently proliferation. The finding that 
both CaV3.1 and CaV3.2 channel expression can increase cellular proliferation is 
significant as many conflicting findings regarding isoform specificity have been 
previously reported. Due to the current lack of isoform specific CaV3.1 or CaV3.2 
pharmacological inhibitors the majority of studies regarding isoform specificity have 
been conducted using knockout mice. Tzeng et al. (2012) demonstrated that Cav3.1
-/- 
knockout mice showed reduced VSMC proliferation and were resistant to neointima 
formation following carotid wire injury whereas Cav3.2
-/- knockout mice showed a 
similar degree of neointima formation compared to wt mice. Contrastingly, Chiang et 
al. (2009) demonstrated that Cav3.2
-/- knockout mice were resistant to both pressure 
overload-induced or angiotensin II-induced cardiac hypertrophy/remodelling (Chiang 
et al., 2009).  
 
A further interesting observation was that HEK293/CaV3.2/clone P cells, transfected in-
house with the CaV3.2-containig mammalian expression vector, proliferated at a rate 
directly comparable to wt HEK293 cells and showed no inhibition by NNC. The similar 
growth profiles and lack of response to NNC suggests that the presence of CaV3.2 
channels per se is not sufficient to drive proliferation. Similarly, Chemin et al. (2000) 
demonstrated that whilst expression of CaV3.1 or CaV3.2 in HEK293 cells increased 
[Ca2+]i, it had no effect on proliferation. A potential explanation for this can be provided 
by current observations that CaV3.2-IR was highly diffuse throughout 
HEK293/CaV3.2/clone P cells whereas, contrastingly, dense perinuclear clusters and 
punctate membranous CaV3.2-IR was additionally prominent within the highly 
proliferative HEK293/CaV3.2 cells. Resultantly, evidence is provided that aggregation or 
clustering of T-type Ca2+ channels within specific sub-cellular domains may be crucial 
for increased basal Ca2+i to drive elevated cellular proliferation. As the development of 
highly specific CaV3.1 and CaV3.2 antibodies is only very recently improving there are 
very few previous studies assessing the subcellular localisation of these channels in 
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VSMCs. One of the few papers that exist however has shown that CaV3.2 Ca
2+ channels 
co-localise within caveolin3 microdomains in ventricular myocytes. It was also 
demonstrated that when CaV3.2 and caveolin3 are co-expressed in HEK293 cells peak 
CaV3.2 density is decreased, indicative of important functional interplay within 
compartmentalisation of Ca2+ signalling (Markandeya et al., 2011). Further 
investigations using antibodies against various sub-cellular markers’ such as caveolin3 
and mitochondrial proteins would be very useful to assess potential co-localisation 
with CaV3.1 and CaV3.2 channels in more detail. It would also be interesting to assess 
the subcellular localisation of different T- and L-type isoforms with A7r5 cells.    
 
3.3.6. Summary and conclusions  
Collectively, findings within this chapter demonstrate that T-type Ca2+ channels control 
basal Ca2+ levels and modulate cellular proliferation. These data additionally 
characterise cell lines and validate techniques subsequently used to assess thioredoxin 
as a novel regulator of T-type Ca2+ channels and VSMC proliferation.  
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Chapter 4 -The role of thioredoxin (Trx) in cellular proliferation 
and [Ca2+]i handling 
4.1. Introduction  
The thioredoxin (Trx) system is ubiquitously expressed within all mammalian cells and 
plays a key role in the maintenance of cellular redox balance. The Trx system is 
composed of Trx, thioredoxin reductase (TrxR), NADPH, and vitamin D3 up-regulated 
protein (VDUP). TrxR reduces Trx to its active form, using electrons donated from 
NADPH, whilst VDUP serves as the endogenous negative regulator. Trx has a range of 
biological activities, including antioxidant, growth promotion, inflammatory response 
modulation and anti-apoptosis. These functions generally require the reducing 
capabilities of Trx, dictated by two cysteine (Cys) residues at positions 32 and 35 within 
the active site (Cys32 and Cys35). Trx has been shown to utilise both intracellular and 
extracellular signalling pathways as nuclear translocation and extracellular secretion 
upon activation have been demonstrated, as reviewed (Burke-Gaffney et al., 2005).  
 
Trx upregulation has been demonstrated in a variety of conditions including cancer 
and cardiovascular disease. For example, elevated serum Trx levels have been 
detected in patients with acute myocardial infarction (AMI), abdominal aortic 
aneurysm as detected within the aortic lumen and circulation (Martinez-Pinna et al., 
2010), atherosclerosis (Okuda et al., 2001) and is positively correlated with platelet 
hyper-aggregability (Miyamoto et al., 2003). Whilst elevations in Trx may initially serve 
to counterbalance increased oxidative stress, Trx over-expression within cancer 
patients is associated with aggressive tumour growth, increased proliferation, 
decreased apoptosis, and reduced patient survival (Raffel et al., 2003).  
 
In order to assess the effects of Trx on cellular proliferation and Ca2+ handling, two 
pharmacological Trx inhibitors, PX-12 (1-methylpropyl 2-imidazolyl disulfide) and 
auranofin (AuF, triethylphosphinegold(I)tetraacetylthioglucose), were employed. PX-12 
is a direct Trx inhibitor currently undergoing clinical trials for the treatment of a variety 
of cancers, including gastrointestinal and pancreatic cancer (Baker et al., 2013; 
Ramanathan et al., 2007; Ramanathan et al., 2011). PX-12 has been shown to directly 
inhibit Trx through thioalkylation of redox-sensitive Cys residues. Thioalkylation of 
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Cys32 and Cys35 residues found within the redox-active site of Trx has been shown to 
occur in a reversible manner with a Ki of 31µM. Contrastingly, thioalkylation of the 
Cys73 residue found outside the active site occurs at PX-12 concentrations several 
orders of magnitude lower, and in an irreversible manner (Kirkpatrick et al., 1998). 
Whilst the reducing capabilities and corresponding cellular functions of Trx generally 
concern Cys32 and Cys35 within the active site (Oblong et al., 1994); other studies have 
demonstrated that Cys73 is also important for the growth promoting effects of Trx 
(Gasdaska et al., 1996). 
 
AuF is a gold-containing compound originally developed as an oral treatment for 
rheumatoid arthritis (RA) (Finkelstein et al., 1976). Due to its potent anti-inflammatory 
effects, AuF has been used as an effective RA treatment for over 30 years, although 
the mechanism of action in vivo is not yet fully established (Kean et al., 1997; Madeira 
et al., 2012). Whilst intramuscular injection of gold compounds such as aurothiomalate 
and aurothioglucose have generally replaced AuF in the treatment of RA (Kean et al., 
1997), AuF has also been shown to inhibit TrxR. Consequently, AuF is currently being 
explored as a re-profiled anti-cancer agent (Roder & Thomson, 2015; Tonissen & Di, 
2009). TrxR is a pyridine nucleotide-disulfide oxidoreductase which uses electrons 
donated from NADPH to reduce Trx. Whilst TrxR is closely related to glutathione 
reductase (GR), it additionally contains a rarely found selenocysteine (Sec) sequence 
(Cys-Sec). Unfortunately, the presence of this Sec sequence has complicated the 
successful recombinant expression of mammalian TrxR. Isolation of TrxR from placenta 
is therefore generally required for experimental studies. In the presence of NADPH and 
Trx, AuF has been shown to inhibit TrxR isolated from human placenta with a K i of 
4nM. Contrastingly, the effects of AuF on GR were shown to be at least three orders of 
magnitude lower. Interestingly, the effects of AuF on TrxR were attributed to the gold 
moiety within the AuF molecule as gold-free thioglucose was without any effect 
(Gromer et al., 1998).  
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4.2. Results  
4.2.1. Trx measurement within A7r5 and recombinant HEK293 cells  
To quantify endogenous Trx activity within cell lines, a fluorescence-based assay 
utilising the reducing capabilities of Trx was conducted. The fluorescence signal of the 
eosin-labelled (EL) insulin substrate at 545nm (after excitation at 520nm) increases 
upon reduction by Trx. The rate of increasing fluorescence (Δf) is therefore 
proportional to Trx activity (Montano et al., 2014). It is crucial to note that as TrxR) and 
NADPH are applied in excess, it can be assumed that all Trx is in its reduced form (rTrx). 
As such, Trx activity reports cellular Trx levels. Following subtraction of background 
fluorescence values, the Δf of cell samples was compared against known Trx standards, 
as detailed in Figure 4.1. Initial attempts to calibrate the assay using Trx standards (0-
24ng) were unsuccessful as the resultant Δf values were similar for each concentration 
used (data not shown). As the assay was shown upon development to be effective with 
Trx (7nm-900nM) (Montano et al., 2014), the concentration of Trx standards was 
increased (0-192ng). As shown in Figure 4.1, this produced different rates of Δf for 
each Trx standard which enabled effective assay calibration.  
 
Endogenous Trx activity was reliably detected within A7r5, wt HEK293, HEK293/CaV3.1 
and HEK293/CaV3.2 cells (~60-215ng per 15µg total protein). Trx levels within wt 
HEK293 cells appeared lower when compared to the other cell types; however, this 
difference was not statistically significant (Figure 4.2). Chronic pre-treatment (72hrs) 
with AuF (300nM) or PX-12 (1µM) was found to be without effect on A7r5, 
HEK293/CaV3.1 or HEK293/CaV3.2 cells Trx levels (Figure 4.3). Acute pre-treatment 
(10mins) with higher concentrations of PX-12 (3-300 µM) did produce significant 
reductions in Trx levels for HEK293/CaV3.1 cells (3µM) and HEK293/CaV3.2 cells 
(30µM). Acute pre-treatment with PX-12 (300µM) produced a more uniform reduction 
in Trx activity, however this was commonly accompanied by a decrease in the 
background fluorescence values. As this produced an amplified final slope value, these 
data had to be omitted from the final analysis (Figure 4.4). 
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A(i) C(i)
A(ii) C(ii)
B D
Calibration Y = 0.0104*X + 0.03059
CaV3.2 (T-B)
CaV3.2 (T)
CaV3.2 (B)
Y = 1.108*X + 38.71
Y = 1.670*X + 283.5
Y = 0.5624*X + 244.8
X=(y-c)/m (1.108- 0.03059)/0.0104
Trx = 103.6ng
 
Figure 4.1. Quantification of unknown Trx concentrations using Trx activity assays  
Illustrative example of a single Trx assay: A(i), mean fluorescence values of eosin-
labelled (EL) insulin (545nm after 520nm excitation) with known Trx concentrations (0-
192ng), monitored for 60mins at 1min intervals (triplicate wells). Grey box highlights 
10min analysis region. A(ii), magnified from A(i), but with background fluorescence 
values (i.e. 0ng Trx) deducted. Linear regression used to calculate line equations. B, 
Calibration-curve generated from slope values calculated in A(ii). Line equation and R2 
values from linear regression are included, red line estimates calculation in D. C(i), As 
A(i), except with HEK293/CaV3.2 cell lysates (15µg), in test conditions (CaV3.2(T), all 
reagents) and background conditions (CaV3.2(B), TrxR omitted). C(ii), As A(ii), except 
showing CaV3.2(T)-CaV3.2(B) fluorescence values. D, Equations and working 
calculations used to quantify Trx concentration from HEK293/CaV3.2 cell lysates. Y=Δ in 
fluorescence, X=Trx (nag), m=slope/gradient and c=y axis intercept.  
 
125 
 
Assay 10 
Assay 6 
A
C
B
D
E
 
Figure 4.2. Quantification of endogenous Trx levels within cell lysates 
Example traces from two Trx assays (further details provided in Figure 4.1) showing 
increasing mean fluorescence values and reporting endogenous Trx activity within: A, 
“new” A7r5, HEK293/CaV3.1 and HEK293/CaV3.2 cell lysates (15µg total protein, 
triplicate wells). B, Calibration-curve corresponding with (A), showing slope values of 
mean fluorescence of known Trx concentrations (0-192ng). Line equation and R2 values 
are included. C-D, As (A-B) except, different assay with A7r5, wt HEK293 and 
HEK293/CaV3.1 cell lysates. E, Bar chart showing (mean ± s.e.m) endogenous Trx levels 
in A7r5, wt HEK293, HEK293/CaV3.1 and HEK293/CaV3.2 cell lysates (15µg total 
protein, all n=3 except HEK293/CaV3.1 (n=6)). Data were analysed via repeated 
measures one-way ANOVA with Dunnett’s post-hoc comparison test, with no 
statistically significant differences observed.  
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Figure 4.3. Trx assays do not detect any effect of chronic treatment with AuF 
(300nM) or PX-12 (1µM) 
Example traces from a single Trx assay (details of method and analysis provided in 
Figure 4.1) showing increasing mean fluorescence values and reporting Trx activity 
under control conditions and after chronic pre-treatment (72hrs) with auranofin (AuF, 
300nM) or PX-12 (1µM). Examples from: A, “new” A7r5 and B, HEK293/CaV3.1 cell 
lysates (15µg total protein, triplicate wells). Line equations are included. C, Calibration-
curve corresponding with (A-B), showing slope values of mean fluorescence of known 
Trx concentrations (0-192ng). Line equation and R2 values are included. D-F, Bar charts 
showing (mean ± s.e.m) Trx levels under control conditions and after chronic pre-
treatment (72hrs) with AuF (300nM) or PX-12 (1µM) within: D, A7r5, E, HEK293/CaV3.1 
and F, wt HEK293 cell lysates (15µg total protein, all n=2). All data were analysed via 
repeated measures one-way ANOVA with Dunnett’s post-hoc comparison test, with no 
statistically significant differences observed.  
 
 
A
B
D
E
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Figure 4.4. Trx levels are altered by acute treatment with PX-12 
Example traces from single Trx assay (further details provided in Figure 4.1) showing 
increasing mean fluorescence values and reporting Trx activity under both control 
conditions and after acute pre-treatment (10mins) with PX-12 (3-300µM) within: A, 
HEK293/CaV3.1 and B, HEK293/CaV3.2 cell lysates (15µg total protein), triplicate wells. 
Line equations are included. A(i), as A, except with individual test and background 
values for control and PX-12 (300µM) conditions. C, Calibration-curve corresponding 
with (A-B), showing slope values of known Trx concentrations (0-192ng). Line equation 
and R2 values included. D-E, Bar charts showing (mean ± s.e.m) Trx levels ± PX-12 pre-
treatment (10mins, 3µM and 30µM), within: D, HEK293/CaV3.1 and E, HEK293/CaV3.2 
cells (both n=3). Note, as PX-12 (300µM) produced decreasing background 
fluorescence values, amplifying the deducted slope value shown in A(i), these data are 
omitted. Data analysed by repeated measures one-way ANOVA with Dunnett’s post-
hoc comparison test,*p≤0.05. 
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4.2.2. The effects of Trx inhibitors on A7r5 cell viability and proliferation  
As Trx serves as an important cellular antioxidant, Trx inhibition may potentially 
disrupt the redox balance within cells. For example, AuF has been shown to induce 
apoptosis in Jurkat T-lymphoma cells (Cox et al., 2008). It was therefore necessary to 
deduce what concentrations of PX-12 and AuF would be tolerated by A7r5 cells before 
using these drugs for proliferation assays. The MTT assay is a means of assessing cell 
viability. It is based on the principle that only active mitochondria are able to cleave 
MTT’s tetrazolium ring and convert the pale yellow soluble substrate to the partially 
soluble, dark blue formazan product. The degree of colorimetric absorbance at 570nm 
is thus directly proportional to the number of living cells present (Mosmann, 1983).  
 
Treatment with a single dose of AuF (≤1µM) or PX-12 (≤1µM) over a 72hr period had 
no significant effect on A7r5 cell viability. Significant reductions were observed with 
AuF (3µM) or PX-12 (10-300µM) when applied for 24-72hrs. PX-12 (3µM) was 
additionally shown to reduce A7r5 cell viability 48-72hrs post-treatment (Figure 4.5). 
Changes in A7r5 morphology that are suggestive of cell death such as rounding-up and 
cell detachment were observed alongside viability reductions. As these morphological 
changes were also apparent following a 72h exposure to 1µM AuF, it was subsequently 
determined that AuF (300nM) and PX-12 (1µM) were the highest concentrations to be 
applied for proliferation assays.  
 
As the IC50 of TrxR inhibition by AuF has been shown experimentally to range between 
20nM (Gromer et al., 1998) and 200nM (Cox et al., 2008), the effects of a variety of 
AuF concentrations within this range were examined on A7r5 cell growth. 
Concentration-response proliferation assays conducted on “old” A7r5 cells revealed 
that AuF (300nM, 72hrs) significantly decreased “old” A7r5 proliferation. AuF (30-
100nM) appeared to have modest but non-significant anti-proliferative effects. As the 
number of dead cells present was consistent between control and drug treatment 
groups, it was confirmed that AuF (10-300nM, 72hrs) did not induce cell death (Figure 
4.6). Daily cell counting of “old” A7r5 cells revealed that the anti-proliferative effects of 
AuF (300nM) positively correlated with the length of exposure.  
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Figure 4.5. Auranofin (AuF ≤1µM) and PX-12 (≤1µM) do not effect ”old” A7r5 cell 
viability  
Concentration-response graphs (mean ± s.e.m) from MTT cell viability assays. Showing 
effects of AuF (1nM- 3µM) on “old” A7r5 cell viability after: A, 24 hrs, B, 48 hrs and C, 
72hrs. D-F, As (A-C), except with PX-12 (300nM-300µM). Data were analysed by one-
way ANOVA with Dunnett’s post-hoc comparison test, AuF compared to control 
condition, PX-12 compared to DMSO (1:1000) condition, all n=3, ***p≤0.001, 
****p≤0.0001. Data were also fitted with log-inhibitor normalised-response curves.  
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The largest reduction in “old” A7r5 cell proliferation compared to control conditions 
was apparent on d3 (Figure 4.6). When these experiments were repeated on “new” 
A7r5 cells, shown to express considerably higher levels of CaV3.1 and CaV3.2 mRNA 
compared to the “old” A7r5 cells (further detailed in Chapter 3), a much larger anti-
proliferative response to AuF was observed. The average number of “new” A7r5 cells 
was significantly lower in AuF (300nM) treatment groups when compared to control on 
d1, d2 and d3. The largest difference was apparent on d2, prior to a plateau growth 
phase (Figure 4.6). These data indicate that higher levels of T-type Ca2+ channel 
expression result in higher sensitivity to AuF. This also suggests that T-type Ca2+ 
channel modulation could potentially be mediating the anti-proliferative effects of 
AuF.   
 
The effect of PX-12 on “new” A7r5 cell proliferation was also examined. The 
mechanism of Trx inhibition by PX-12 is complex as different cysteine residues within 
Trx are sensitive to considerably different PX-12 concentrations. Regarding its anti-
proliferative effects, PX-12 has been previously shown to inhibit the growth of MCF-7 
cells, with IC50 values of 1.2µM or 3.2µM when using Trx or FBS as the mitogenic 
stimulus respectively (Kirkpatrick et al., 1998). As PX-12 (≥3µM) was shown to induce 
significant reductions in A7r5 cell viability (Figure 4.5), a single PX-12 concentration 
was used in the proliferation assays. PX-12 (1µM) had small but significant anti-
proliferative effects on “new” A7r5 cells, being most apparent on d2. When further 
experimental repeats comprising of d3 counts in isolation were conducted, PX-12 
(1µM) was also found to significantly reduce average cell number on d3 (Figure 4.7).  
 
. 
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Figure 4.6. Auranofin (AuF) reduces A7r5 proliferation 
Proliferation (plotted against the left-hand y-axis), was monitored on day 0 and day 3 ± 
AuF (n=4). Red circles show the corresponding non-viable cell count (plotted against 
the right-hand y-axis). A, Bar graph showing the proliferative response (mean ± s.e.m) 
of “old” A7r5 cells to AuF (10-300nM). B, Daily counts of “old” A7r5 cells illustrate that 
the anti-proliferative effects of AuF (300nM, red line) are most apparent on day 3 
(n=3). B(i), Bar graph showing CaV3.1 (upper y-axis) and Cav3.2 (lower y-axis) mRNA 
expression levels, determined in “old” A7r5 cells. Channel expression is plotted as 
(mean ± s.e.m) % expression of the housekeeping gene, hypoxanthine 
phosphoribosyltransferase (HPRT1) (n=7) (Duckles et al., 2015). C, As (B), except with 
“new” A7r5 cells showing higher sensitivity to AuF (n=3), and higher CaV3.1 and CaV3.1 
expression in C(i), n=8.  All cell counts were made in triplicate with the mean value 
counting as n=1. Data were analysed by; (A,B,C), one-way ANOVA with Dunnett’s (A) or 
Bonferroni’s (B,C) post-hoc comparison tests, or (B(i)-C(i)), unpaired Student’s t-tests, * 
p≤0.05,        ** p≤0.01, **** p ≤0.0001. 
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Figure 4.7. PX-12 reduces “new” A7r5 proliferation 
 A, Line graph showing (mean ± s.e.m) daily cell counts of “new” A7r5 cells in both 
control conditions (blue line) and after PX-12 (1µM) treatment (red line), and thereby 
illustrating that the anti-proliferative effects of PX-12 are most apparent on day 2 
(n=4). B, Bar graph (mean ± s.e.m) showing proliferative response (mean ± s.e.m) of 
“new” A7r5 cells to PX-12 (1µM) as counted on day 3 (n=8). All cell counts were made 
in triplicate with the mean value counting as n=1.Data were analysed using unpaired 
Student’s t-tests, *p≤0.05.  
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4.2.3. The effects of AuF on A7r5 Ca2+ handling 
As discussed in detail in Chapter 3, oscillations in intracellular Ca2+ levels [Ca2+i] could 
be stimulated by modest depolarisation of “old” A7r5 cells, achieved by application of 
a high [K+] (20mM) perfusate. This project has previously demonstrated that Ca2+ 
oscillations are dependent on both T- and L-type Ca2+ channels (Chapter 3). In order to 
investigate potential effects of Trx inhibition on Ca2+ handling, “old” A7r5 cells were 
pre-treated with AuF (2µM, 25min). Unfortunately, PX-12 could not be used for Ca2+ 
microfluorimetry as it selectively enhanced the fluorescence signal at 340nm indicating 
direct interactions between Fura-2 and PX-12 (data not shown). For both control and 
AuF pre-treatment conditions, two high [K+] stimuli were applied to each A7r5 
population. Importantly, it was ensured that baseline [Ca2+i] was re-established prior to 
the 2nd high [K+] stimulus. The effects of AuF (2µM, 25min) pre-treatment on the 
amplitude of the response were variable. When compared to control conditions, the 
amplitude of the response to the 1st depolarisation was significantly reduced in AuF 
conditions, within some experiments (Figure 4.9), although not in others (Figure 4.8). A 
more reproducible analysis parameter to quantify the qualitative effects of AuF was 
found to be the frequency of depolarisation-induced [Ca2+]i oscillations (i.e. firing 
frequency). To ensure that re-application of the depolarising stimulus did not produce 
a decline in the observed firing frequencies, matching control data was gathered for all 
experiments (Figure 4.8, Figure 4.9). 
 
Pre-treatment of “old” A7r5 cells with AuF significantly reduced the frequency of 
[Ca2+]i oscillations, in response to the 1
st and 2nd depolarisations when compared to 
control responses. The oscillation frequency in response to the 2nd depolarisation was 
significantly greater than for the 1st depolarisation in AuF conditions. The effects of AuF 
were therefore shown to be time-dependent (Figure 4.8). Dithiothreitol (DTT) is a 
commonly used reducing agent that was applied to some A7r5 populations, between 
the 1st and 2nd depolarisations. DTT treatment completely reversed AuF-mediated 
inhibition and normalised the firing frequencies in response to the 2nd depolarisation. 
DTT was additionally shown to significantly increase the frequency of Ca2+ oscillations 
under control conditions (Figure 4.9). As A7r5 Ca2+ oscillations were shown to be 
dependent of T- and L-type Ca2+ channels (Chapter 3), these data collectively indicate 
that AuF regulates CaV channels via a redox-dependent mechanism.   
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The effects of pre-treatment with AuF (2µM, 25min) on basal Ca2+ levels in “new” A7r5 
cells were also examined. Previous investigation within the current project had shown 
a measurable window current in “new” A7r5 cells, detected as a fall in the baseline 
Ca2+ level upon removal of extracellular Ca2+ (CF) (Chapter 3). Pre-treatment with AuF 
significantly reduced the response to CF, revealing partial AuF-mediated window 
current inhibition (Figure 4.10). This window current has been shown to be partially 
facilitated by T-type Ca2+ channels (Chapter 3), and is believed to be crucial for cellular 
proliferation. Evidence that AuF may regulate basal Ca2+ levels and proliferation 
through modulation of CaV channels is therefore provided.    
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Figure 4.8. Auranofin (AuF) reduces depolarisation-induced Ca2+ oscillations in “old” 
A7r5 cells 
Example Ca2+ microfluorimetry traces showing Fura 2 ratio units (340:380). 
Representing Δ[Ca2+]i in response to depolarisation, achieved by switching to a high 
[K+] perfusate (20mM vs. 5mM, black line above traces) under: A, control conditions 
and B, after auranofin pre-treatment (AuF, 2µM 25mins). C, Bar graph showing the 
(mean ± s.e.m) firing frequency in response to the 1st and 2nd depolarisations in control 
(blue bars, n=19) or AuF pre-treated (red bars, n=13) conditions. D, As (C), except 
showing (mean ± s.e.m) response amplitude. All data were analysed using one-way 
ANOVA with Tukey’s post-hoc comparison test, (*p≤0.05, ****p≤0.0001). 
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Figure 4.9. DTT reverses the effects of AuF on depolarisation-induced Ca2+ oscillations 
in “old” A7r5 cells 
Example Ca2+ microfluorimetry traces showing the effects of dithiothreitol (DTT, 1mM, 
red bar) on Fura 2 ratio units (340:380). Representing Δ[Ca2+]i in response to 
depolarisation achieved by switching to a high [K+] perfusate (20mM vs. 5mM, black 
line above traces) under: A, control conditions and B, after auranofin pre-treatment 
(AuF, 2µM, 25mins). C, Bar graph showing the (mean ± s.e.m) firing frequency in 
response to the 1st and 2nd depolarisations (i.e. before and after DTT application), in 
control (blue bars, n=24) or AuF pre-treated (red bars, n=18) conditions. D, As C, 
except showing (mean ± s.e.m) response amplitude. All data were analysed using one-
way ANOVA with Tukey’s post-hoc comparison test, **p≤0.01, ***p≤0.001, 
****p≤0.0001. 
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Figure 4.10. Auranofin inhibits the window current in “new” A7r5 cells 
Example Ca2+ microfluorimetry traces showing Fura 2 ratio units (340:380) 
representing Δ[Ca2+]i upon removal of extracellular Ca
2+ (CF, purple bar) under: A, 
control conditions and B, after pre-treatment with auranofin (AuF, 3µM, 25mins). C, 
Bar graph showing (mean ± s.e.m) the decrease in ratio units (340:380) in response to 
CF in: control conditions (black bar, n=11), and after AuF pre-treatment (grey bar, 
3µM, 25mins, n=7). Data were analysed using unpaired Student’s t-tests, ***p≤0.001.  
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4.2.4. Effects of Trx inhibitors on HEK293 cell viability and proliferation  
Previous investigations revealed that CaV3.1 or CaV3.2 expression increased the Ca
2+ 
window current and proliferation of HEK293 cells (Chapter 3). The effects of Trx 
inhibitors on wt HEK293, HEK293/CaV3.1 and HEK293/CaV3.2 cell proliferation were 
therefore next examined. These experiments enabled further investigation of the 
potential interactions between Trx and T-type Ca2+ channels and any isoform specific 
differences.  
 
Firstly, MTT assays were conducted to determine the potential effects of both AuF and 
PX-12 on HEK293 cell viability. HEK293/CaV3.2 cells showed no significant reductions in 
cell viability after 72hrs of treatment with AuF (≤300nM) or PX-12 (≤1µM). At higher 
concentrations, AuF (3µM) and PX-12 (10-300µM) caused rapid and significant 
reductions in cell viability, as measured 24hrs post-treatment. Furthermore, 48-72 hrs 
post-treatment, AuF (1µM) and PX-12 (3µM) further reduced HEK293/CaV3.2 cell 
viability (Figure 4.11). All conditions exhibiting viability reductions were accompanied 
by morphological changes such as “rounding-up” and cell detachment indicating cell 
death. As these observations are in direct agreement with the findings from A7r5 cells 
(Figure 4.5), the cytotoxicity thresholds of AuF and PX-12 appears to be independent of 
cell type. Consequently, the optimal concentrations of AuF and PX-12, as determined 
for A7r5 cell proliferation assays, were also deemed appropriate for use in all HEK293 
cell proliferation assays.  
 
To assess the effects of Trx inhibition on the elevated proliferation of HEK293 cells 
resulting from CaV3.1 or CaV3.2 channel expression as described in Chapter 3, the 
effects of PX-12 and AuF were examined. For all experiments, HEK293/CaV3.1 and 
HEK293/CaV3.2 cells, shown on some occasions to be partially inhibited by NNC (1µM), 
proliferated more than wt HEK293 cells (Figure 4.13). Concentration-response 
proliferation assays revealed that both wt HEK293 and HEK293/CaV3.1 cell 
proliferation was unaffected by AuF (10-300nM), as shown in Figure 4.12. Similarly, PX-
12 (1µM) was also without effect on either wt HEK293 or HEK293/CaV3.1 cell 
proliferation, when applied alone or in combination with NNC (Figure 4.13). 
Contrastingly, HEK293/CaV3.2 cell proliferation was significantly reduced by AuF 
(300nM) and PX-12 (1µM). The effects of PX-12 and NNC were shown to be non-
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additive on HEK293/CaV3.2 cells, indicating that both drugs were acting via CaV3.2 
inhibition. As the number of dead cells present was consistent between control and 
drug treatment groups, it was confirmed that the observed reduction in cell number 
was due to the anti-proliferative effects of AuF and PX-12, as opposed to increased cell 
death (Figure 4.12 and Figure 4.13). All drugs used for proliferation assays throughout 
the project were dissolved in double distilled water (ddH2O) or DMSO. We examined 
the effects of DMSO at the highest concentration used (1:1000) and found that it had 
no effect on the proliferative rate of any of the HEK293 cell types used (Figure 4.13).  
Collectively, these data demonstrate that Trx regulates cellular proliferation through 
selective modulation of CaV3.2 channels.  
 
In order to validate the observation that wt HEK293 and HEK293/CaV3.1 cell 
proliferation was insensitive to Trx inhibition, EdU assays were employed as an 
alternative to the direct cell counting proliferation assay. EdU (5-ethynyl-2´-
deoxyuridine) is a nucleoside analog of thymidine which becomes incorporated into 
newly synthesised DNA. It is detected by a copper-catalyzed covalent reaction 
between an alkyne (EdU incorporated into DNA) and an azide (Alexa Fluor detection 
reagent). When DAPI is co-applied to label total cell nuclei, the percentage of 
proliferating cells (i.e. those labelled by EdU) can be calculated. As this assay had not 
been previously conducted within the group, optimisation of EdU incubation times, 
concentrations and analysis methods was required. Pulse-labelling i.e. incubation with 
EdU (10µM) for 1-4 hours, produced a small percentage of EdU positive 
HEK293/CaV3.1 cell nuclei. Contrastingly, incubation with EdU (10µM) for 16 or 24hrs 
resulted in EdU labelling in almost 100% of HEK293/CaV3.1 cell nuclei. Incubation with 
EdU (5µM, 12hrs) produced approximately 60-70% of EdU positive nuclei, enabling 
potential decreases or increases in proliferation to be observed. As pulse-labelling 
represented only a small percentage of cells which had proliferated within a narrow 
time-frame, results regarding potential anti-proliferative effects could be masked by 
alterations in the rate of cell cycle progression. It was subsequently decided that EdU 
(5µM, 12hrs) was the optimal condition and would be used for all future EdU 
experiments (Error! Reference source not found.). 
 
140 
 
B
A
E
D
C F
 
Figure 4.11. Auranofin (AuF ≤300nM) and PX-12 (≤1µM) did not affect 
HEK293/CaV3.2 cell viability 
Concentration-response graphs (mean ± s.e.m), from mitochondrial activity-based MTT 
cell viability assays, showing the effects of auranofin (AuF, 1nM- 3µM) on 
HEK293/CaV3.2 cell viability after: A, 24 hrs, B, 48 hrs and C, 72hrs treatment. D-F, As 
(A-C), except showing the effects of PX-12 (300nM-300µM). Data were analysed by 
one-way ANOVA with Dunnett’s post-hoc comparison test, AuF compared to control, 
PX12 compared to DMSO, ***p≤0.001, ****p≤0.0001, all n=3. Data were fitted with 
log-inhibitor normalised-response curves. 
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Figure 4.12. Auranofin selectively reduces HEK293/CaV3.2 cell proliferation 
Bar charts (mean ± s.e.m) showing live cell number (white boxes, left Y axis) and dead 
cell number (red circles, right Y axis), counted on day 3 of proliferation assays. 
Illustrating effects of auranofin (AuF, 10-300nM) on: A, wt HEK293 cell (n=3), B, 
HEK293/CaV3.1 cell (n=4), and C, HEK293/CaV3.2 cell proliferation (n=5). All cell counts 
were made in triplicate with the mean value counting as n=1. Data were analysed by 
one-way ANOVA with Dunnett’s post-hoc comparison test,*p≤0.05, **p≤0.01.  
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Figure 4.13. PX-12 selectively reduces HEK293/CaV3.2 cell proliferation  
Bar charts (mean ± s.e.m) showing live cell number (white boxes, left Y axis) and dead 
cell number (red circles, right Y axis), counted on day 3 of proliferation assays. 
Illustrating effects of PX-12 (1µM), applied alone or in combination with NNC55-0396 
(NNC, 1µM) or with DMSO (1:1000) alone on: A, wt HEK293 cell (all n=5), B, 
HEK293/CaV3.1 cell (control and PX-12 n=5, NNC +/- PX-12 n=4, DMSO, n=3)and C, 
HEK293/CaV3.2 cell proliferation (all n=4). All cell counts were made in triplicate with 
the mean value counting as n=1. Data were analysed by one-way ANOVA with 
Dunnett’s post-hoc comparison test,*p≤0.05, **p≤0.01.  
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CellProfilerTM is free open-source software that allows users to custom build a wide 
range of analysis pipelines enabling automated processing of immunofluorescence 
images. Comparison of the results from manual and automated counts of 
HEK293/CaV3.1 cell nuclei revealed the two counting techniques to yield significantly 
different results. The automated count under-estimated the number of DAPI nuclei by 
30% and under-estimated the number of EdU positive nuclei by a factor of 10%, as 
detailed by Error! Reference source not found.. Resultantly, all future image counting 
was conducted manually to ensure accuracy. Treatment with PX-12 (1µM, 48hrs) 
significantly reduced HEK293/CaV3.1 cell proliferation (Error! Reference source not 
found.) but was without significant effect on wt HEK293 cell proliferation (Error! 
Reference source not found.). A noteworthy point is that the % EdU-positive value was 
almost identical for HEK293/CaV3.1 and wt HEK293 cells, and did not reflect the 
elevated proliferative rate of HEK293/CaV3.1 and wt HEK293 cells (Error! Reference 
source not found. & Error! Reference source not found.). The average total number of 
HEK293/CaV3.1 nuclei (DAPI labelled) was considerably greater than for wt HEK293 
cells (164 vs. 69 respectively, data not shown). This confirmed the proliferative 
advantage of CaV3.1 expression. In summary, these data collectively demonstrate that 
CaV3.2-expressing cells are most sensitive to Trx inhibition-mediated anti-proliferative 
effects. In addition, data suggest that HEK293/CaV3.1 cells are slightly sensitive to PX-
12-mediated anti-proliferative effects, whilst wt HEK293 cells show complete 
insensitivity. 
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Figure 4.14. Optimisation of EdU incubation time and concentration for subsequent 
proliferation assays 
Representative images showing EdU incorporation in HEK293/CaV3.1 cells following 
incubation with EdU (1-16hrs, 5-10µM). Total cell nuclei are labelled by DAPI (left 
panel, blue images) and nuclei containing newly synthesised DNA are labelled by EdU 
(centre panel, orange images), merged images illustrating co-localisation (right panel, 
pink images). A, EdU (10µM, 1hr). B, EdU (10µM, 4hrs). C, EdU (10µM, 16hrs). D, EdU 
(5µM, 12hrs). Scale bars 50µm. 
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Figure 4.15. Comparison of automated and manual counting techniques for analysis 
of EdU incorporation assays 
A-C, Representative images showing HEK293/CaV3.1 cell nuclei labelled by DAPI (left 
panel, blue images) and nuclei containing newly synthesised DNA are labelled by EdU 
(centre panel, orange images), from the same field of view, following incubation with 
EdU (5µM, 12hrs). Scale bars 50µm. B, Nuclei identified by automated analysis 
software CellProfilerTM using DAPI and EdU images, number of identified nuclei given in 
top left corner of each image. C, As B, except nuclei counted and outlined manually. D, 
Trend graph showing the difference in the number of counted nuclei labelled by DAPI; 
between automated and manual techniques. Data were analysed using paired 
student’s t-tests, **p≤0.01, ***p≤0.001, n=10.  E, As D, except for EdU labelled nuclei.    
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Figure 4.16. PX-12 (1µM) reduces HEK293/CaV3.1 cell proliferation 
Representative images showing EdU incorporation in HEK293/CaV3.1 cells following 
incubation with EdU (12hrs, 5µM). Total cell nuclei are labelled by DAPI (left panel, 
blue images) and nuclei containing newly synthesised DNA are labelled by EdU (centre 
panel, orange images), merged images illustrating co-localisation (right panel, pink 
images). Showing differences between: A, control conditions and B, following PX-12 
incubation (1µM, 48hrs). C, Bar graph showing, (mean ± s.e.m) EdU positive nuclei (% 
of DAPI labelled nuclei) within HEK293/CaV3.1 cells, calculated by manual counting, 
n=5. Five randomly selected fields of view were counted with the mean value 
represented as n=1.Data were analysed using paired Student’s t-tests, **p<0.01.  
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Figure 4.17. PX-12 (1µM) has no effect on wt HEK293 cell proliferation 
Representative images showing EdU incorporation in wt HEK293 cells following 
incubation with EdU (12hrs, 5µM). Total cell nuclei are labelled by DAPI (left panel, 
blue images) and nuclei containing newly synthesised DNA are labelled by EdU (centre 
panel, orange images), merged images illustrating co-localisation (right panel, pink 
images). Showing differences between: A, control conditions and B, following PX-12 
incubation (1µM, 48hrs). C, Bar graph showing, (mean ± s.e.m) EdU positive nuclei (% 
of DAPI labelled nuclei) within wt HEK293 cells, calculated by manual counting, n=5 
Five randomly selected fields of view were counted with the mean value represented 
as n=1.Data were analysed using paired Student’s t-tests, although significance was 
not observed.   
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4.3. Discussion  
Trx is ubiquitously expressed in both prokaryotic and eukaryotic organisms and is 
known to have a variety of important functions. In light of this, literature regarding the 
structure, function and localisation of Trx is extremely wide ranging and so reference is 
constrained to studies conducted within mammalian cells. Trx inhibitors are currently 
being explored clinically as anti-cancer agents. Consequently, much of the following 
discussion concerns malignant cell lines. Angiogenesis involves excessive VSMC 
proliferation and is a key pathological phenotype crucial for tumour growth. Malignant 
cells also share other similarities with proliferative VSMCs, such as elevated T-type Ca2+ 
channel expression (Dziegielewska et al., 2014) and increased Trx levels (Powis et al., 
2000). As such, studies examining the effects of Trx inhibition on cancer cells relate 
well to the current investigation.  
 
4.3.1. Comparison of methods for the quantification of endogenous Trx levels  
The principles of determining Trx activity spectrophotometrically, using insulin 
reduction assays, utilise the properties of Trx as a major cellular protein disulphide 
reductase. Whilst this technique is longstanding, many different fluorescent reporters 
have been used. Upon initial development, turbidity analysis was used to detect the 
precipitation of free A and B chains, resulting from Trx-mediated reduction of two 
inter-chain disulphide bonds, within the insulin molecule. This was detected as 
increases in absorbance at 650nm (Holmgren, 1979). Other spectrophotometric 
variants include monitoring (i) NADPH consumption, observed as a decrease in 
absorbance at 340nm (Zhang et al., 2014), (ii) reduction of tryptophan, observed as an 
increase in fluorescence at 350nm (Holmgren, 1979), and (iii) reduction of 5,5-
dithiobis(2-nitrobenzoic acid) (DTNB), detected as increasing fluorescence at 412nm 
(Huang et al., 2014; Schulze et al., 2002). A key problem with these assays however, is 
that they lack substrate specificity which results in large background values. Two key 
advantages of the newly developed assay currently used are: it does not require the 
addition of DTT to reduce Trx, and due to the high degree of substrate specificity it 
enables more accurate quantification of unknown Trx concentrations (Montano et al., 
2014).  
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Within the current investigation, Trx levels were measured by assessing the rate of 
increasing fluorescence of eosin-labelled insulin which in turns corresponds with the 
rate of Trx-mediated reduction. As insulin reduction requires Trx to be in its reduced 
and active form (rTrx), the assay involves pre-incubation with excess amounts of both 
TrxR and NADPH. Resultantly, it is assumed that all endogenous oxidised Trx (oTrx) is 
converted to rTrx. It is important to emphasise that as known Trx standards were used 
to calibrate the assay, Trx levels are deduced from Trx activity. Endogenous Trx was 
reliably detected within A7r5, HEK293/CaV3.1, HEK293/CaV3.2 and wt HEK293 cells. 
Despite standardising the total amount of protein loaded for each sample (15µg), Trx 
levels were highly variable between experimental repeats and cell types. As previous 
studies looking at Trx levels in cell lysates often only report increases or decreases in 
Trx activity with reference to control values (Schulze et al., 2002), only limited 
comparison is possible. Using an identical protocol as currently implemented, Trx 
levels within peripheral blood mononuclear cells (PBMCs) and human histocytic 
lymphoma (U937) cell lysates have been shown to be 1.75ng and 2.25ng per 1µg total 
protein respectively (Montano et al., 2014). Although performed in different cell types, 
current values were relatively higher (~4-16ng/µg). Further investigations, comparing 
A7r5 and U937 Trx levels within the same assay, would be useful to establish whether 
this difference is due to disparate Trx levels between cell lines or inter-laboratory assay 
variability.  
 
In the current investigation, chronic treatment of A7r5, wt HEK293 or HEK293/CaV3.1 
cells with low concentrations of AuF (300nM, 72hrs) did not produce any measurable 
decrease in Trx levels. This observation is consistent with the indirect nature by which 
AuF inhibits Trx, i.e. via TrxR. As the assay requires the addition of exogenous TrxR and 
NADPH in excess, potential effects of TrxR inhibition by AuF were unlikely to be 
detected. A very similar fluorescence assay which requires Trx to be added in excess, 
as opposed to TrxR, has been used successfully to study TrxR activity within cell lysates 
(Cox et al., 2008; Lessa et al., 2011). This alternative assay would be more suitable for 
subsequent investigations into the interactions between AuF and Trx.  
 
The effects of PX-12 treatment on Trx activity were also examined. This indicated that 
chronic PX-12 pre-treatment (1µM, 72hrs) had no effect on Trx levels within A7r5, wt 
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HEK293 or HEK293/CaV3.1 cells. Contrastingly, acute PX-12 treatment (3µM or 30µM, 
10mins) did produce a small but significant reduction in Trx levels within 
HEK293/CaV3.1 and HEK293/CaV3.2 cells respectively. Whilst, PX-12 (300µM) produced 
a clear and uniform reduction in Trx activity, it also caused the rate of background 
fluorescence to decrease. Resultantly, this concentration was excluded from the final 
analysis. The effects of PX-12 on Trx were originally described by Kirkpatrick et al., 
(1998), who used spectrophotometric analysis alongside electrophoresis and mass 
spectrometry. The mechanism by which PX-12 inhibited human Trx (hTrx) was shown 
to be highly complex as different Trx cysteine (Cys) residues  were found to be 
sensitive to considerably different PX-12 concentrations.  
 
Firstly, Cys32 and Cys35 within the redox active site of Trx were shown to be rapidly 
inhibited by reversible thioalkylation, with a dissociation constant (Ki) of 31µM 
(Kirkpatrick et al., 1998). As redox-sensitive Cys residues within the active site are 
known to mediate the disulphide reductase abilities of Trx, this mechanism appears to 
correspond with the reductions in Trx activity currently observed following acute pre-
treatment with PX-12 (3µM or 30µM, 10mins). In addition, Cys73 found outside of the 
Trx active site was also originally shown to be modified by irreversible thioalkylation, at 
PX-12 concentrations several orders of magnitude lower than observed for Cys32 and 
Cys35, and with a considerably slower rate of reaction. Furthermore, irreversible 
thioalkylation of Cys73 as a result of pre-treating hTrx with PX-12 for 24hrs prior to 
measuring Trx activity was reported to prevent TrxR-mediated reduction of Trx. As 
substitution of Cys73 with a serine (Ser) residue (C73S Trx mutant) did not prevent the 
effects of TrxR on Trx, it was suggested that irreversible thioalkylation of Cys73 
produced a steric blockade of the interaction between Trx and TrxR (Kirkpatrick et al., 
1998). This mechanism would also theoretically prevent Trx-mediated insulin 
reduction, which would be detected currently as a decrease in Trx levels. However, as 
PX-12 (1µM, 72hrs) was currently found to be without effect on Trx levels, evidence 
against this alternative mechanism of Trx inhibition is provided.   
 
It should be noted that the reductions in Trx levels observed following acute PX-12 pre-
treatment were not concentration-dependent and also highly variable between cell 
types and experimental repeats. A potential explanation for this could be the 
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reversible nature of Cys32 and Cys35 thioalkylation. Specifically, PX-12 could not be 
directly applied to cell lysate samples using the current technique due to known 
interactions of alkylating agents with reaction components. As such, PX-12 had to be 
washed off immediately prior to measuring its effects on Trx. This could theoretically 
result in some reversal of the effects of PX-12 upon the NADPH and TrxR pre-
incubation step. An alternative explanation, which would also additionally account for 
the general variability in results, may concern the sensitivity of the recording 
equipment used for Trx assays. The current investigation used a dual-monochromator 
microplate reader (Varioskan Flash; Thermo Scientific, UK), whereas quad-
monochromator devices (Enspire or Victor3, PerkinElmer) are recommended by the 
assay developers. In support of this, especially when compared to the findings of 
Montana et al. (2014), the current investigation required higher Trx reference samples 
to generate accurate calibration curves and the absolute fluorescence values were 
much lower. Suggested improvements to the current assay would be to ensure that a 
quad-monochromator spectrophotometric recording device was used, and that the 
alternative TrxR assay was implemented to assess the effects of AuF. Further 
investigation could then be conducted to conclusively establish potential differences in 
both endogenous Trx levels between different cell lines and also the effects of AuF and 
PX-12.  
 
As a final note on the subject of Trx quantification, the majority of previously described 
methods do not differentiate between reduced and oxidised forms. As the balance 
between oTrx and rTrx is a crucial feature of its activity, important effects of AuF and 
PX-12 may be masked when reducing agents are applied exogenously. The redox 
western blot provides a way of independently measuring oTrx and rTrx. This technique 
requires incubating Trx with a maleimide derivative prior to separating samples using 
non-reducing SDS gel electrophoresis and detecting with antibodies. Maleimide is only 
able to bind to rTrx and thereby selectively increases its molecular size, whilst having 
no effect on oTrx. The ratio of rTrx/oTrx can be calculated using band densitometry, 
and the redox state quantified using the Nernst equation (Hansen, 2012). To 
investigate Trx activity within HeLa cells, redox western blotting using iodoacetamide 
and iodoacetic acid to detect the redox state of Trx has been used effectively alongside 
a spectrophotometric assay identical to that currently used (Zhang et al., 2014).  
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4.3.2. High concentrations of Trx inhibitors induce cell death  
The current investigation demonstrated that AuF (1-3µM) and PX-12 (3-300µM) 
significantly reduced A7r5 and HEK293/CaV3.2 cell viability following 72hrs of 
treatment. Similar findings have been previously reported within a variety of cell lines. 
A key point to emphasise is that MTT assays were used in the current investigation to 
assess cell viability and not cell number as referenced in some other studies (Raninga 
et al., 2015; Shin et al., 2013; You et al., 2014). It is possible that a reduction in cell 
number could correspond with reduced production of the formazan product (i.e. 
absorbance at 560nm), due to a lower number of cells and thus total mitochondria. 
However, within the current investigation morphological changes indicating cell death, 
such as rounding-up and cell detachment, were observed within all treatment groups 
exhibiting reduced absorbance. This supported the conclusion that reduced 
absorbance values were due to reductions in cell viability and not anti-proliferative 
effects. Resultantly, previous studies which used MTT assays to quantify cell number 
will be interpreted with this caveat in mind. 
 
Treatment of tumour cell lines, including Jurkat and MCF-7 cells, with high 
concentrations of AuF (10µM, 48hrs) has been shown to induce significant reductions 
in cell viability, as measured using MTT assays. MCF-7 cells showed the greatest 
sensitivity and also exhibited cellular DNA fragmentation in approximately 20% of cells. 
This indicated that the cytotoxic effects of AuF were mediated, in part, by apoptosis 
induction. Spectrophotometric TrxR activity assays using DTNB as the fluorescent 
reporter were also implemented and revealed that AuF (500nM) inhibited TrxR activity 
by 79%. Whilst these findings confirmed that TrxR is a biological target of AuF, they 
employ considerably higher AuF concentrations than currently used to investigate 
effects on cell viability (Lessa et al., 2011). The effects of lower AuF concentrations on 
Jurkat T-lymphoma cell viability were also examined in an alternative study. Using 
propidium iodide uptake as a measurement, AuF (0.5-4µM, 24hrs) was found to 
reduce Jurkat cell viability in a concentration-dependent manner with a half maximal 
lethal dose (LD50) of 1.4µM. In addition, AuF (2-3µM, 24hrs) increased caspase-3 
activity, confirming a role of apoptosis in AuF-mediated cell death (Cox et al., 2008). 
These findings are in close agreement with current observations that AuF (≥1µM) 
reduced A7r5 and HEK293/CaV3.2 cell viability. In contrast with the current finding that 
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the cytotoxicity threshold of AuF was independent of cell type, Cox et al. (2008) also 
reported that not all cells responded to AuF in the same manner. Compared to Jurkat 
cells, mouse B cell hybridoma (B9) cells were comparatively resistant to AuF-induced 
apoptosis. Treatment of B9 cells with AuF (3µM, 24hrs) had no effect on cell viability, 
although direct cell counting revealed that it did completely halt cell proliferation. All 
of the effects of AuF in this study are attributed to inhibition of TrxR, confirmed 
directly using DTNB reduction assays to have an IC50 of 200nM (Cox et al., 2008). Of 
note, however, is that AuF was applied at relatively higher concentrations for 
apoptosis experiments than were shown necessary to inhibit TrxR. Though potential 
off-target effects of AuF should be considered, this discrepancy in concentrations may 
be due to the indirect nature of Trx inhibition. Specifically, it could take more than 
24hrs for the effects of TrxR inhibition on the redox-state of Trx to fully equilibrate. 
Current observations that AuF (1µM) was without significant effect on HEK293/CaV3.2 
cell viability after 24hrs, although did reduce viability 48 and 72hrs post-treatment, are 
in agreement with this interpretation.  
 
Regarding the PX-12 (≥3µM)-mediated reductions in A7r5 and HEK293/CaV3.2 cell 
viability currently observed, a limited number of studies exploring the effects of PX-12 
on cellular apoptosis have also recently been reported. Treatment of hepatocellular 
carcinoma (HCC) cell lines HepG2 and SMMC-7721 with PX-12 (48hrs) was shown to 
reduce average cell number with IC50 values of 6.32μM and 13.38μM respectively. 
Importantly, these findings were demonstrated using a commercially-available cell 
counting kit (CCK-8, Dojindo, Japan) which although referred to as a viability assay, did 
not differentiate between cytotoxic and anti-proliferative effects. Further investigation 
was subsequently conducted using Annexin V-FITC assays to directly measure 
apoptosis, dichlorofluorescein (DCF) assays to quantify reactive oxygen species (ROS) 
levels and flow cytometry for cell cycle analysis. This revealed that PX-12 reduced 
average cell number via both ROS-induced apoptosis and S-phase cell cycle arrest. 
Furthermore, these effects were prevented by pre-treatment with the antioxidant N-
acetyl cysteine (NAC). As PX-12 was also found to sensitise HCC cells in vitro and in vivo 
to 5-fluorouracil (5-FC), the principal cytotoxic chemotherapy agent for HCC, the 
authors suggest that these drugs provide an effective drug combination to reduce 
tumour growth (Li et al., 2015a). An alternative study implemented MTT assays to 
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show that PX-12 decreased human cervical adenocarcinoma (HeLa) cell number with 
an IC50 value of 7µM. This reduction was shown to involve both ROS-induced apoptosis 
and cell cycle G2/M-phase arrest. In direct agreement with current findings, PX-12 
(1µM, 72hrs) was without effect on the MTT signal at 570nm (Shin et al., 2013). In 
addition, the growth of A549 lung cancer cells has also been shown to be reduced by 
PX-12 (IC50 20µM) and similarly found to be mediated through G2/M-phase arrest and 
ROS-dependent apoptosis (You et al., 2014).  
 
Of final interest is a study which explored the suitability of PX-12 and AuF as novel 
treatments for multiple myeloma (MM), a haematological disorder involving aberrant 
growth and accumulation of clonal plasma cells. Human PBMCs were isolated from 
healthy volunteers and used as control cells to directly compare against MM cell lines. 
Elevated Trx and TrxR protein levels alongside higher ROS levels were detected in MM 
cells when compared to PBMCs, as measured using western blotting and DCF analysis 
respectively. In direct contrast with current methodologies, the authors incorrectly 
used direct cell counting as a measure of cell viability and MTT assays to quantify 
proliferation. Following incubation with AuF ≤8µM) or PX-12 (≤40µM) for 24hrs the 
average number of cells was reduced in a concentration-dependent manner. MM cell 
lines showed the greatest sensitivity to these reductions. MM cells cultured in 
methylcellulose additionally revealed that PX-12 (5µM) and AuF (4µM) reduced colony 
formation. Regarding the potential mechanisms of these anti-clonogenic effects, PX-12 
(5µM) was found to induce ROS-mediated apoptosis in MM cells but not in PBMCs. In 
addition, PX-12 sensitised cells to apoptosis induced by nuclear transcription factor 
(NF) NF-κβ inhibitors such as curcumin (Raninga et al., 2015). This may be significant as 
NF-κβ regulates the expression of various genes involved in cell proliferation and 
tumorigenesis (Matthews et al., 1992). 
 
In conclusion, the ability of the AuF (≤1µM) and PX-12 (≤3µM) to induce cell death are 
well established. Whilst the ROS-induced apoptotic effects of Trx inhibition may have 
therapeutic potential in the treatment of cancer, apoptosis could have detrimental 
effects on healthy VSMCs. Therefore, when assessing the suitability of Trx inhibitors as 
novel treatments for proliferative cardiovascular disorders, only AuF and PX-12 
concentrations below those directly shown to reduce cell viability are considered.  
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4.3.3. Low concentrations of Trx inhibitors selectively reduce cellular proliferation in 
CaV-expressing cells.  
The current investigation demonstrated that PX-12 (1µM) and AuF (300nM) 
significantly reduced A7r5 and HEK293/CaV3.2 cell proliferation following 72hrs of 
treatment. Notably, direct cell counting suggested that the proliferation of wt HEK293 
and HEK293/CaV3.1 cells was not significantly altered. To confirm this observation, 
DNA synthesis was assessed using EdU nucleoside incorporation assays over a 12hr 
period. Results confirmed that the proliferation of wt HEK293 was unaltered by PX-12 
(1µM, 48hrs). In contrast, significant reductions in the number of HEK293/CaV3.1 cells 
which had progressed through the G1-S phase of the cell-cycle were apparent. Findings 
within HEK293 cells therefore indicate that Trx inhibitors selectively reduce the 
proliferation of T-type Ca2+ channel expressing cells. In support of this conclusion, 
“new” A7r5 cells were shown using qRT-PCR to express considerably higher levels of T-
type Ca2+ channels when compared to “old” A7r5 cells and were much more sensitive 
to the anti-proliferative effects of AuF. Whilst this proposal is novel, many previous 
studies report anti-proliferative effects of Trx inhibitors within cell lines coincidently 
shown to express T-type Ca2+ channels.  
 
In addition to studies in cancer cell lines showing AuF- and PX-12-mediated cell cycle 
arrest (as described in section 4.3.2), the anti-proliferative effects of Trx inhibition 
have also been examined in a variety of other cell types. Interestingly, early studies 
provided conflicting findings regarding the effects of Trx on cell growth. For example, 
AuF (100-500nM) significantly decreased the proliferation of primary cultures of 
vascular endothelial cells (VECs) when determined using thymidine incorporation 
measurements and without affecting viability (Matsubara & Ziff, 1987). Contrastingly, 
an alternative study additionally used direct cell counting to show that application of 
Trx to the culture media inhibited the growth of HepG2 cells. This same study also 
reported opposing stimulatory growth effects of Trx on the B-cell lymphoma cell line, 
A20 (Rubartelli et al., 1995). 
 
Within pulmonary hypertensive (PH) diseases associated with hypoxia, pathological 
pulmonary artery SMC (PASMC) proliferation leads to vascular remodelling. A recent 
study determined that Trx levels from lung homogenates, isolated from mice 
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maintained in hypoxic conditions (10% oxygen, 4 weeks) were double that of controls 
(normoxia) (Chen et al., 2013). In vitro studies additionally compared Trx levels in 
HPASMCs cultured in hypoxic conditions (1% O2, 24-72hrs) to controls, using western 
blotting. Under normoxic conditions, Trx expression remained constant whilst hypoxia-
exposed HPASMCs showed considerable elevations in Trx (65%, 72hrs). HPASMCs 
cultured for 120 days under normoxia or hypoxia were also counted using a direct cell 
counting approach. Hypoxia was found to increase HPASMC proliferation. 
Furthermore, genetic knockdown of Trx using siRNA abolished hypoxia-induced 
elevations in proliferation, and also reduced HPASMC proliferation under normoxic 
conditions. In close agreement with current observations, PX-12 (2µM) was found to 
fully reproduce the anti-proliferative effects of genetic Trx inhibition. Regarding 
potential mechanisms for the pro-proliferative effects of Trx, increased Trx expression 
was found to correlate with activation of hypoxia-inducible factor (HIF) and 
phosphatidylinositol 3-kinase (PI3K)/serine/threonine kinase (Akt). It was concluded 
that Trx regulates hypoxia-induced PASMC proliferation via HIF-dependent 
mechanisms with downstream effects on PI3KAkt signalling (Chen et al., 2013). Of 
significant interest to the current investigation is that chronic hypoxia has also been 
shown to up-regulate the expression of CaV3.2 channels in HPASMCs (Wan et al., 
2013). These findings are therefore also consistent with the suggestion that Trx 
regulates T-type Ca2+ channels and controls cell proliferation.  
 
The effects of AuF on vascular endothelial cell (VEC) proliferation have also been 
studied recently. Angiogenesis is the process by which existing blood vessels form a 
network of new vessels, and involves the proliferation, invasion, migration and tube 
formation of VECs. Human umbilical VECs (HUVECs) were used to examine the anti-
proliferative effects of AuF in vitro. Using a cell-counting kit-8, the number of HUVECs 
was found to be reduced by AuF in a concentration-dependent manner with an IC50 
value 178nM. It should be noted however, that this technique does not differentiate 
between cytotoxic and anti-proliferative effects. To compensate for this, cellular 
migration was assessed using a wound-healing assay, whereby a small strip of cells are 
removed from a confluent monolayer of cultured HUVECs. HUVECs cultured under 
control conditions for 10hrs showed significant migration into the denuded region, 
which was inhibited by AuF (25-390nM) in a concentration-dependent manner. As no 
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morphological changes, such as blebbing, cell shrinkage, nuclear fragmentation or 
chromatin condensation were observed potential cytotoxic effects of AuF were 
therefore ruled out. In addition, under control conditions, culture of HUVECs on 
matrigel resulted in tube formation which was also significantly inhibited by AuF (98-
390nM) (He et al., 2014). The concentrations of AuF shown to be anti-angiogenic 
within this study are very similar to those currently found to reduce A7r5 and 
HEK293/CaV3.2 cell proliferation.  
 
The anti-angiogenic properties of AuF were confirmed in vivo using transgenic 
zebrafish. In addition to its anti-angiogenic effects, treatment of zebrafish embryos 
with AuF (98nM) was found to up-regulate vascular endothelial growth factor (VEGF) 
expression whilst higher doses caused a sharp down-regulation in VEGF mRNA. 
Expression of the VEGF receptors flt-1 and kdr was consistently down-regulated by AuF 
in a concentration-dependent manner. As the expression of TrxR remained unaltered 
by AuF treatment, the authors postulate that the anti-proliferative and anti-angiogenic 
effects of AuF are due to direct interaction with VEGF signalling. This conclusion is 
debateable however as AuF exerts its effects by altering the activity of TrxR (Gromer et 
al., 1998) and has not previously been shown to alter TrxR expression. Downstream 
regulation of VEGF signalling pathways by Trx is therefore an equally plausible 
conclusion, though not explored within the study (He et al., 2014). As T-type Ca2+ 
channels have been previously shown to be expressed within VECs, for example CaV3.1 
within HUVECs (Wang et al., 2006), these observations may also correspond with the 
proposed regulation of T-type Ca2+ channels by Trx.    
 
Confirmation that the anti-proliferative effects of AuF and PX-12 are mediated by Trx is 
provided by genetic studies. Vitamin D3-upregulated protein (VDUP), also known as Trx 
interacting protein or Trx-binding protein interacts with the redox active site of Trx and 
functions as its endogenous inhibitor. Over-expression of Trx or VDUP using 
adenovirus-mediated gene transfer has been conducted in primary aortic SMCs. Trx 
transfection increased Trx activity (2.8- fold), as determined by spectrophotometric 
insulin reduction assays. Correspondingly, cellular DNA synthesis was also increased 
(3.8- fold) when determined by methyl-[3H] thymidine incorporation over a 5hr period. 
Platelet derived growth factor (PDGF), a powerful mitogenic stimulus, was found to 
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increase both Trx activity and cellular DNA synthesis within SMCs. As Northern analysis 
did not detect any increases in Trx mRNA with PDGF treatment, it was suggested that 
changes to the redox status of Trx was mediating its effects. Furthermore, as PDGF 
treatment significantly decreased VDUP mRNA and protein levels, and subsequently 
inhibited by NAC, evidence suggested that VDUP expression is a redox-regulated 
process. Conversely, transfection with VDUP reduced Trx activity (61%) in SMCs and 
also completely blocked PDGF-induced increases in Trx activity. Whilst VDUP over-
expression alone did not alter methyl-[3H] thymidine incorporation it did block PDGF-
induced increases in SMC proliferation. VDUP over-expression was also shown to have 
no effect on the apoptotic rate. The authors therefore conclude that VDUP 
suppression increases Trx activity, and as such endogenously regulates cellular redox 
state and SMC mitogenesis. Findings also suggest that the pro-proliferative effects of 
PDGF act via this mechanism (Schulze et al., 2002). 
 
Schulze et al. (2002) also assessed the cellular distribution of Trx using 
immunohistochemistry. In quiescent cells serum starved for 48hrs, a homogenous 
cytoplasmic Trx distribution was detected with nuclear staining evident in only ~10% of 
cells. Interestingly, PDGF induced rapid translocation of Trx to cell nuclei in 58% of 
cells. This nuclear translocation was inhibited by VDUP over-expression. Translocation 
of Trx to VSMC nuclei has been previously shown to produce lipopolysaccharide and 
interleukin 1 (IL1)–induced increases in the DNA-binding activity of the transcription 
factor AP-1 (Wiesel et al., 2000). These findings therefore suggest an alternative 
potential mechanism for the growth modulating effects of Trx which could be 
influenced by intracellular Ca2+ levels. Furthermore, as discussed previously in Chapter 
3, T-type Ca2+ channels are widely expressed in VSMCs and therefore the anti-
proliferative effects of VDUP may also concern reduced interaction between Trx and T-
type Ca2+ channels.  
 
The effects of genetic-mediated Trx over-expression have also been examined. 
Following myocardial infarction (MI), pathological cardiac remodelling commonly 
occurs. Engraftment of mesenchymal stem cells (MSCs) is currently being explored as a 
potential therapeutic approach to mediate myocardial repair following MI. Rat MSCs 
were genetically modified to over-express Trx via adenoviral transfection. The 
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proliferation and differentiation potential of wild type MSCs (wt-MSC), MSCs over-
expressing Trx (Trx-MSC) and MSCs transfected with control plasmids (LacZ-MSC) were 
compared. Immunohistochemical markers such as α-tubulin to label microtubules and 
Ki-67 as a marker of proliferation were applied. This revealed that under hypoxia Trx-
MSCs had increased proliferative capacity and maintained better pluripotency when 
compared to wt-MSCs and LacZ-MSCs. This enabled successful differentiation into 
cardiomyocytes, SMCs and endothelial cells (Suresh et al., 2015).  
 
The effects of Trx expression in vivo were also examined. Rats were subject to MI prior 
to administration of pre-conditioned Trx-MSCs or LacZ-MSCs into the peri-infarct 
region. Interestingly, 7 days post MI, the number of proliferating cells was elevated in 
mice treated with Trx-MSCs. Furthermore, 60 days post MI, echocardiography and 
immunohistochemistry revealed increased myocardial function and capillary density 
alongside reduced fibrosis in Trx-MSC mice when compared to MSC-LacZ or sham MI 
controls. A significantly smaller improvement was observed in mice treated with wt-
MSCs. Western blot analysis of MI mice exposed to Trx-MSCs revealed increased 
expression of the pro-angiogenic factors VEGF and heme oxygenase-1. Furthermore, 
the expression of chemokine receptor CXCR4 was also increased, thus indicating the 
contribution of paracrine effects. It was subsequently concluded that administration of 
MSCs over-expressing Trx provides therapeutic potential in the treatment of ischemic 
disease (Suresh et al., 2015).  
 
Electrophysiological and biochemical investigations in embryonic SCs, has revealed 
that Ca2+ currents within these cells are primarily mediated by CaV3.2 channels. As 
CaV3.2 expression peaked at the G1/S transition phase of the cell-cycle it was suggested 
that CaV3.2 channels play an important role in the maintenance of undifferentiated 
states (Rodriguez-Gomez et al., 2012). Collectively, these studies support the view that 
Trx is pro-proliferative. Findings are also indirectly consistent with the potential 
involvement of T-Type Ca2+ channels in Trx-mediated growth regulation.  
 
A final interesting point to consider is what structural determinants of Trx mediate its 
growth promoting effects. The characterised actions of Trx as a ubiquitous disulphide 
reductase generally involve Cys32 and Cys35 within the active site. Resultantly, these 
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residues appear most likely to mediate the stimulatory growth effects. In support of 
this notion, a study conducted by Oblong et al. (1994) used site-directed mutagenesis 
to substitute either or both of the Cys32 and Cys35 residues in the Trx active site to 
serine residues (C32S, C35S, C32S/C35S). When applied to murine fibroblasts, Trx 
stimulated both DNA synthesis and proliferation. When the C32S, C35S, or C32S/C35S 
mutated forms of Trx were applied however, no such effects were observed. This 
indicated that the Cys residues in the redox-active site were required for Trx-mediated 
growth stimulation (Oblong et al., 1994). In contrast, current observations indicated 
that low PX-12 concentrations not expected to modify catalytic Cys residues did have 
anti-proliferative effects in both A7r5 and HEK293/CaV3.2 cells. This was similarly 
observed for MCF-7 cells where low concentrations of PX-12 inhibited proliferation, 
with IC50 values of 1.2µM or 3.2µM, when using Trx or FBS as the mitogenic stimulus 
respectively (Kirkpatrick et al., 1998). Collectively, this emphasises that the slower 
irreversible thioalkylation of Cys73 residues in Trx, which occurs at low PX-12 
concentrations (Kirkpatrick et al., 1998), may account for the growth inhibitory effects 
of PX-12.  
 
The above studies conclusively support current findings that Trx inhibition using low 
concentrations of PX-12 or AuF reduces cellular proliferation. They also propose a 
range of intracellular mechanisms which may account for this effect, including 
regulation of VEGF signalling (He et al., 2014; Suresh et al., 2015), HIF and Akt 
activation (Chen et al., 2013), increased expression of HO-1 and chemokine receptors 
(Suresh et al., 2015) and also modulation of AP-1 transcription factor activity (Schulze 
et al., 2002). Of potential significance is the observation that the majority of these 
studies were conducted on cells which have also previously been shown to express T-
type Ca2+ channels. Indirect support is therefore also provided to current observations 
that only CaV3.1 and/or CaV3.2-expressing cells are sensitive to the anti-proliferative 
effects of Trx inhibition. Changes in intracellular Ca2+ regulates a huge variety of 
signalling cascades, including those which mediate proliferation and gene transcription 
(Berridge et al., 2000). It is subsequently possible that alterations in Ca2+ influx, via 
modulation of T-type Ca2+ channels by Trx, provides an initial upstream signalling event 
which controls cell proliferation. This proposal is summarised by the following 
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schematic diagram, which also provides examples of how Ca2+ and Trx-mediated 
signalling pathways regulate gene transcription (Figure 4.14).  
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Figure 4.14. Schematic diagram showing how Trx and Ca2+ can regulate proliferation 
Showing examples of both Ca2+ (black lines) and Trx (red lines)-mediated signalling 
pathways that function to control gene transcription and cell proliferation. Potential 
interactions between these pathways, i.e. via CaV3.2 channel regulation (red dashed 
line) are highlighted. Ca2+ enters the cell membrane through voltage-gated Ca2+ 
channels (e.g. CaV3.2) which may lead to Ca
2+-induced Ca2+ release from internal 
stores. Cytosolic Ca2+ regulates protein kinase C (PKC) leading to nuclear translocation 
of nuclear transcription factor (NF-κβ). In addition, nuclear Ca2+ stimulates the 
transcription factor CREB via Ca2+/calmodulin-dependent protein kinase type IV 
(CaMKIV) (Berridge et al., 2000). Reduced Trx (Trx(SH)2) is generated by thioredoxin 
reductase (TrxR) which in turn regulates the activity of transcription factors NF-κβ and 
AP-1, in addition to various progression factors. Oxidised Trx (TrxS2) is then re-
generated via oxidation. Trx is also found bound to the cell membrane and is secreted 
extracellularly; occasionally in the form of Trx80. The molecular targets of the direct 
and indirect Trx inhibitors, PX-12 and auranofin (AuF) are also shown. Diagram adapted 
from Arner & Holmgren (2000) and Lu & Holmgren (2014). (Arner & Holmgren 2000; Lu 
& Holmgren 2014) 
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4.3.4. The potential for Trx as a T-type Ca2+ channel modulator  
Current observations that AuF augments Ca2+ handling in A7r5 cells support the 
suggestion that modulation of T-type Ca2+ channels may mediate the  growth 
promoting effects of Trx. Specifically, AuF pre-treatment reduced depolarisation-
induced Ca2+ oscillations in “old” A7r5 cells, and also partially inhibited the Ca2+-
mediated window current recorded from “new” A7r5 cells. Both of these measures of 
A7r5 Ca2+ handling were previously confirmed to involve T-type Ca2+ channels (Chapter 
3). As AuF-mediated inhibition of Ca2+ oscillations in “old” A7r5 cells was reversed by 
DTT, evidence is also provided that the Trx-mediated regulation of T-type Ca2+ 
channels occurs via a redox-dependent mechanism. Unfortunately, the effects of PX-12 
on Ca2+ handling could not be examined as PX-12 was found to interfere with 
microfluorimetric signals, selectively increasing the fluorescence signal excited at 
340nm but not at 380nm. In addition, due to time constraints of the project, the 
effects of AuF on recombinant HEK293 cell window currents were not determined.  
 
Previous investigations looking at the effects of AuF on [Ca2+]i levels are limited and 
their findings somewhat contrast with current observations. A previous study used 
Fura-2 Ca2+ microfluorimetry to demonstrate that AuF (10-50µM) induced Ca2+ release 
from intracellular stores, thus elevating basal [Ca2+]i. These findings do not translate 
well to the present discussion however, as considerably higher AuF concentrations 
likely to induce apoptosis were applied (Wong et al., 1990). A more recent study 
examined the effects of AuF on [Ca2+]i within MCF-7 cells. MTS assays (an alternative to 
the MTT assay) were used to assess cell viability. Using fluo-4 as the ratiometric 
indicator, baseline [Ca2+]i levels were monitored for 30mins before AuF was perfused 
continually for 2hrs. It was subsequently demonstrated that AuF (1-10µM) produced a 
sustained increase in [Ca2+]i in a concentration- and time-dependent manner. AuF 
(24hrs) was also shown to cause apoptotic cell death, confirmed using flow cytometry, 
with a calculated IC50 value of 3.37µM. Whilst the mechanism of Ca
2+ entry was not 
established, these data suggest that the apoptosis-inducing effects of higher AuF 
concentrations may also be dependent on [Ca2+]i (Varghese & Busselberg, 2014). 
Whilst these findings contrast with current observations (i.e. AuF decreases Ca2+ 
influx), they refer specifically to cytosolic [Ca2+]i and not Ca
2+ influx. It would therefore 
be interesting to determine whether higher doses of AuF, applied for longer periods of 
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time, alters Ca2+ influx in A7r5 cells. In addition, further investigation to determine the 
effects of AuF on wt HEK293, HEK293/CaV3.1 and HEK293/CaV3.2 window currents 
would be useful to establish any potential isoform specific effects.  
 
4.3.5.  Summary and conclusions 
Findings discussed within chapter 3 demonstrate that T-type Ca2+ channels contribute 
to the regulation of basal Ca2+ levels. In addition, they emphasise that selective T-type 
Ca2+ channel inhibition reduces A7r5, HEK293/CaV3.1 and HEK293/CaV3.2 cell 
proliferation, whilst inhibition of L-type Ca2+ channels is without effect. Findings 
reported in the current chapter demonstrate that Trx inhibition using high 
concentrations of AuF or PX-12 increases cell death, whilst lower concentrations 
reduce the proliferation of HEK293/CaV3.2 and A7r5 cells. AuF was also found to 
reduce Ca2+ influx within A7r5s cells. The degree of the anti-proliferative effect of AuF 
was similar to those observed with the selective T-type Ca2+ channel inhibitor NNC. 
Furthermore, as the effects of PX-12 and NNC on HEK293/CaV3.2 cell proliferation 
were shown to be non-additive, evidence is provided that both drugs may act via the 
same target, i.e. CaV3.2 channels. Further investigation (using EdU incorporation assays 
as an alternative measure of cellular proliferation) confirmed that wt HEK293 cells 
were insensitive to the anti-proliferative effects of PX-12. They also indicated that DNA 
synthesis within HEK293/CaV3.1 cells was altered by PX-12 (1µM, 48hrs). This 
highlighted the potential involvement of CaV3.1, in addition to CaV3.2, channels as 
targets for Trx regulation and should also be considered in subsequent investigations. 
Support is therefore provided that Trx controls cellular proliferation via modulation of 
T-type Ca2+ channels.  
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Chapter 5 -The effects of thioredoxin (Trx) and inhibitors on 
voltage-gated Ca2+ (CaV) channels  
5.1. Introduction  
Cell-surface proteins within the extracellular environment are subject to oxidising 
conditions and are rich in stabilising disulphides (S2). In contrast, intracellular proteins 
contain many free sulfhydryl or thiol (SH) groups as the intracellular environment is 
maintained in a reduced state. Thioredoxin (Trx) serves as a major disulphide 
reductase and can counterbalance the effects of oxidative stress when up-regulated or 
over-expressed (Nakamura et al., 1997). Whilst the intracellular actions of Trx are well 
characterised, it can be excreted by cells, via a leaderless secretory pathway (Rubartelli 
et al., 1992; Tanudji et al., 2003). Although the physiological consequences of 
extracellular Trx remain relatively undetermined, it has been found to have both 
mitogenic and co-cytokine effects on monocytes (Bertini et al., 1999; Pekkari et al., 
2001). Significantly, increased levels of circulating extracellular Trx are detected within 
pathological conditions involving aberrant cellular proliferation including, but not 
limited to, a variety of cancers (Baker et al., 2013), abdominal aortic aneurysm 
(Martinez-Pinna et al., 2010) and atherosclerosis (Okuda et al., 2001).  
 
Within rat vascular smooth muscle cells (VSMCs), a coordinated elevation in [Ca2+]i is 
required for cell cycle progression (Husain et al., 1997). Whilst L-type Ca2+ channels 
have been shown to mediate VSMC contraction, T-type Ca2+ channel expression is 
restricted to proliferative phases of the cell-cycle (Kuga et al., 1996). As such, T-type 
Ca2+ channels can control basal Ca2+ levels and regulate cellular proliferation, as 
discussed extensively in Chapter 3. A key feature of CaV3.2 channels which 
distinguishes them from other T-type Ca2+ channel isoforms is their unique sensitivity 
to redox modulators and trace metals, such as ascorbate (Nelson et al., 2007a), Ni2+ 
(Kang et al., 2006; Lee et al., 1999) and Zn2+ (Kang et al., 2010). As described in Chapter 
4, CaV3.2-expressing cells were the most sensitive to the anti-proliferative effects of 
Trx inhibitors. In addition, previous findings from the research group have shown that 
Trx selectively regulates CaV3.2 channels (Boycott et al., 2013). This chapter will 
therefore examine the potential interactions between Trx and T-type Ca2+ channels 
using whole-cell patch-clamp electrophysiology.  
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5.2. Results  
5.2.1.  The effects of Trx inhibitors on native and recombinant T-type Ca2+ currents 
Findings detailed within Chapters 3 & 4 show that Trx inhibitors and selective T-type 
Ca2+ channel blockers (CCBs) reduce A7r5 cell proliferation and Ca2+ window currents 
to similar extents. In order to explore potential interactions between Trx and T-type 
Ca2+ channels directly, electrophysiology was employed. Firstly, the effects of PX-12 on 
native T- and L-type Ca2+ currents were examined in A7r5 cells. Due to the potential 
activation of L-type mediated Ca2+ current using the T-type SS protocol and vice versa, 
current subtypes are labelled with quotation marks.  Initial experiments revealed that 
PX-12 (30µM) partially inhibited native “T-type” Ca2+ currents, but at a slow rate (data 
not shown). As A7r5 recordings did not typically last for long periods of time, 
quantification of the maximal effects of PX-12 (≤30µM) was unreliable. PX-12 (100µM) 
was found to produce a faster rate of inhibition and was applied for subsequent 
experiments. As shown in Figure 5.1, bath application of PX-12 (100µM) partially 
inhibited T-type Ca2+ currents in a poorly reversible manner. L-type Ca2+ currents were 
similarly inhibited by PX-12 (100µM; Figure 5.1) although to a slightly lesser extent 
than was observed for T-type Ca2+ currents. T-type Ca2+ currents were recorded under 
conditions which favour T-type Ca2+ channels (i.e. low stimulating-voltages and using 
Ca2+ as the charge carrier). However, the sustained component of some T-type Ca2+ 
current traces indicated a small contribution of high voltage-activated (HVA) channels 
(Figure 5.1). Due to the potential summation of A7r5 T- and L-type Ca2+ currents, 
further discussed in Chapter 3, recombinant HEK293/CaV3.1 and HEK293/CaV3.2 cells 
were used for all subsequent recordings. 
 
Proliferation studies described in Chapter 4 demonstrated that HEK293/CaV3.2 cells 
were more sensitive to the anti-proliferative effects of PX-12 and AuF, when compared 
to HEK293/CaV3.1 and wild-type (wt) HEK293 cells. In order to investigate this isoform 
specific difference further, CaV3.1 and CaV3.2 currents were recorded from 
HEK293/CaV3.1 and HEK293/CaV3.2 cells respectively. Bath application of PX-12 (1-
300µM) was found to inhibit both CaV3.1 and CaV3.2 channels in a concentration-
dependent manner, with almost complete inhibition achieved with 300µM PX-12. The 
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sensitivity of each channel type was similar, although PX-12 was slightly more potent in 
inhibiting CaV3.2 compared to CaV3.1 currents (Figure 5.2).  
 
Current-voltage (I-V) protocols demonstrated that PX-12 (30mM) significantly inhibited 
CaV3.1 and CaV3.2 currents at all activating test potentials (-100mV to +60mV), as 
shown in Figure 5.3. This revealed that PX-12-mediated inhibition was voltage-
independent. Importantly, no significant effects on CaV3.1 and CaV3.2 current 
amplitude were observed when the vehicle control (DMSO) was applied alone. As PX-
12 washout was not accompanied by any recovery in current amplitude, PX-12-
mediated inhibition was shown to be irreversible, at least over the ~10-15min 
timescale examined. Contrastingly, following inhibition with PX-12 (30mM) the 
amplitude of both CaV3.1 and CaV3.2 currents was essentially fully recovered by 
exposure to the reducing agent dithiothreitol (DTT, 1mM). DTT also enhanced CaV3.1 
and CaV3.2 current amplitudes when applied in isolation, as shown by Figure 5.4 and 
Figure 5.5 for CaV3.1 and CaV3.2 currents respectively. These findings show that PX-12 
inhibits both Cav3.1 and Cav3.2 channels by a redox-sensitive mechanism. 
 
During its development PX-12 was shown to inhibit Trx directly, through both 
reversible and irreversible thioalkylation of Cys residues (Kirkpatrick et al., 1998). In 
order to determine whether PX-12-mediated inhibition of CaV3.1 and CaV3.2 currents 
was due to Trx inhibition, the effects of reduced thioredoxin (rTrx) on current 
amplitudes was examined. As illustrated in Figure 5.6, bath application of rTrx 
(4mg/mlwas without significant effect on CaV3.1 currents. In addition, rTrx failed to 
reverse the inhibitory effects of PX-12. In direct contrast, rTrx caused significant 
reversal of the effects of PX-12 on CaV3.2 currents, and also modestly enhanced the 
amplitude of CaV3.2 currents when applied in isolation (Figure 5.7). These findings 
demonstrate that PX-12-mediated inhibition of CaV3.2, but not CaV3.1, is in part due to 
Trx inhibition. They also indicate that a Trx-independent mechanism of PX-12-
mediated T-type Ca2+ channel inhibition occurs, which does not discriminate between 
CaV3.1 and CaV3.2 channels.  
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Figure 5.1. PX-12 inhibits native T-type and L-type Ca2+ currents in A7r5 cells 
Whole-cell patch-clamp recordings from A7r5 cells; A-C, “T-type” Ca2+ channel 
recordings evoked by 200ms step-depolarisations from -80 to -20mV (0.1Hz), with Ca2+ 
(15mM) as the charge carrier. D-F, “L-type” Ca2+ channel recordings evoked by 100ms 
step-depolarisations from -50 to +20mV (0.1Hz), with Ba2+ (20mM) as the charge 
carrier.  Due to the potential activation of L-type mediated Ca2+ current using the T-
type SS protocol and vice versa, “T-type” and “L-type” currents are labelled with 
quotation marks. A, Example time-series plot illustrating “T-type” Ca2+ current 
amplitude and the effects of bath application of PX-12 (100µM, black bar). B, Example 
“T-type” Ca2+ current trace corresponding with (A) showing effects of PX-12 (as 
labelled), scale bar, 100pA (vertical), 40ms (horizontal). C, Bar chart illustrating peak 
(mean ± s.e.m) “T-type” Ca2+ current amplitude (% of control amplitude) following 
exposure to DMSO (vehicle control 1:1000, grey box, n=4) and PX-12 (100µM, black 
box, n=6). D-F, As (A-C), except showing L-type Ca2+ currents. F, DMSO n=4, PX-12 n=7.  
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Figure 5.2. PX-12 inhibits CaV3.1 and CaV3.2 channels in a concentration-dependent 
manner 
Whole-cell patch-clamp recordings from HEK293/CaV3.1 (A-C) and HEK293/CaV3.2 cells 
(D-F), currents evoked by step-depolarisations (200ms duration, 0.1Hz) from -80mV to 
-20mV. A, Example CaV3.1 current trace under control conditions (red trace) and 
during exposure to PX-12 (300µM) over a 10 minute period as labelled. Scale bar 
400pA (vertical), 40ms (horizontal). B, Example time-series plots showing 
representative examples of the effects of PX-12 (1-300µM, as indicated), applied to the 
extracellular solution (black bar), on peak CaV3.1 current amplitude (% of control 
amplitude). C, Concentration-response (mean ± s.e.m) relationship graph showing the 
effects of PX-12 (1-300µM) on peak Cav3.1 current amplitude (% of control amplitude), 
n numbers in parentheses. Data were fitted with log-inhibitor normalised-response 
curves with extended ranges. D-F, As (A-C), except showing CaV3.2 currents. D, Scale 
bar 200pA (vertical), 40ms (horizontal).  
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Figure 5.3. PX-12 inhibits CaV3.1 and CaV3.2
 currents in a voltage-independent 
manner 
Whole-cell patch-clamp recordings from HEK293/CaV3.1 (A-B) and HEK293/CaV3.2 (C-
D) cells. Currents evoked by 80ms step-depolarisations (-100mV to +60mV in 10mV 
increments) from -80mV (Vh). A, Current-density (mean ± s.e.m.) vs. voltage (I-V) 
relationships for CaV3.1, before (open triangles) and during (solid circles) exposure to 
PX-12 (30µM, n=6). B, Example CaV3.1 I-V traces in (i) control conditions and (ii) during 
PX-12 (30µM) treatment. C-D, As (A-B), except showing CaV3.2 responses, n=11.  
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Figure 5.4. DTT fully reverses PX-12-mediated inhibition of CaV3.1 channels 
Whole-cell patch-clamp recordings from HEK293/CaV3.1 cells, currents evoked by 
200ms (0.1Hz) step-depolarisations from -80 to -20mV. A, Example time-series plot 
showing inhibition of CaV3.1 current amplitude by PX-12 (30µM, black bar) and 
reversal by DTT (1mM, red bar). B, Corresponding, CaV3.1 current traces (from A) 
under control conditions (red trace) and during exposure to PX-12 and DTT (as 
labelled). Scale bar 500pA (vertical), 40ms (horizontal). C-D, As (A-B), except showing 
the effects of DTT (1mM) applied in isolation. E, Bar chart (mean ± s.e.m) showing the 
effects on CaV3.1 current amplitude (% of control) of DMSO (blue bar, 1:1000, n = 5), 
PX-12 (black bar, 30µM, n=12), PX-12 washout (grey bar, n=5), DTT (1mM) applied 
after PX-12 (red bar, n=7) and DTT applied in isolation (white bar, 1mM, n=11). Data 
were analysed by one-way ANOVA with Bonferroni’s post-hoc comparison test, 
***p≤0.001, ****p≤0.0001. 
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Figure 5.5. DTT fully reverses PX-12-mediated inhibition of CaV3.2 currents  
Whole-cell patch-clamp recordings from HEK293/CaV3.2 cells, currents evoked by 
200ms (0.1Hz) step-depolarisations from -80 to -20mV. A, Example time-series plot 
showing inhibition of peak CaV3.2 current amplitude by PX-12 (30µM, black bar) and 
reversal by DTT (1mM, red bar). B, Corresponding CaV3.2 current traces (from A) under 
control conditions (red trace), and during exposure to PX-12 and DTT (as labelled). 
Scale bar 400pA (vertical), 40ms (horizontal). C-D, As (A-B), except showing the effects 
of DTT (1mM) applied in isolation. Scale bar 500pA (vertical), 40ms (horizontal). E, Bar 
chart (mean ± s.e.m) showing the effects on CaV3.2 current amplitude (% of control) of 
DMSO (blue bar, 1:1000, n = 5), PX-12 (black bar, 30µM, n=13), PX-12 washout (grey 
bar, n=6), DTT applied after PX-12 (red bar, 1mM, n=7) and DTT applied alone (white 
bar, 1mM, n=12). Data were analysed using one-way ANOVA with Bonferroni’s post-
hoc comparison test, *p≤0.05, **p≤0.01.  
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Figure 5.6. rTrx does not reverse PX-12-mediated inhibition of CaV3.1 channels 
Whole-cell patch-clamp recordings from HEK293/CaV3.1 cells, currents evoked by 
200ms (0.1Hz) step-depolarisations from -80 to -20mV. A, Example time-series plot 
showing inhibition of peak CaV3.1 current amplitude by PX-12 (30µM, black bar) and 
the lack of effect of rTrx (4µg/ml, red bar). B, Corresponding CaV3.1 current traces 
(from A) under control conditions (red trace), and during exposure to PX-12 and rTrx 
(as labelled). Scale bar 200pA (vertical), 40ms (horizontal). C-D, As (A-B), except 
showing no effect of rTrx (4µg/ml, red bar) applied in isolation. E, Bar chart (mean ± 
s.e.m) showing the effects on CaV3.1 current amplitude (% of control) of PX-12 (black 
bar, 30µM, n=13), rTrx (4µg/ml) applied after PX-12 (red bar, n=13) or rTrx applied in 
isolation (white bar, 4µg/ml, n=11). PX-12 and rTrx conditions were analysed using 
paired Student’s t-tests, no significant differences were observed.  
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Figure 5.7. rTrx partially reverses PX-12-mediated inhibition of CaV3.2 channels 
Whole-cell patch-clamp recordings taken from HEK293/CaV3.2 cells, currents evoked 
by 200ms (0.1Hz) step-depolarisations from -80 to -20mV. A, Example time-series plot 
showing inhibition of peak CaV3.2 current amplitude by PX-12 (30µM, black bar) and 
partial reversal by rTrx (4µg/ml, red bar). B, Corresponding CaV3.2 current trace (from 
A) under control conditions (red trace), and during exposure to PX-12 and rTrx (as 
labelled). Scale bar 200pA (vertical), 40ms (horizontal). C-D, As (A-B), except showing 
the effects of rTrx (4µg/ml, red bar) in isolation. E, Bar chart (mean ± s.e.m) showing 
the effects on CaV3.2 current amplitude (% of control) of PX-12 (black bar, 30µM, 
n=10), rTrx (4µg/ml) applied after PX-12 (red bar, n=10) or rTrx applied alone (white 
bar, 4µg/ml, n=6). Data were analysed using paired Student’s t-tests, ****p≤0.0001.  
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To further investigate the apparent selective regulation of CaV3.2 channels by Trx, the 
effects of AuF on HEK293/CaV3.1 and HEK293/CaV3.2 currents were also examined. As 
AuF inhibits Trx indirectly via inhibition of thioredoxin reductase (TrxR), cells were pre-
treated with AuF (3µM, 30mins) prior to recording currents to allow the effects of AuF 
on Trx to equilibrate. As illustrated in Figure 5.8, the current-density of HEK293/CaV3.1 
cells was not significantly altered by pre-treatment with AuF. Furthermore, the degree 
of CaV3.1 current potentiation by DTT was similar between control and AuF conditions. 
In stark contrast however, AuF pre-treatment significantly reduced the current-density 
of HEK293/CaV3.2 cells, and also dramatically increased the degree of CaV3.2 current 
enhancement by DTT (Figure 5.9). These data confirmed that Trx positively and 
selectively regulates CaV3.2 channels.  
 
Initial experiments in A7r5 cells had shown that both native T- and L-type Ca2+ currents 
were inhibited by PX-12, indicating that both CaV subtypes were regulated by Trx 
(Figure 5.1). However, as PX-12 was subsequently found to inhibit recombinant CaV3.1 
currents via a Trx-independent mechanism (Figure 5.6), further investigation was 
required to establish if Trx regulates native Cav3 channels in these cells. As illustrated 
in Figure 5.10, bath application of rTrx did not significantly reverse PX-12-mediated 
inhibition of T-type Ca2+ current amplitudes, confirming that PX-12 was acting 
independently of Trx. Furthermore, rTrx did not generally alter T-type Ca2+ current 
amplitude when applied in isolation (Figure 5.10). As previous investigations had 
shown that Trx selectively regulated CaV3.2 currents, this observation is consistent 
with CaV3.1 being the primary T-type Ca
2+ channel isoform expressed within A7r5 cells 
(Chapter 3). These findings indicate that Trx does not regulate A7r5 T-type Ca2+ 
currents, and also supports the finding that PX-12-mediated inhibition of CaV channels 
is Trx-independent.   
 
Of considerable interest however, is that the amplitude of a very limited number of T-
type Ca2+ currents in A7r5 cells (1 of 5 cells) was clearly enhanced by rTrx under control 
conditions (i.e. when applied without prior treatment with PX-12). Corresponding 
immunohistochemistry conducted on the same batch of A7r5 cells revealed a dramatic 
increase in CaV3.2-immunoreactivity (IR) when compared to CaV3.1-IR, which very 
likely accounted for the observed increase in sensitivity to Trx (Error! Reference source 
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not found.). Additionally, whilst CaV3.1-IR was directly comparable in terms of intensity 
and localisation to that previously reported (Chapter 3), findings regarding CaV3.2-IR 
were contrasting. Specifically, the pattern of CaV3.2-IR was much brighter with dense 
peri-nuclear regions detected alongside the nuclear staining previously reported 
(Chapter 3). Whilst this observation is only preliminary it suggests that CaV3.2 
expression may be dynamically regulated in A7r5 cells. It is also consistent with the 
idea that only T-type Ca2+ currents facilitated in part by CaV3.2 channels in A7r5 cells 
are regulated by Trx. This suggests that the pro-proliferative effects of Trx in VSMCs 
may be dependent on CaV3.2 expression levels.   
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Figure 5.8. Pre-treatment with AuF has no effect on CaV3.1 currents 
Whole-cell patch-clamp recordings from HEK293/CaV3.1 cells under control conditions 
(A-B) and following pre-treatment with AuF (3µM, 30mins, C-D). Currents evoked by 
200ms (0.1Hz) step-depolarisations from -80 to -20mV. A, Example time-series plot 
showing effects of DTT (1mM) on CaV3.1 current peak amplitude under control 
conditions. B, Corresponding CaV3.1 current trace (from A) under control conditions 
(red trace) and during exposure to DTT (as labelled). Scale bar 400pA (vertical), 40ms 
(horizontal). C-D, As (A-B), except showing the effects of DTT (1mM) following AuF pre-
treatment. E, Bar chart showing (mean ± s.e.m) CaV3.1 current-density under control 
conditions (blue bar, n=5) and after pre-treatment with AuF (3µM, 30mins, red bar, n = 
6). F, Bar chart showing (mean ± s.e.m) CaV3.1 current amplitude enhancement by DTT 
(1mM), applied under both control conditions (blue bar, n=6) and after pre-treatment 
with AuF (3µM, 30mins, red bar, n = 6). Data were analysed using unpaired Student’s t-
tests, no significant differences observed. 
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Figure 5.9. AuF reduces HEK293/CaV3.2 cell current-density and increases DTT-
mediated current enhancement 
Whole-cell patch-clamp recordings from HEK293/CaV3.2 cells under control conditions 
(A-B) and following AuF (3µM, 30mins) pre-treatment (C-D). Currents evoked by 200ms 
(0.1Hz) step-depolarisations from -80 to -20mV. A, Example time-series plot showing 
effects of DTT (1mM) on CaV3.2 current peak amplitude under control conditions. B, 
Corresponding CaV3.2 current trace (from A) under control conditions (red trace), and 
during exposure to DTT (as labelled). Scale bar 200pA (vertical), 40ms (horizontal). C-D, 
As (A-B) except showing the effects of DTT (1mM) following AuF pre-treatment. E, Bar 
chart showing (mean ± s.e.m) CaV3.2 current-density under control conditions (blue 
bar, n=11) and after pre-treatment with AuF (3µM, 30mins, red bar, n = 14). F, Bar 
chart showing (mean ± s.e.m) CaV3.2 current amplitude enhancement by DTT (1mM), 
applied under both control conditions (blue bar, n=13) and after pre-treatment with 
AuF (3µM, 30mins, red bar, n = 14). Data were analysed using unpaired Student’s t-
tests, *p≤0.05.  
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Figure 5.10. rTrx does not reverse PX-12-mediated inhibition of A7r5 T-type Ca2+ 
currents 
Whole-cell patch-clamp recordings from A7r5 cells, currents evoked by 200ms (0.1Hz) 
step-depolarisations from -80 to -20mV. A, Example time-series plot showing inhibition 
of T-type Ca2+ current peak amplitude by PX-12 (30µM, black bar) and the lack of effect 
of rTrx (4µg/ml, red bar) when applied to the perfusate. B, Corresponding T-type Ca2+ 
current trace (from A) under control conditions (red trace), and during exposure to PX-
12 and rTrx (as labelled). Scale bar 40pA (vertical), 40ms (horizontal). C-D, As (A-B), 
except showing the effects of rTrx (4µg/ml, red bar) in isolation. E, Bar chart (mean ± 
s.e.m) showing the effects of PX-12 (black bar, 100µM, n=4) and rTrx (4µg/ml) applied 
after PX-12 (red bar, n=4) or rTrx applied alone (white bar, 4µg/ml, n=5), on A7r5 T-
type Ca2+ current amplitude (% of control). Data were analysed using unpaired 
Student’s t-tests, no significant differences were observed. 
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 Figure 5.11. Increased A7r5 CaV3.2 channel expression correlates with T-type Ca
2+ 
current rTrx-sensitivity 
Electrophysiology and immunohistochemistry was conducted on the same batch of 
A7r5 cells (A-D). A-B, Whole-cell patch-clamp recordings from A7r5 cells, currents 
evoked by 200ms (0.1Hz) step-depolarisations from -80 to -20mV. A, Example time-
series plot showing regulation of T-type Ca2+ current amplitude by rTrx (4µg/ml, red 
bar) applied to the perfusate. B, Corresponding T-type Ca2+ current traces (from A) 
under control conditions (red trace), and during exposure to rTrx (as labelled). Scale 
bar 50pA (vertical), 40ms (horizontal). C-D, Dual-label immunofluorescence using anti-
CaV3.1 (1:100, C) or anti-CaV3.2 (1:1000, D) with Alexa Fluor-555 secondary antibody 
(1:500) (left panels, red images) and DAPI to label cell nuclei (centre panel, blue 
images), merged CaV3.1 or CaV3.2 and DAPI images (right panels). Scale bars 50µm. E-F, 
As (C-D), except conducted on a different batch of A7r5 cells (images reproduced from 
Chapter 3) and showing only merged DAPI/CaV3.1 (E), and DAPI/CaV3.2 (F), images.   
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5.2.2. Mechanism of Trx-mediated CaV3.2 regulation 
After establishing that CaV3.2 channels were positively and selectively regulated by Trx, 
the mechanism and molecular determinants of Trx sensitivity were next explored using 
HEK293/CaV3.2 cells. I-V protocols revealed that AuF preferentially inhibited CaV3.2 
currents at lower stimulating voltages, and produced a rightwards shift in I-V profiles 
(Figure 5.11). Interestingly, as T-type Ca2+ channels activate and inactivate at similar 
voltages they can facilitate a window current at resting membrane potential (Vm), 
which can control basal [Ca2+]i. In confirmation of this suggestion, CaV3.2-mediated 
window currents were recorded directly from HEK293/CaV3.2 cells using Ca
2+ 
microfluorimetry (Chapter 3). As a “window current” is operationally defined as the 
overlap between activation and steady-state inactivation curves (Perez-Reyes, 2003), 
the observed AuF-mediated shift in I-V profile (Figure 5.11) could theoretically 
decrease the CaV3.2-mediated Ca
2+ window current. The AuF-mediated reduction in 
HEK293/CaV3.2 current-density observed (Figure 5.9) is also likely to reduce basal Ca
2+ 
influx.  
 
CaV3.2 currents were augmented by bath-application of rTrx (Figure 5.7) indicating that 
the molecular determinant(s) of rTrx-sensitivity was located on the extracellular 
surface of the channel. As Trx uptake has been previously reported in Jurkat T-
lymphoma cells (Kondo et al., 2004), it was also important to assess any potential 
effects of applying rTrx to the intracellular environment. As shown by Figure 5.12, 
inclusion of rTrx (20µg/ml) to the patch-pipette solution did not significantly alter the 
current-density in HEK293/CaV3.2 cells, after a minimum of 5 min dialysis. 
Furthermore, intracellular rTrx had no effect on the degree of PX-12-mediated CaV3.2 
channel inhibition. Interestingly, whilst intracellular application of rTrx did not 
significantly alter HEK293/CaV3.2 cell current-density, a modest enhancement was 
detected (Figure 5.12). This may potentially be due to cellular Trx secretion.  
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Figure 5.11. AuF inhibits CaV3.2
 currents in a voltage-dependent manner  
Whole-cell patch-clamp recordings from HEK293/CaV3.2 cells, currents evoked by 
80ms step-depolarisations (-100mV to +60mV in 10mV increments) from -80mV (Vh). 
A, Current-density (mean ± s.e.m.) vs. voltage (I-V) relationships for CaV3.2 currents 
under control conditions (open triangles, n=11) or following AuF (3µM, 25mins) pre-
treatment (solid circles, n=7). B, Example CaV3.2 I-V traces under (i), control conditions 
and (ii), following AuF (3µM, 25mins) pre-treatment. Scale bar 400pA (horizontal), 
20ms (vertical).  
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Figure 5.12. Intracellular rTrx application has no effect on CaV3.2 currents 
Whole-cell patch-clamp recordings from HEK293/CaV3.2 cells under control conditions 
(A-B) and with rTrx (20µg/ml) applied to the intracellular solution ((rTrx)i)(C-D). 
Currents evoked by 200ms (0.1Hz) step-depolarisations from -80 to -20mV. A, Example 
time-series plot showing the effects of PX-12 (100µM) on the peak CaV3.2 current 
amplitude recorded using standard intracellular solution. B, Corresponding CaV3.2 
current traces (from A) under control conditions (red trace), and during exposure to 
PX-12 (as labelled). Scale bar 200pA (vertical), 40ms (horizontal). C-D, As (A-B), except 
showing the effects of PX-12 (100µM) when rTrx (20µg/ml) is applied to the 
intracellular solution. E, Bar chart showing (mean ± s.e.m) CaV3.2 current-density 
under control conditions (black bar, n=5) and with intracellular rTrx (20µg/ml, (rTrx)i, 
white bar, n=5) exposure. F, Bar chart showing (mean ± s.e.m) inhibition of CaV3.2 
current amplitudes (% of control) by PX-12 (100µM) applied under control conditions 
(black bar, n=5) or with intracellular rTrx (20µg/ml, (rTrx)i) application (white bar, n=5). 
Data were analysed using unpaired Student’s t-tests, no significant differences were 
observed. 
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A distinguishing feature of CaV3.2 channels is their unique sensitivity to both redox 
modulators and trace metals. For example, CaV3.2 channels are blocked by significantly 
lower Ni2+ concentrations (IC50 value of 13µM) than either CaV3.1 and CaV3.3 channels 
(IC50 values of 250µM and 216µM respectively), (Lee et al., 1999). Interestingly, 
mutation of a single extracellular His residue at position 191 (H191) to a glutamine (Q) 
residue (CaV3.2(H191Q)), located within the S3-S4 loop of domain I, significantly 
reduced Ni2+ blockade of CaV3.2 channels (Kang et al., 2006). His
191 has also been 
shown to be responsible for ascorbate-mediated inhibition of CaV3.2 channels as the 
CaV3.2(H191Q) mutant channel is completely insensitive to ascorbate (Nelson et al., 
2007a). In order to explore the His191 residue as a potential molecular target for Trx, 
currents were recorded from HEK293 cells stably expressing recombinant 
CaV3.2(H191Q) mutant channels (HEK293/CaV3.2(H191Q)). In agreement with previous 
reports, bath application of ascorbate had no effect on CaV3.2(H191Q) activity (Figure 
5.13). 
 
 When applied in isolation or in combination with ascorbate, PX-12 inhibited 
CaV3.2(H191Q) currents (Figure 5.13) to a similar degree as was observed for wt CaV3.2 
channels (Figure 5.2). A key difference with wt CaV3.2 channels, however, was that rTrx 
was completely unable to reverse PX-12-mediated inhibition of CaV3.2(H191Q) 
currents (Figure 5.14). Application of rTrx under control conditions was also found to 
be without effect on CaV3.2(H191Q) currents (Figure 5.14), thereby showing that this 
single point mutation (H191Q) abolished CaV3.2 channel sensitivity to rTrx. Whilst PX-
12 inhibited CaV3.2(H191Q) currents, when applied in isolation or co-applied with 
ascorbate (Figure 5.13), rTrx was unable to reverse the PX-12-mediated inhibition 
(Figure 5.14). These data provide conclusive evidence that the molecular target(s) of 
PX-12 is not the molecular determinant of CaV3.2 channel rTrx-sensitivity i.e. His
191. 
 
The effects of ascorbate on wt CaV3.2 currents were also examined, initially for control 
purposes. As illustrated in Figure 5.15, bath application of ascorbate inhibited CaV3.2 
current amplitude, in contrast with its lack of effect on CaV3.2(H191Q) currents (Figure 
5.13). Strikingly, when PX-12 was co-applied with ascorbate, wt CaV3.2 current 
enhancement and full reversal of ascorbate-mediated inhibition was observed. This 
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was highly unusual considering that both ascorbate and PX-12 had inhibitory effects on 
wt CaV3.2 current amplitudes when applied in isolation (Figure 5.15). Furthermore, co-
application of ascorbate and PX-12 also significantly enhanced CaV3.2 tail current 
amplitudes on some occasions (7 out of 18 cells recorded), and appeared to reduce 
channel inactivation. Contrastingly, when PX-12 was applied initially in isolation prior 
to the subsequent co-application with ascorbate, a dual-inhibitory effect was observed 
(Figure 5.15). This indicates that the, as of yet unidentified, molecular target(s) for PX-
12 may interact in a complex manner with His191.  
 
The disulphide reductase capabilities of Trx are generally dictated by two Cys residues 
(Cys32 and Cys35) within the active site. When in their reduced dithiol form ((SH)2), 
these Cys residues transfer reducing equivalents to target proteins, as reviewed 
(Holmgren, 1995). In order to generate rTrx, Trx applied previously had been pre-
incubated with DTT, which was removed prior to application. To examine whether the 
redox-state of Trx determined its ability to modulate HEK293/CaV3.2 currents, the 
effects of oxidised Trx (oTrx, i.e. non-reduced) were next examined. Findings were 
compared with the effects of rTrx, as detailed in Figure 5.7. Under control conditions, 
bath application of oTrx enhanced CaV3.2 current amplitudes to a similar extent as 
rTrx, (Figure 5.16), indicating that the effects of Trx were independent of its redox-
status. Furthermore, oTrx also caused a small degree of CaV3.2 current enhancement 
following PX-12 application. In contrast to rTrx, the reversal of PX-12-mediated 
inhibition of CaV3.2 channels by oTrx was non-significant (Figure 5.17). 
 
Under storage conditions (i.e. non-reduced), Trx lacks disulphide reductase activity, 
indicating that active site Cys residues will be in their oxidised disulphide form 
(Montano et al., 2014). Freezing of tissue and cell samples, and also exposure to air, 
has been shown to oxidise active site Cys residues and inactivate Trx (Luthman & 
Holmgren, 1982). A further important, and generally overlooked, consideration when 
using mammalian Trx is the redox state of non-active site Cys residues (Cys62, Cys69 and 
Cys73). These non-canonical Cys residues do not infer disulphide reductase properties 
per se, but can influence the overall structure of Trx. Specifically, homodimer 
formation via inter-molecule disulphide bond formation between Cys73 residues 
(Weichsel et al., 1996), and intra-molecule disulphide bond 
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Figure 5.13. CaV3.2(H191Q) currents are inhibited by PX-12 but not ascorbate 
Whole-cell patch-clamp recordings from HEK293/CaV3.2(H191Q) cells, currents evoked 
by 200ms (0.1Hz) step-depolarisations from -80 to -20mV. A, Example time-series plot 
showing the effects of ascorbate (asc, 300µM, orange bar) and PX-12 (30µM, black bar) 
on peak CaV3.2(H191Q) current amplitudes. B, Corresponding CaV3.2(H191Q) current 
traces (from A) under control conditions (red trace) and during exposure to ascorbate 
(asc, 300µM) and PX-12 (30µM) as labelled. Scale bar 500pA (vertical), 40ms 
(horizontal). C-D, As (A-B), except showing the effect of PX-12 (30µM, black bar) in 
isolation. E, Bar chart (mean ± s.e.m) showing the effects of ascorbate (asc, 300µM, 
orange bar, n=4), ascorbate with PX-12 (30µM) (black bar, n=4) and PX-12 alone 
(30µM, white bar, n=5) on CaV3.2(H191Q) current amplitudes (% of control).  
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Figure 5.14. rTrx has no effect on CaV3.2(H191Q) currents 
Whole-cell patch-clamp recordings from HEK293/CaV3.2(H191Q) cells, currents evoked 
by 200ms (0.1Hz) step-depolarisations from -80 to -20mV. A, Example time-series plot 
showing inhibition of CaV3.2(H191Q) current amplitude by PX-12 (30µM, black bar) and 
no reversal by rTrx (4µg/ml, red bar). B, Corresponding CaV3.2(H191Q) current traces 
(from A) under control conditions (red trace), and during exposure to PX-12 and rTrx 
(as labelled). Scale bar 200pA (vertical), 40ms (horizontal). C-D, As (A-B), except 
showing the effects of rTrx (4µg/ml, red bar) in isolation. E, Bar chart (mean ± s.e.m) 
showing the effects of PX-12 (black bar, 30µM, n=4), rTrx (4µg/ml) applied after PX-12 
(red bar, n=4) and rTrx applied alone (white bar, 4µg/ml, n=4), on CaV3.2(H191Q) 
current amplitudes (% of control). PX-12 and rTrx conditions were analysed using 
paired Student’s t-tests, no significant difference was observed.  
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Figure 5.15. CaV3.2 currents are enhanced by co-application of ascorbate and PX-12 
Whole-cell patch-clamp recordings from HEK293/CaV3.2 cells, currents evoked by 
200ms (0.1Hz) step-depolarisations from -80 to -20mV. A, Example time-series plot 
showing the effects of ascorbate (asc, 100µM, orange bar) in isolation and when co-
applied with PX-12 (30µM, black bar) on both the CaV3.2 current peak amplitude 
(white circles) and tail current amplitude (blue circles). B, Corresponding CaV3.2 
current traces (from A) under control conditions (red trace), and during exposure to 
ascorbate (asc, black trace, 100µM) and ascorbate + PX-12 (green trace, 30µM) as 
labelled. Scale bar 500pA (vertical), 40ms (horizontal). C, Bar chart (mean ± s.e.m) 
showing the effects of ascorbate (asc, 100µM, orange bar, n=16), ascorbate co-applied 
with PX-12 (30µM) (green bar, n=16) and NNC (3µM, black bar, n=3) on CaV3.2 peak 
current amplitudes (solid bars, LHS axis) and tail current amplitudes (striped bars, RHS 
axis); both expressed as % of control. D-E, As (A-B), except showing the effects of PX-
12 applied in isolation prior to co-application with ascorbate. Scale bar 200pA 
(vertical), 40ms (horizontal). F, As (C), except showing the effects of PX-12 (30µM, 
black bars, n=5) and PX-12 co-applied with ascorbate (asc, 100µM) (green bar, n=5). 
Data were analysed using paired Student’s t-test, *p≤0.05,**p≤0.01. 
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formation between Cys62 and Cys69 residues (Watson et al., 2003), modifies the 
structure of Trx in such a manner that it is no longer a substrate for TrxR. An early 
study examined differences between the crystal structures of human rTrx and oTrx; 
oTrx crystals were generated by allowing rTrx to oxidise in air for 2 months, without 
the addition of further DTT. It was subsequently demonstrated that oTrx and rTrx 
exhibited only very subtle structural differences, specifically concerning a slight 
conformational modification around the active site (Weichsel et al., 1996). In stark 
contrast however, an alternative study generated oTrx crystals by leaving non-reduced 
Trx to oxidise for 6 months. This study revealed that intra-molecule disulphide bond 
formation occurred between Cys62 and Cys69 residues within fully oxidised Trx. The 
non-active site disulphide bond completely disrupted the structure of the α3 helix, 
exposing hydrophobic residues to the solvent (Hwang et al., 2015). This study 
emphasises that different Cys residues within Trx show differential sensitivities to 
oxidation. Consequently, it was important to consider whether the redox-state of non-
canonical Cys residues in Trx influenced its CaV3.2 channel enhancing activity.  
 
Due to time constraints, Trx could not be allowed to oxidise for the full 6 months, as 
shown previously necessary to oxidise Cys62 and Cys69 residues (Hwang et al., 2015). In 
an attempt to further oxidise oTrx however, non-reduced oTrx was subject to air-
mediated oxidation for 1 week and then bubbled with oxygen for 24hrs prior to use. 
Oxygenated oxidised Trx (ooTrx) was found to modestly enhance HEK293/CaV3.2 
currents under control conditions. Importantly, the degree of ooTrx-mediated current 
enhancement under control conditions was directly comparable to those observed 
following rTrx and oTrx exposure (Figure 5.16). Importantly, application of the Trx 
elution buffer (EB) was without significant effect. However, when the effects of all Trx 
redox forms, applied under control conditions, were combined and compared against 
the effects of EB exposure, a significant enhancement in CaV3.2 current amplitude was 
apparent (Figure 5.16). In contrast to rTrx (Figure 5.7), ooTrx was without any effect on 
HEK293/CaV3.2 currents following inhibition with PX-12 (Figure 5.17). Collectively, 
these data show that the ability of Trx to enhance CaV3.2 currents under control 
conditions was independent of its redox state. Contrastingly, Trx-mediated reversal of 
PX-12-mediated CaV3.2 current inhibition was shown to be redox-dependent.  
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Figure 5.16. Trx-mediated regulation of CaV3.2 channels under control conditions is 
Trx redox state-independent 
Whole-cell patch-clamp recordings from HEK293/CaV3.2 cells, currents evoked by 
200ms (0.1Hz) step-depolarisations from -80 to -20mV. A, Example time-series plot 
showing enhancement of CaV3.2 current amplitude by oxidised Trx (oTrx, 4µg/ml, blue 
bar) and no effect of the elution buffer (EB, 1:500, black bar) when applied to the 
perfusate. B, Corresponding CaV3.2 current traces (from A) under control conditions 
(red trace), and during exposure to oTrx (black trace). Scale bar 200pA, 40ms 
(horizontal). C-D, As A-B, except showing the effect of oxygenated oxidised Trx (ooTrx, 
4µg/ml, green bar). E, Bar chart (mean ± s.e.m) showing the effects of EB (black bar, 
1:500, n=8), rTrx (red bar, 4µg/ml, n=7), oTrx (blue bar, 4µg/ml, n=8) and ooTrx (green 
bar, 4µg/ml, n=3) on CaV3.2 current amplitude (% of control). Data were analysed 
using one-way ANOVA followed by Dunnett’s multiple comparison test, no significant 
difference. F, As E, except showing the combined effects of all forms of Trx (red bar, 
4µg/ml, n=18) compared to the effect of the EB (black bar, 1:500, n=8) on CaV3.2 
current amplitude (% of control). Data were analysed using un-paired Student’s t-test, 
**p≤0.01. 
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Figure 5.17. Trx-mediated reversal of PX-12 mediated CaV3.2 channel inhibition is Trx 
redox state-dependent 
Whole-cell patch-clamp recordings from HEK293/CaV3.2 cells, currents evoked by 
200ms (0.1Hz) step-depolarisations from -80 to -20mV. A, Example time-series plot 
showing inhibition of CaV3.2 current amplitude by PX-12 (30µM, black bar) and a very 
small degree of reversal by oxidised Trx (oTrx, 4µg/ml, blue bar) when applied to the 
perfusate. B, Corresponding, CaV3.2 current traces (from A) under control conditions 
(red trace) and during exposure to PX-12 and oTrx (as labelled). Scale bar 200pA 
(vertical), 40ms (horizontal). C-D, As (A-B), except showing no reversal with 
oxygenated oxidised Trx (ooTrx, 4µg/ml, green bar). E, Bar chart (mean ± s.e.m) 
showing the effects of PX-12 (black bar, 30µM, n=22), rTrx (red bar, 4µg/ml, n=10), 
oTrx (blue bar, 4µg/ml, n=8) and ooTrx (green bar, 4µg/ml, n=4) on CaV3.2 current 
amplitude (% of control). Data analysed using one-way ANOVA followed by Dunnett’s 
multiple comparison test, **p≤0.01.  
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5.3. Discussion  
Results described within Chapters 3 and 4 show how inhibitors of both T-type Ca2+ 
channels and Trx reduced the proliferation of CaV3.2-expressing cells. Ca
2+ 
microfluorimetry further revealed that both T-type Ca2+ channel and Trx inhibitors 
decreased basal Ca2+ influx within A7r5 cells. These data collectively indicate that Trx 
may regulate proliferation via modulation of CaV3.2 channels (Chapters 3 & 4). Results 
described in the current chapter confirm that CaV3.2 channels are positively and 
selectively regulated by Trx.  
 
5.3.1. Trx regulates CaV3.2 channels via an extracellular histidine residue at position 
191 (His191) 
The novel finding that CaV3.2 channels are selectively regulated by Trx via an 
interaction with His191 is consistent with a previous study conducted by the Peers’ 
group. This study revealed that AuF selectively inhibited CaV3.2 channels whilst having 
no effect on CaV3.1 or CaV3.3 channels. Specifically, AuF (2-5µM) pre-treatment (30-
60mins) selectively reduced the current-density of HEK293/CaV3.2 cells in a time- and 
concentration-dependent manner. Additionally, AuF (2µM, 30mins) increased DTT- 
and rTrx-mediated enhancement of CaV3.2 current amplitudes. In contrast with the 
current finding that AuF shifted CaV3.2 I-V profiles to more positive potentials, the 
previous study indicated that AuF-mediated inhibition of CaV3.2 channels was voltage-
independent. A potential explanation for this discrepancy is that a higher AuF 
concentration (5µM) was applied than currently used, which was reported to cause 
visible damage and detachment of some cells (Boycott et al., 2013).  
 
Boycott et al. (2013) also determined that all 3 T-type Ca2+ channel isoforms (CaV3.x) 
were inhibited by carbon monoxide (CO). Interestingly, AuF pre-treatment selectively 
decreased CO-mediated inhibition of CaV3.2 currents indicating that CO was acting, in 
part, by disrupting tonic Trx-mediated CaV3.2 regulation. Of relevance to the current 
finding that Trx regulates CaV3.2 channels via His
191, is that mutant CaV3.2(H191Q) 
channels (as used currently) were shown to be equally sensitive to CO. Furthermore, 
the membrane-impermeant oxidising agent 5,5-dithiobis(2-nitrobenzoic acid) (DTNB) 
and also the endogenous reducing agent L-cysteine dramatically reduced the ability of 
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CO to inhibit CaV3.2 currents. As such, it was confirmed that CO acts via a redox-
sensitive extracellular location, likely to be Cys residues that are conserved amongst 
CaV3.x channels (Boycott et al., 2013). This proposed mechanism of CO-mediated 
inhibition of CaV3.x channels appears to share similarities with the isoform 
indiscriminate nature of PX-12-mediated inhibition of CaV3.1 and CaV3.2 channels, as 
currently reported. Interestingly, as CO appeared to interrupt Trx-mediated CaV3.2 
regulation (Boycott et al., 2013), it is possible that the molecular determinant(s) of CO 
sensitivity are in close physical proximity to His191. Consistent with this proposal, Cys 
residues conserved amongst all CaV3.x channels are located in close physical proximity 
to His191 in CaV3.2 channels, as further discussed in section 5.3.2 and illustrated in 
Figure 5.18.  
 
Trx has also previously been shown to regulate transient receptor potential canonical 
(TRPC) channels (Xu et al., 2008). TRPC channels are non-selective cation channels, 
which in terms of their structure and ability to form heteromultimeric channels, are 
most closely related to the voltage-gated K+ channel KV1.2. TRPC channels are typically 
made up of combinations of TRPC-1, TRPC-4 or TRPC-5 subunits (Bon & Beech, 2013). 
Xu et al. (2008) determined that recombinantly-expressed TRPC5 homomultimeric and 
TRPC5/TRPC1 heteromultimeric channels were both regulated by extracellular rTrx. 
Regarding potential mechanisms, TRPC5 channels are activated by application of 
lanthanide. The molecular target of lanthanide is a glutamic acid (Glu) residue at 
position 543 (Glu543), located within an extracellular loop adjacent to the ion pore. The 
authors determined that both the membrane-impermeant disulphide reducing agent 
Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) and DTT activated TRPC5 currents. 
Substitution of Cys553 and Cys558 with alanine residues resulted in currents which were 
constitutively active. The effects of DTT and TCEP were correspondingly abolished. This 
revealed that Cys553 and Cys558 residues, found in close proximity to Glu543, form a 
disulphide bridge which constrains TRPC5 channels in a state of limited open 
probability. In a manner comparable to DTT, rTrx stimulated both TRPC5 and 
TRPC5/TRPC1 channels. Contrastingly, oTrx was without effect. It was subsequently 
proposed that extracellular rTrx activates TRPC5 and TRPC5/TRPC1 channels by 
breaking the disulphide bridge which forms between Cys553 and Cys558 around the ion 
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pore. Interestingly, following activation of TRPC5 channels with lanthanide rTrx 
subsequently caused channel inhibition (Xu et al., 2008).  
 
Upon comparison of the findings of Xu et al. (2008) with current results, a key 
similarity was that Trx acted via an extracellular site on the ion channel, supporting the 
conclusion that Trx released by cells can modulate ion channel activity. Contrastingly, 
the molecular determinants of Trx-mediated TRPC channel regulation i.e. Cys residues, 
were disparate to the molecular determinant in the CaV3.2 channel, His
191. 
Importantly, oTrx was without effect on TRPC channels suggesting that modification of 
TRPC channel Cys residues was reliant on the disulphide reductase abilities of Trx, 
imparted by active site Cys residues being in their reduced dithiol form (Xu et al., 
2008). In direct contrast however, Trx-mediated regulation of CaV3.2 channels under 
control conditions, but not following PX-12 mediated inhibition, was independent of 
the Trx redox state, and as such dithiol-exchange. Resultantly, the potential role of 
non-active site Trx residues will also be considered in the subsequent discussion of Trx-
mediated CaV3.2 channel regulation.  
 
The suggestion that some of the physiological effects of extracellular Trx are 
independent of active site Cys residues dithiol-exchange is not a novel proposal. A key 
difference between hTrx and other mammalian Trx forms when compared to bacterial 
forms is that in addition to highly conserved active site Cys32 and Cys35 residues, hTrx 
contains three additional non-canonical Cys residues at positions 62, 69, and 73 (Cys62, 
Cys69 and Cys73) (Weichsel et al., 1996). Significantly, when hTrx was applied to culture 
medium lacking serum, MCF-7 breast cancer cell proliferation was stimulated. 
Contrastingly, no effect on MCF-7 cell proliferation was observed when E. coli rTrx was 
applied. Mutant hTrx(C32S/C35S) was also unable to stimulate MCF-7 cell proliferation 
(Gasdaska et al., 1995). It is important to note however, that extracellular application 
of bacterial Trx has been shown to exert mitogenic effects within certain cell lines. For 
example, a study reported that E. coli Trx, reduced using TrxR and NADPH, elevated 
cellular DNA synthesis in human B-cell lines when applied to the culture medium 
(Biguet et al., 1994). These previous studies collectively indicate that the growth-
promoting effects of extracellular Trx can be dependent on both intra- and extra-active 
site residues.  
194 
 
 
Interestingly, the pro-proliferative effects of hTrx were most apparent in minimal 
culture medium, and completely abolished by daily medium replacement. Evidence 
that extracellular hTrx can exert autocrine mitogenic effects was therefore provided. 
Application of radioisotope-labelled Trx further revealed that hTrx bound to MCF-7 cell 
membranes in a time-dependent manner (Gasdaska et al., 1995). It was suggested that 
this was due to Trx binding to a specific, but undetermined, cell surface receptor. 
Importantly, as MCF-7 cells have been shown to express CaV3.2 channels which 
influence cell proliferation (Taylor et al., 2008b), an alternative possibility consistent 
with current findings is that Trx binds to membranous CaV3.2 channels via His
191. This 
proposed binding could account for both the membranous localisation of hTrx and also 
its stimulatory effects on MCF-7 cell proliferation (Gasdaska et al., 1995). An important 
and interesting future experiment, using immunohistochemistry, would be to assess 
the subcellular localisation of Trx within both HEK293/CaV3.2 and A7r5 cells. The 
effects of AuF treatment on the potential patterns of Trx and CaV3.2 channel co-
localisation could also be examined. A key consideration however, would be the 
epitope sequence to which the Trx primary antibody binds. This could be significant as 
a modified form of Trx has been previously identified within the extracellular 
environment (Di et al., 1998), which may not contain the antibody recognition 
sequence.    
 
The human cytotrophoblast cell lines BeWo, Jar and Jeg-3 have been shown to 
synthesise and secrete Trx to varying degrees (Di et al., 1998). Intracellular Trx was 
comprised entirely of the typical 12kDa form. Contrastingly, in addition to the 12kDa 
form, a previously unidentified 10kDa Trx form was detected in abundant amounts 
within the extracellular environment. This 10kDa form of Trx was similarly isolated 
from the conditioned media of stimulated human platelets. N-terminal sequencing 
indicated that the 10kDa form was derived from the standard 12kDa form of Trx (Di et 
al., 1998). Interestingly, subsequent investigations have confirmed the existence of a 
truncated form of Trx, referred to as Trx80 in the literature, and showing it to be an 
extracellular cleavage product of cytosolic Trx. Interestingly, Trx80 lacks C-terminal 
amino acid residues and correspondingly shows no disulphide reductase activity, as 
reviewed (Holmgren & Lu, 2010). Significantly, Trx80 has been shown to act as a 
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mitogenic cytokine in human peripheral blood mononuclear cells (PBMCs) and to 
stimulate the release of interleukin 2 (IL-2) (Pekkari et al., 2001). These findings are 
consistent with the current suggestion that Trx residues contained outside of the 
active site can be important for the physiological effects of Trx within the extracellular 
environment. In further support of this, an alternative study reported that intra-
peritoneal injection of hTrx reduced ischemic-reperfusion injury in mice, following 
myocardial infarction (MI). Pre-treatment of hTrx with S-nitrosoglutathione, which 
causes S-nitrosation of Cys69, significantly enhanced the cardio-protective effects of 
hTrx. Importantly, E. coli Trx which lacks Cys69 was without effect (Tao et al., 2004). 
This study therefore illustrates how post-translational modification of Cys residues in 
the non-active site of Trx can determine its function(s) as an extracellular signalling 
molecule.   
 
Regarding the observation that oTrx was equally capable at potentiating 
HEK293/CaV3.2 currents under control conditions as rTrx, an alternative consideration 
is that Trx could be endogenously reduced at the cell-surface. A previous report 
demonstrated that TrxR was localised at the cell membrane of both murine 
macrophage and human monocytes, particularly on the extracellular surface. The 
expression of cell-surface TrxR was also found to be increased by arylselenium 
compounds (Zhang et al., 2013). In agreement with these findings, TrxR has also been 
detected in human blood plasma. This study reported that in addition to an abundant 
membranous localisation, TrxR was secreted from peripheral blood cells, tumour-
transformed leukaemia cells and also melanoma cells. Metabolic labelling further 
revealed that in contrast with Trx, TrxR secretion occurred via the typical ER-Golgi 
pathway (Soderberg et al., 2000). These studies collectively indicate that reduction of 
oTrx at the cell surface, within the extracellular environment, is feasible.  
 
Bath application of mutant forms of Trx e.g. C32S/C35S, C73S and Trx80, which are 
available commercially (IMCO Corporation Ltd AB; Stockholm, Sweden), and 
subsequent assessment of their effects on CaV3.2 current amplitude would address 
this possibility. If Trx(C32S/C35S) and Trx80 did not enhance CaV3.2 current amplitude 
under control conditions, evidence, this would indicate that endogenous reduction of 
Trx, applied exogenously, was occurring at the cell membrane. This would 
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correspondingly indicate that Trx-mediated CaV3.2 channel regulation is actually 
dependent on the redox state of Trx. As reversal of PX-12-mediated CaV3.2 channel 
inhibition by Trx was currently shown to be Trx redox state-dependent, PX-12 could 
potentially prevent the reduction of oTrx at the cell surface (Kirkpatrick et al., 1998). 
 
5.3.2. PX-12 may inhibit CaV3.x channels via interaction with conserved cysteine 
residues 
Another important finding of the current investigation is that PX-12 inhibited CaV 
channels via a Trx-independent redox-regulated mechanism.  Recombinant CaV3.1 and 
CaV3.2 channels were inhibited by PX-12 in a DTT-reversible manner, with virtually 
identical sensitivities. Contrastingly, only CaV3.2 channels were regulated by Trx. Whilst 
Cys is one of the least abundant amino acids, due to the unique chemistry of its thiol 
(sulfhydryl) groups, Cys residues are highly conserved within functionally important 
protein regions. Indeed, Cys residues are the only thiol-bearing amino acids, and are 
commonly found in close proximity to each other and thereby participating in 
disulphide bond formation. As thiol groups (R-SH) are readily deprotonated, whereby 
they lose H+ to form distinct thiolate groups (R-S-), Cys residues are highly redox-
sensitive (Poole, 2015).  
 
Upon development, PX-12 was shown to inhibit Trx directly via thioalkylation of Cys 
residues. As PX-12 was without effect on TrxR or glutathione reductase, it was 
introduced as a selective Trx inhibitor (Kirkpatrick et al., 1998). A proceeding study has 
however demonstrated that in addition to inhibiting Trx with an IC50 value of 20µM, 
PX-12 directly oxidised Cys residues in tubulin (18 out of 20), thus preventing 
polymerisation. PX-12 was also shown to inhibit the protease enzymes papain and ficin 
via oxidative inactivation of active site Cys residues (Huber et al., 2008). These findings 
illustrate that PX-12 is a more prolific oxidising agent than was originally described. 
Huber et al. (2008) also emphasised that the observed anti-proliferative effects of low 
concentrations of PX-12 on MCF-7 breast cancer cells and HUVECs were not solely 
attributable to Trx inhibition. Whilst MCF-7 cells express both CaV3.2 and CaV3.1 
channels (Taylor et al., 2008b), HUVECs primarily express CaV3.1 channels (Wang et al., 
2006). It is therefore possible that direct PX-12-mediated inhibition of CaV3.x channels 
may contribute to the anti-proliferative effects of this drug. This conclusion is 
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consistent with current findings that whilst CaV3.1 channels were not sensitive to Trx, 
EdU incorporation assays revealed PX-12 (1µM) had small but significant anti-
proliferative effects on HEK293/CaV3.1, but not wt HEK293 cells (Chapter 4).  
 
With regards to its stated purpose as a Trx inhibitor, PX-12 is currently undergoing 
clinical trials as an anti-cancer agent (Baker et al., 2013; Ramanathan et al., 2007; 
Ramanathan et al., 2011). Importantly, the non-specific effects of PX-12 currently 
described raise important questions about the validity of its clinical use. Whilst direct 
inhibition of T-type Ca2+ channels by PX-12 could arguably contribute favourably to the 
drugs’ anti-cancer properties, it is highly likely that indiscriminate oxidation of Cys 
residues would be accompanied by a host of adverse physiological effects. In support 
of this proposal, a recent clinical trial analysed the proteomic profile of clinical trial 
patients both pre- and post-PX-12 treatment. In addition to Trx modification, 8 unique 
peaks resulting from PX-12 treatment were observed in all patients, further indicating 
that the effects of PX-12 are not restricted to Trx (Baker et al., 2013).  
 
Redox regulation of T-type Ca2+ channels is well established. For example, CaV3.2 
currents are approximately doubled in amplitude under reducing conditions i.e. when 
exposed to DTT or L-cysteine, and are conversely inhibited by oxidising agents such as 
DTNB (Todorovic et al., 2001). Of key relevance to the PX-12-mediated inhibition of 
CaV3.x channels currently described is α-lipoic acid (LA), a ubiquitous mitochondrial co-
factor which participates in redox reactions involving thiol groups (Smith et al., 2004). 
LA has been shown to inhibit CaV3.1 and CaV3.2 currents with similar sensitivities, via 
modification of extracellular Cys residues. As illustrated in Figure 5.18, the four target 
Cys residues of LA are highly-conserved amongst T-type Ca2+ channels. Three are 
located within the extracellular loop connecting S1-S2 in domain I (DI) (Cys123, Cys128 
and Cys133) and the other in the loop connecting S5 to the pore within DII (Cys939) (Lee 
et al., 2009). Within biological systems, the majority of Cys residues are found in close 
proximity to each other and form disulphide bonds which, although crucial for protein 
structure, are relatively inert. Resultantly, extracellular loops containing odd numbers 
of Cys residues, such as those regulated by LA, appear the most likely molecular 
target(s) to mediate the inhibitory effects of PX-12 on CaV channels. Further 
investigation exploring whether site-directed mutagenesis of the Cys residues at 
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positions 123, 128, 133 and 939 of CaV3.x channels alters their sensitivity to PX-12 
would be required to confirm this proposal.  
 
Current findings demonstrated that reversal of PX-12-mediated CaV3.2 channel 
inhibition was dependent on Trx being in its reduced form. Due to the Trx-independent 
mechanism by which PX-12 inhibited CaV3.1 channels however, only limited 
conclusions can be drawn from this observation. Specifically, rTrx could potentially 
reverse the effects of PX-12 via a mechanism separate to the non Trx redox state-
dependent mechanism found to regulate CaV3.2 channels under control conditions. 
For example, rTrx could undergo dithiol-disulphide exchange with CaV3.2 channel Cys 
residues previously oxidised by PX-12. As rTrx did not reverse PX-12-mediated 
inhibition of CaV3.1 or CaV3.2(H191Q) channels, this would also suggest interaction 
between conserved Cys residues and His191 in CaV3.2 channels, as further discussed in 
section 5.3.3.  
 
Boycott et al. (2013) previously described that when rTrx was applied under control 
conditions, significantly less CaV3.2 current amplitude enhancement was apparent 
than when rTrx was applied post AuF pre-treatment. To further extend this 
observation, and also current findings, it would be useful to examine any variation 
between different redox forms of Trx on HEK293/CaV3.2 currents following AuF pre-
treatment. This would establish whether reversal of Auf-mediated CaV3.2 channel 
inhibition is dependent on the redox status of Trx. An interesting consideration is that 
due to the indirect nature of AuF-mediated Trx inhibition i.e. via TrxR, a Trx redox 
state-dependent mechanism would arguably be predicted. Importantly however, Trx-
mediated regulation of CaV3.2 currents under control conditions was currently shown 
to be redox state-independent. Correspondingly, as the redox state of Trx influences 
its release (Bertini et al., 1999; Kondo et al., 2004), the effects of AuF on CaV3.2 
currents, proliferation and Ca2+ handling (Chapter 4) could be attributable to reduced 
extracellular Trx levels and a corresponding decrease in tonic CaV3.2 channel 
activation. 
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5.3.3.  Potential interaction of Trx with CaV3.2 channel trace metal binding  
Interestingly, the molecular determinant of CaV3.2 channel Trx-sensitivity (His
191) is 
known to also contribute to the unique sensitivity of CaV3.2 channels to trace metals 
i.e. Ni2+, Zn2+ and redox modulators such as ascorbate. Initial studies described that 
when recombinantly expressed in Xenopus Oocytes or HEK293 cells, CaV3.2 currents 
were blocked by much lower Ni2+ concentrations (IC50 value of 13µM) when compared 
to CaV3.1 and CaV3.3 channels (IC50 values of 250µM and 216µM respectively) (Lee et 
al., 1999). A later study generated chimeric CaV3.x channels to investigate the 
structural determinants of CaV3.2 Ni
2+-sensitivity. Chimeric channels are commonly 
used for preliminary CaV channel structure-function investigations. Their construction 
involves the isolation of individual α1 subunit domains (DI-IV), which can then be re-
assembled in various combinations and expressed recombinantly. For example, when 
DIII of the CaV3.2 channel is substituted with DIII of the CaV3.1 channel the chimeric 
channel is referred to as HHGH. As HGGG channels showed a Ni2+-sensitivity similar to 
wt CaV3.2 channels, it was predicted that the Ni
2+ binding site was located within DI of 
the CaV3.2 channel (Kang et al., 2006). 
 
By aligning the amino acid sequences of DI from the three CaV3.x channel isoforms, un-
conserved regions likely to underpin the differential isoform sensitivities were 
identified. Specifically, a glutamic acid (Glu or E) residue (E137) and a His residue 
(H191), found within the extracellular loop linking S3-S4 within DI were unique to 
CaV3.2 channels. These residues were then individually mutated to glutamine (Gln or 
Q) residues. Whilst the CaV3.2(E137Q) mutant showed Ni
2+-sensitivity comparable to 
wt CaV3.2 channels, the CaV3.2(H191Q) mutant channel exhibited significantly reduced 
Ni2+-sensitivity. Furthermore, when the Gln residue found within the equivalent 
position of CaV3.1 channels (Q172) was mutated to His (Q172H), CaV3.1 channel 
sensitivity to Ni2+ was increased (5-fold). As such, it was concluded that His191 
participated in Ni2+ binding. Importantly, as only partial Ni2+-sensitivity was imparted 
by the CaV3.1(Q172H) mutation, evidence that additional amino residues contributed 
to the Ni2+-binding site was also provided (Kang et al., 2006).  
 
Subsequent studies have also demonstrated that Zn2+ selectively inhibits CaV3.2 
channels over other CaV3.x isoforms. As the CaV3.2(H191Q) mutant was insensitive to 
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Zn2+ a crucial role for His191 in metal-binding was thus confirmed. Furthermore, Zn2+ 
chelation enhanced CaV3.2 current amplitude, indicating that Zn
2+ may tonically bind 
to CaV3.2 channels via His
191 (Kang et al., 2010; Nelson et al., 2007b). Generation of 
chimeric channels, alongside site-directed mutagenesis, revealed that aspartic acid 
(Asp or D) and glycine (Gly or G) residues immediately preceding His191 (D189 and 
G190) within the extracellular S3-S4 loop, and a second Asp residue on the outside in 
S2 (D140), were also critical determinants of CaV3.2 Zn
2+ sensitivity (Kang et al., 2010). 
It was subsequently shown that this unique metal binding in CaV3.2 channels was 
responsible for trace metal binding, shown in Figure 5.18. Trace metal binding at this 
high affinity site is believed to stabilise CaV3.2 channels in their closed state, as 
reviewed (Perez-Reyes & Lee, 2014).  
 
Ascorbate is an endogenous redox agent which can function as both an anti- and pro-
oxidant. Regarding its functions as a pro-oxidant, ascorbate promotes the generation 
of reactive oxygen species (ROS) such as hydroxyl (OH-) superoxide (O2
-) and hydrogen 
peroxide (H2O2), via the reduction of transition metals such as iron (Fe
3+, Fe2+) and 
copper (Cu+ and Cu2+). This process is collectively referred to as metal-catalysed 
oxidation (MCO). Significantly, MCO provides the major endogenous mechanism for 
oxidation of aliphatic and aromatic amino acids (Stadtman, 1991; Stadtman, 1993). 
When recorded from native tissues, or recombinantly expressed, CaV3.2 channels are 
potently inhibited by ascorbate whilst CaV3.1 and CaV3.3 channels are insensitive. 
Importantly, the mutant CaV3.2(H191Q) channel is also insensitive to ascorbate-
mediated inhibition. As such, His191 was shown to be a structural determinant of 
CaV3.2 channel ascorbate-sensitivity. Increasing extracellular Cu
2+ concentrations 
significantly enhanced ascorbate-mediated inhibition of wt CaV3.2 channels. It was 
therefore suggested that ascorbate interacted with the metal binding site in CaV3.2 via 
His191 to initiate MCO and thereby inhibit CaV3.2 channels (Nelson et al., 2007a). 
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Figure 5.18. Schematic diagram highlighting key amino acid residues of CaV3.2 
channels 
Representative view looking through a cross-section of a stretched lipid bilayer (orange 
box) showing the arrangement of the α1H subunit (CaV3.2 channel). Domain I (DI) is 
highlighted (dashed box) and magnified below. The unique metal binding site in CaV3.2 
channels within DI is composed of a motif containing aspartic acid (D189, purple 
circle), glycine (G190, green circle) and histidine (H191, blue circle) residues found 
within the extracellular S3-S4 loop, and a second Asp residue on the outside S2 (D140, 
purple circle). Amino acid residues composing the metal binding site are in close 
proximity to cysteine residues (C123, C128, C133, red circles), which are conserved 
amongst CaV3.x isoforms. In addition to a further cysteine residue within the 
extracellular region of DII(S5) (C939, not shown) these residues provide the targets of 
α-lipoic acid, and potentially PX-12 and CO. Figure adapted from Perez-Reyes (1999); 
Todorovic & Jevtovic (2014). (Perez-Reyes 1999; Todorovic & Jevtovic-Todorovic 2014) 
 
An as of yet undetermined consideration is whether metal binding itself, or the 
resultant effects of MCO on surrounding amino acids, stabilises CaV3.2 channels in 
their closed state. Considering the dependency of Trx–mediated CaV3.2 current 
enhancement on His191, this consideration is highly relevant when discussing potential 
interactions between Trx and CaV3.2 channels. As extensive further research will be 
required to establish which (if any) of the proposed mechanisms are relevant, 
corresponding future experiments will also be outlined. Firstly, Trx could bind directly 
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to His191 and prevent trace metal binding. This could destabilise the CaV3.2 channel 
closed-conformation due to a direct absence of the metal ion itself, or due to an 
indirect reduction in MCO. Regarding additional experiments, if pre-treatment of 
CaV3.2 currents with metal chelators prevented the effects of Trx, the requirement of 
trace metals to the effects of Trx would be confirmed.  
 
The metal binding site in DI of CaV3.2 channels is mainly contained within the S3-S4 
extracellular loop (Kang et al., 2010). Also present in DI of all CaV3.x channels are 3 Cys 
residues (Cys123, Cys128, Cys133), located within the extracellular S1-S2 loop. 
Modification of these Cys residues using LA, and potentially following PX-12 and CO 
exposure (discussed in sections 5.3.2 and 5.3.1 respectively), inhibits CaV3.2 channels 
(Todorovic & Jevtovic-Todorovic, 2014). In terms amino acid sequence, these Cys 
residues are in close proximity to metal binding site residues (Figure 5.18). 
Furthermore, inferences can also be made regarding their 3D proximity. Although the 
crystal structure of CaV channels remains unresolved, a single domain of the α1 subunit 
is believed to bear close resemblance to KV subunits. As such, the extracellular S1-S2 
loop and the S3-S4 loop of CaV3.2 channels subunits are predicted to be in close 3D 
proximity (Long et al., 2007).  
 
Thiol-containing Cys residues are highly redox-sensitive (Poole, 2015). Interestingly, 
within many biological systems, Cys residues cluster around and contribute to the 
functional significance of metal-binding sites at the surface of proteins (Marino & 
Gladyshev, 2010). It is correspondingly feasible that CaV3.2 channel Cys residues are 
targets of MCO. In this regard, Cys residues may be the ultimate determinants of the 
stabilising effects of Zn2+, Ni2+ and ascorbate on CaV3.2 channels. Trx-mediated 
enhancement of CaV3.2 channels currently reported here could be explained by Trx 
binding to His191, thereby preventing metal binding and interrupting MCO of 
surrounding Cys residues.  
 
Interestingly, current findings highlight the potential for interaction between the 
CaV3.2 channel metal binding site and Cys residues. For example, co-application of 
ascorbate and PX-12 following ascorbate treatment significantly enhanced wt CaV3.2, 
but not CaV3.2(H191Q) current amplitude. This starkly contrasted with the inhibitory 
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effects each drug had on wt CaV3.2 channels when applied in isolation. Furthermore, 
co-application of PX-12 and ascorbate to wt CaV3.2 channels also commonly 
augmented the shape of CaV3.2 currents. Specifically, dramatically increasing tail 
current amplitude and appearing to reduce inactivation. These opposing effects of co-
application may concern the ability of  ascorbate to function as both an anti- and pro-
oxidant (Stadtman, 1991), and potential cross-reaction with PX-12. Alternatively, the 
targets of ascorbate (i.e. metal-binding site residues) that are unique to CaV3.2 
channels may interact with the potential targets of PX-12 (i.e. conserved Cys residues 
as detailed in section 5.3.2). Point-mutation of CaV3.2 channel Cys
123 Cys128 and Cys133 
residues and subsequent application of Trx, Ni2+ and ascorbate would confirm, or 
disprove, the involvement of Cys residues in MCO within CaV3.2 channels.  
 
If subsequent experiments did not provide evidence in support of the aforementioned 
mechanisms, an alternative proposal as to the mechanism of Trx-mediated CaV3.2 
channel regulation is that His191 itself provides the end target of MCO. Studies 
conducted in E. coli have determined that metal-binding sites within the glutamine 
synthetase (GS) enzyme facilitate MCO, which thereby inhibits enzyme activity. 
Specifically, MCO inhibited GS activity by converting a single His residue to asparagine  
(Asp) and a single arginine (Arg) residue to glutamic semialdehyde (Farber & Levine, 
1986). It is correspondingly feasible that His191 serves as the end target for MCO. This 
could explain its role within, or be in addition to, the involvement of His191 in the 
CaV3.2 channel-stabilising effects of metal binding. With specific regard to the Trx-
mediated CaV3.2 channel regulation currently observed here, direct binding to His
191 
could provide protection against MCO. A further possibility is that Trx does not bind to 
the channel directly but serves as the substrate for MCO, thus indirectly reducing 
the oxidative effects of MCO on CaV3.2 channels. If co-application of ascorbate 
reduced Trx-mediated CaV3.2 channel enhancement, evidence in support of this idea 
would be provided.   
 
Many of the data presented throughout this thesis (Chapters 3, 4 and 5) are 
preliminary in nature but provide interesting insights which warrant further research. 
In order to ensure the statistical validity of future investigations, it would be useful to 
implement power analyses to estimate the number of experimental repeats required. 
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Effective power analysis requires that the effect size i.e. the difference between the 
hypothesis and the null hypothesis, and the standard deviation or data spread, is 
known. Current data therefore would enable effective power analysis to be conducted 
prior to each future experiment.  
 
5.3.4. Summary and conclusions  
Results in this chapter demonstrate that CaV3.2 channels are positively and selectively 
regulated by Trx, via an interaction with a singular extracellular His191 residue that is 
unique to CaV3.2 channels. They also suggest that Trx-mediated CaV3.2 channel 
regulation, under control conditions, is independent of the redox state of Trx. PX-12 
was found to inhibit CaV channels indiscriminately, via a Trx-independent mechanism, 
raising important questions about its safety and validity as a Trx inhibitor for clinical 
use. Interestingly, the selective and observed reversal of PX-12-mediated inhibition of 
CaV3.2 currents by Trx was Trx redox state-dependent. This indicated that CaV3.2 
channel regulation may be dependent on both intra- and extra-active site residues in 
Trx. Further work is required to establish the exact mechanism of interaction between 
Trx and His191 in the CaV3.2 channel. Findings detailed within previous chapters show 
that AuF selectively reduced the proliferation of CaV3.2-expressing cells, therefore 
providing evidence that Trx can modulate cellular proliferation via CaV3.2 channel 
regulation.  
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Chapter 6 -The implications of Trx-mediated CaV3.2 channel 
regulation on cellular proliferation  
 
6.1. Principle findings 
6.1.1.  HEK293 cells  
It is ultimately important to consider the functional significance of Trx-mediated CaV3.2 
channel regulation on cellular proliferation. Findings from recombinant HEK293 cells 
are relatively simple to interpret; primarily because the contribution of CaV3.1 or 
CaV3.2 channel expression on cellular proliferation, basal Ca
2+ influx and peak Ca2+ 
current amplitude can be examined individually. Expression of CaV3.1 or CaV3.2 
channels significantly elevated cell proliferation and basal Ca2+ influx in HEK293 cells. 
Crucially, as NNC reduced cell proliferation and [Ca2+]i influx in HEK293/CaV3.1 and 
HEK293/CaV3.2 cells, but not wt HEK293 cells, a causative role for both CaV3.1 and 
CaV3.2 channels in elevated proliferation was thus provided (Chapter 3). Significantly, 
inhibition of thioredoxin (Trx) using auranofin (AuF) selectively reduced 
HEK293/CaV3.2, but not HEK293/CaV3.1 or wt HEK293, cell proliferation (Chapter 4). 
These findings were consistent with previous observations that AuF and Trx selectively 
regulated CaV3.2 currents (Boycott et al., 2013). Furthermore, AuF produced a 
rightwards shift in the I-V profile of HEK293/CaV3.2 currents, which is likely to shift the 
voltage range for the CaV3.2-mediated window current away from the resting 
membrane potential (Vm) (Chapter 5).  
 
Both CaV3.1- and CaV3.2-facilitated window currents have been previously shown to 
elevate basal [Ca2+]i when expressed recombinantly (Chemin et al., 2000). 
Furthermore, recombinant expression of human CaV3.1 (Wang et al., 2002a) and 
CaV3.2 (Wang et al., 2002b) channels in HEK293 cells has been reported to confer 
significant growth advantages. Specifically, CaV3.1 or CaV3.2 channel expression 
significantly reduced population doubling times to similar extents, likely by promoting 
progression through the G1/S phase of the cell cycle (Wang et al., 2002a; Wang et al., 
2002b). The proliferative rate of HEK293/CaV3.2/clone P cells, transfected in-house 
with a CaV3.2-containing mammalian expression vector, was directly comparable to wt 
HEK293 cells and unaltered by NNC. It was coincidentally observed that in contrast to 
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the perinuclear clusters and punctate membranous patterns of CaV3.2- 
immunoreactivity (IR) observed in the highly proliferative HEK293/CaV3.2 cells, CaV3.2-
IR in HEK293/CaV3.2/clone P cells was highly diffuse. This suggested that aggregation 
or clustering of CaV3.2 channels in specific sub-cellular domains might be important for 
increased basal Ca2+ to result in elevated cellular proliferation (Chapter 3).  
 
These observations collectively indicate that Trx-mediated regulation of CaV3.2 
channels can promote cellular proliferation, potentially by enhancing the CaV3.2-
facilitated window current and corresponding basal [Ca2+]i. Further direct assessment 
of the effects of AuF and Trx on recombinant HEK293 cell window currents, using 
either Ca2+ microfluorimetry or electrophysiological protocols to individually measure 
the voltage-dependencies of CaV3.2 channel activation and steady-state inactivation, 
would substantiate this conclusion.   
 
6.1.2. A7r5 cells  
Interpretation of results gathered in the native VSMC A7r5 cell line is somewhat more 
complex than the situation in HEK293 cells. Whilst the high levels of T-type Ca2+ 
channel expression and relatively small size of recombinant HEK293 cells meant they 
were highly conducive to patch-clamp electrophysiology, the exact opposite applied to 
A7r5 cells. A7r5 cells were directly shown to express CaV3.1 channels primarily, in 
addition to CaV3.2 channels (Chapter 3). Therefore, an important consideration (given 
that AuF-mediated inhibition of HEK293 cell proliferation was dependent on CaV3.2 
channel expression) is whether CaV3.2 channels specifically influence VSMC 
proliferation. Whilst AuF reliably inhibited proliferation and basal Ca2+ influx in A7r5 
cells (Chapter 4), Trx only potentiated A7r5 T-type Ca2+ currents on a small number of 
occasions (Chapter 5).  
 
A potentially reconciling and preliminary observation for this discrepancy was that 
sensitivity of T-type Ca2+ channel currents to Trx was apparent when high CaV3.2 
channel expression levels were detected using immunohistochemistry (Chapter 5). This 
observation also indicated that CaV3.2 channel expression was dynamically regulated 
in A7r5 cells. With regard to this, a recent study has reported that expression of CaV3.2 
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channels within the plasma membrane is regulated by asparagine-linked glycosylation 
of CaV3.2 channel residues. It was also identified that increasing external glucose 
concentrations increased CaV3.2 channel glycosylation and surface expression in 
human embryonic kidney tsA-201 cells (Weiss et al., 2013). Interestingly, CaV3.2-IR in 
A7r5 cells reliably localised around the nucleus (Chapters 3 & 5). This directly 
contrasted with the diffuse pattern of CaV3.1-IR reliably observed in A7r5 cells 
(Chapter 3). In agreement with observations in recombinant HEK293 cells, it appears 
that the subcellular distribution of CaV3.2 channels determined their ability to 
influence cellular proliferation. Low levels of peri-nuclear CaV3.2 expression could 
potentially have a larger pro-proliferative effect than high levels of cytosolic CaV3.1 
channel expression.  
 
 
6.2. Clinical significance  
Previous studies examining the contribution of CaV3.x channels to VSMC proliferation 
have implicated CaV3.1 channels as a major proliferative driving force in both 
developmental and pathological vascular remodelling. The ductus arteriosus (DA) is 
the foetal vascular shunt vessel which undergoes developmental remodelling 
postpartum. VSMCs isolated from the DA of CaV3.1
-/- mice show significantly less 
proliferation and migration (Akaike et al., 2009). Regarding pathological vascular 
remodelling, carotid wire injury has been shown up-regulate CaV3.1 channels leading 
to neointima formation in mice. Significantly, CaV3.1
-/-, but not CaV3.2
-/-, mice were 
shown to be resistant to neointima formation following vascular injury (Tzeng et al., 
2012).  
 
6.2.1. Hypoxia-induced vascular remodelling  
As discussed extensively in Chapter 1, many cardiovascular disorders are associated 
with VSMC dedifferentiation and increased proliferation. As T-type Ca2+ channels are 
selectively expressed in the proliferative phases of the VSMC cell-cycle (Kuga et al., 
1996), more VSMC proliferation logically equates to increased T-type Ca2+ channel 
levels. Importantly, the specific contribution of CaV3.2 channels to VSMC proliferation 
may be more significant in pathological situations. Pulmonary hypertension (PH) can 
be induced by hypoxia and is associated with elevated VSMC levels, leading to vascular 
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remodelling. Exposure of mice to chronic hypoxia resulted in PH, observed as a 
significant increase in right ventricular systolic pressure alongside significant thickening 
of the medial layer of pulmonary vessel walls (Satoh et al., 2014; Wan et al., 2013). 
Hypoxia has also been shown to induce a significant up-regulation in CaV3.2 and CaV1.2 
mRNA expression in pulmonary arteries (Wan et al., 2013). When pulmonary artery 
smooth muscle cells (PASMCs) were isolated from normoxic mice, exposure to high 
[K+] (40mM) caused only very small elevations in [Ca2+]i. In contrast, PASMCs isolated 
from hypoxic mice showed significant increases in [Ca2+]i in response to the same high 
[K+] stimulus, indicating that elevated CaV3.2 and CaV1.2 mRNA levels led to increased 
functional CaV channel expression (Wan et al., 2013). A more recent study conducted 
with rat PASMCs and pheochromocytoma (PC12) cells demonstrated that acute 
exposure to hypoxia (12-24hrs) induced prominent rises in CaV3.2 mRNA, protein and 
functional channel expression. No changes in these parameters were observed for 
CaV3.1 channels. It was also identified that hypoxia-induced CaV3.2 upregulation 
required the binding of hypoxia-inducible factor (HIF) to hypoxia-response elements 
within the promoter regions of the CaV3.2 channel (CACNA1H) gene (Sellak et al., 
2014). 
 
The effects of hypoxia on CaV3.2 channel expression levels, has also been examined in 
other vascular beds. Coronary interventions are commonly associated with neointima 
formation. Internal mammary arteries (IMA) often serve as replacement conduit 
vessels for coronary artery bypass surgeries, as they are less prone to restenosis when 
compared to saphenous vein grafts (Nwasokwa, 1995). During surgical procedures and 
subsequent revascularisation, grafted VSMCs can be subject to periods of hypoxia. 
Correspondingly, supplemental oxygen has been shown to reduce neointima 
formation and reduce VSMC proliferation in the aortic media, following intra-aortic 
stent implantation in rabbits (Tretinyak et al., 2002). In proliferating IMA SMCs 
(IMASMCs), exposure to hypoxia has been shown to increase functional T-type Ca2+ 
channels and decrease functional L-type Ca2+ channel levels. This was determined by 
measurement of depolarisation-induced Ca2+ entry, in the presence or absence of 
various specific Ca2+ channel blockers (CCBs). As no changes in CaV1.2 or CaV3.2 mRNA 
levels were detected, it was suggested that altered membrane trafficking of T-type 
Ca2+ channels accounted for the functional differences (Aley et al., 2008).  
209 
 
 
Of further key interest is that when mice were subject to chronic hypoxia, a doubling 
of Trx levels in lung tissue was observed. In agreement with these observations, acute 
exposure of HPASMCs to hypoxia more than doubled Trx levels and significantly 
increased HPASMC proliferative rates. Final confirmation that Trx was pro-proliferative 
in hypoxia-exposed HPASMCs was the finding that siRNA-mediated Trx knockdown 
abolished hypoxia-induced elevations in proliferation. Increased activation of HIF was 
also reported by this study (Chen et al., 2013). Collectively, these studies emphasise 
that the pro-proliferative effects of Trx-mediated CaV3.2 current enhancement would 
be increased by hypoxia. Correspondingly, this novel signal pathway is likely to be 
involved in pathological vascular remodelling associated with hypoxia-induced PH.  
 
Regarding current results, A7r5 cell proliferation and basal Ca2+ influx was similarly 
inhibited by both selective T-type CCBs and AuF. Evidence that Trx-mediated 
regulation of CaV3.2 could modulate VSMC proliferation was therefore provided. 
Regarding future experiments, it would be interesting to see if high glucose 
concentrations, and or hypoxia, increased A7r5 CaV3.2 channel expression. If this was 
demonstrated, enhancement of the anti-proliferative effects of AuF would be 
correspondingly predicted, alongside a greater Trx-sensitivity of native A7r5 T-type 
Ca2+ currents. Conversely, genetic knockdown of CaV3.2 channels in A7r5 cells would 
be expected to reduce A7r5 proliferation and abolish the effects of AuF on both 
proliferation and Ca2+ handling.  
 
6.2.2. MI-induced cardiac remodelling  
The novel Trx-CaV3.2 channel signalling pathway characterised in the current 
investigation may also bear clinical significance to cardiac remodelling. Importantly, 
whilst hypertrophic remodelling involves increased growth of individual myocytes as 
opposed to increased proliferation, this process is also highly dependent on [Ca2+]i. 
Specifically, elevations in [Ca2+]i can activate Ca
2+-dependent transcription factors 
leading to the expression of hypertrophic genes via a process termed excitation-
transcription (ET) coupling (Dominguez-Rodriguez et al., 2012). For example, 
myocardin is a transcription co-factor which plays an important role in the 
development of cardiac hypertrophy. Using embryonic rat heart-derived cells(H9c2), 
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elevated Ca2+ influx was shown to increase myocyte size and produce morphological 
phenotypic alteration to hypertrophic myocytes. Increased [Ca2+]i also resulted in 
elevated levels of hypertrophic markers such as B-type natriuretic peptide (BNP). 
Levels of myocardin mRNA were also increased significantly. Importantly, genetic 
knockdown of myocardin using siRNA dramatically attenuated Ca2+-induced 
hypertrophy of cardiomyocytes (Li et al., 2015b). 
 
Regarding the route of Ca2+ influx in Ca2+-dependent hypertrophy, CaV3.1 channels are 
known to be important for functional cardiac remodelling; e.g. elevations in heart rate 
and ventricular tachycardia post-myocardial infarction (MI) (Le et al., 2011). In 
contrast, a specific role for CaV3.2 channels in structural cardiac remodelling post-MI 
has been established. Within feline ventricular myocytes (or SMCs), MI-induced cardiac 
hypertrophy functionally up-regulated T-type Ca2+ channels, observed as an increased 
sensitivity of LVA currents to Ni2+ (Nuss & Houser, 1993). A subsequent study found 
that pressure-induced cardiac hypertrophy achieved by aortic banding was virtually 
abolished in CaV3.2
-/- mice, but not in CaV3.1
-/- mice. In direct contrast with CaV3.1
-/- 
mice, the heart weight vs. body weight ratio measured 2 weeks post-surgery was not 
significantly altered in CaV3.2
-/- mice when compared to control animals subject to 
sham surgical procedures. In wt mice, aortic banding led to a dramatic thickening of 
ventricular walls and a significant increase in the cross-sectional diameter of individual 
myocytes. No significant changes in any of these parameters were observed in the 
CaV3.2
-/- mice. Additionally, myocytes isolated from neonatal CaV3.2
-/- mice showed no 
hypertrophic response when stimulated with angiotensin II, as was observed for wt 
myocytes. As no changes in blood pressure were observed between wt and CaV3.2
-/- 
mice, a specific role for CaV3.2 channels in structural as opposed to functional 
hypertrophic remodelling was indicated (Chiang et al., 2009). In support of these 
findings, a further study in wt mice observed increased CaV3.2 channel expression in 
response to aortic banding. The sharp up-regulation in CaV3.2 mRNA expression 
provided an early event in the development of cardiac hypertrophy. It was also shown 
that the transcription factor early growth response 1 (Egr1) provided the initial signal 
leading to hypertrophic CaV3.2 over-expression (Hsu et al., 2013).  
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Interestingly, alterations in the Trx system have also been reported in cardiac 
hypertrophy. Specifically, following aortic banding of mice, myocardial Trx activity was 
increased considerably whilst vitamin D3 up-regulated protein (VDUP) mRNA and 
protein levels were decreased in ventricular cells. Concurrently, genetic over-
expression of VDUP in mice significantly reduced cellular hypertrophy (Yoshioka et al., 
2004). In vitro studies of rat cardiomyocytes also revealed that Trx over-expression 
increased protein synthesis, whilst over-expression of VDUP reduced protein synthesis 
(Yoshioka et al., 2004). Elevated Trx expression has also been directly implicated in the 
differentiation and proliferation of SMCs, leading to pathological cardiac remodelling 
following MI in rats (Suresh et al., 2015). In light of current findings, activation of 
increased levels of CaV3.2 channels by elevated levels of Trx is likely to increase the 
window current. This would elevate [Ca2+]i leading to ET-coupling and Ca
2+-induced 
hypertrophic remodelling post-MI. The potential of disrupting the interaction between 
Trx and CaV3.2 therefore provides a novel pathway which could also potentially be 
targeted for therapeutic advantage in cardiac hypertrophy.  
 
6.2.3. Cancer  
The pathophysiological significance of the growth promoting effects of Trx-mediated 
CaV3.2 channel regulation also readily extends to carcinogenesis. Increased CaV3.2 
channel expression has been specifically implicated in the increased basal Ca2+ levels 
and corresponding high proliferative rates of many cancer cells. This includes 
neuroblastoma (Panner et al., 2005), prostate (Mariot et al., 2002) and breast cancer 
cells (Taylor et al., 2008b). In agreement with findings from VSMCs (Kuga et al., 1996), 
expression of CaV3.1 and CaV3.2 channels in breast cancer MCF-7 cells has been shown 
to be restricted to the proliferative phases of the cell-cycle. High levels of CaV3.1 and 
CaV3.2 mRNA expression were detected in rapidly growing cultures of MCF-7 cells, but 
not cytostatic confluent cells. Furthermore, inhibition of T-type Ca2+ channels using 
NNC significantly reduced MCF-7 cell proliferation. A similar anti-proliferative effect 
was observed when CaV3.1 and CaV3.2 channels were knocked-down using siRNA 
(Taylor et al., 2008a). 
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 Significantly, elevated levels of extracellular Trx have also been determined in many 
cancers such as breast (Mariot et al., 2002), pancreatic (Nakamura et al., 2000), lung 
(Kahlos et al., 2001; Kakolyris et al., 2001; Soini et al., 2001) and cervical cancers (Fujii 
et al., 1991). Current findings therefore indicate that simultaneous increases in CaV3.2 
and Trx may provide a highly detrimental positive-feedback loop. Specifically, 
activation of CaV3.2 by Trx would increase proliferation, leading to more CaV3.2 
channel expression and further potentiation of the growth promoting effects of Trx. 
Resultantly, the rationale of blocking the interaction between Trx and CaV3.2 channels 
holds realistic therapeutic potential for the treatment of cancer. 
 
In light of the broad spectrum of crucial intracellular functions of Trx, an appealing 
prospect by which to minimise the potential side effects of Trx inhibition would be to 
develop a drug which specifically targets extracellular Trx. Interestingly, a recent study 
has explored how modification of the structure of PX-12 could make the drug 
membrane impermeant and correspondingly act as a selective inhibitor of extracellular 
Trx (DiRaimondo et al., 2013). Importantly, this study overlooks many important 
considerations such as the Trx-independent effects of PX-12, the potential of Trx being 
endogenously reduced in the extracellular environment and also the potential 
contribution of non-canonical Trx residues to its role as an extracellular signalling 
molecule and CaV3.2 channel modulator (Chapter 5). These issues should be of key 
consideration when assessing the clinical suitability of the novel asymmetric disulphide 
PX-12 variants engineered by DiRaimondo et al. (2013). 
 
 
6.3. Summary and conclusion  
This project has provided evidence showing that Trx-mediated CaV3.2 channel 
regulation has pro-proliferative effects. Both CaV3.2 channels and Trx have been 
associated with vascular and cardiac remodelling, induced by hypoxia or MI 
respectively. As such, pharmacological disruption of the interaction between Trx and 
CaV3.2 channels holds novel, therapeutic potential for the treatment of both PH and 
cardiac hypertrophy. Importantly however, further investigations into the mechanisms 
and extent of CaV3.2 channel upregulation, in other cardiovascular disorders involving 
excessive proliferation, are required to establish the full clinical relevance. The 
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involvement of CaV3.2 channels in the aberrant proliferation of cancerous cells is also 
well established. Current observations therefore conclusively support the rationale 
that Trx inhibitors provide effective chemotherapy agents. Significantly, compelling 
evidence that PX-12 is not a selective Trx inhibitor was provided. This is highly 
indicative of the potential undesirable side effects and contraindications of clinical use 
of PX-12 as a Trx inhibitor. As the site for Trx-mediated CaV3.2 channel regulation was 
located extracellularly (His191), the development of membrane impermeant Trx 
inhibitors may provide an opportunity to develop novel treatments for proliferative 
disorders involving cells which express CaV3.2 channels.  
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